Novel ionizable lipids and lipid nanoparticles and methods of use thereof

Through the combination of novel ionizable lipid nanoparticle compositions with neutral lipids and cholesterol, the problem of delivery of macromolecular bioactive agents in cells is solved, and the efficient delivery of mRNA and CRISPR/Cas9 system components is achieved, suitable for Treatment of various diseases.

CN119072464APending Publication Date: 2024-12-03SENDA BIOSCIENCES INC
View PDF 78 Cites 0 Cited by

Patent Information

Application Number
CN202380035765.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-25
Filing Date
2023-03-24
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently deliver macromolecules such as mRNA and CRISPR/Cas9 system components, especially during intracellular delivery.

Method used

A novel ionizable lipid nanoparticle (LNP) composition has been developed to form lipid nanoparticles with excellent nucleic acid delivery characteristics by combining lipid conjugated with neutral lipids, cholesterol and polymers to promote nucleic acid delivery in In vitro and in vivo intracellular delivery.

Benefits of technology

The efficient delivery of encoded and non-coding RNA is achieved, suitable for the treatment of various diseases, including conditions caused by infection or protein deficiency, and improves the delivery efficiency and stability of therapeutic agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072464A_ABST
    Figure CN119072464A_ABST
Patent Text Reader

Abstract

The present disclosure relates to novel ionizable lipids that can be used to deliver therapeutic agents, as well as lipid compositions and pharmaceutical compositions comprising these ionizable lipids.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to related applications

[0002] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 323,948, filed on March 25, 2022, which is incorporated herein by reference in its entirety. Background Art

[0003] Lipid nanoparticles ("LNPs") formed from lipids containing ionizable amines can be used as therapeutic cargo vehicles for delivering bioactive agents, such as coding RNA (i.e., messenger RNA (mRNA), guide RNA) and non-coding RNA (i.e., antisense, siRNA) into cells. LNPs can facilitate the delivery of oligonucleotide agents across cell membranes and can be used to introduce components and compositions into living cells.

[0004] Bioactive agents that are particularly difficult to deliver to cells include proteins, nucleic acid-based drugs and their derivatives, especially drugs containing relatively large oligonucleotides (such as mRNA or guide RNA). Compositions for delivering promising mRNA therapies or editing technologies into cells (such as for delivering components of the CRISPR / Cas9 system) have received particular attention.

[0005] With the emergence of recent pandemics, messenger RNA therapeutics have become an increasingly important option for treating a variety of diseases, including viral infections and diseases associated with one or more protein deficiencies. Compositions with useful properties that can stabilize and / or deliver RNA components for in vitro and in vivo delivery have also received particular attention.

[0006] Therefore, there is still a need in the art for novel lipid compounds to develop lipid nanoparticles or other lipid delivery mechanisms for therapeutic agent delivery. The present invention addresses this need. Summary of the Invention

[0007] Disclosed herein are novel ionizable lipids that can be used in combination with at least one other lipid component (e.g., neutral lipids, cholesterol, and polymer-conjugated lipids) to form lipid nanoparticle compositions. The lipid nanoparticle compositions can be used to facilitate intracellular delivery of therapeutic nucleic acids in vitro and / or in vivo.

[0008] Disclosed herein are lipids containing ionizable amines that can be used to form lipid nanoparticle compositions. Such LNP compositions can have properties that are conducive to delivering nucleic acid cargo (e.g., delivering coding and non-coding RNA) to cells. Also provided are methods for using the disclosed lipid nanoparticles to treat various diseases or conditions (e.g., diseases or conditions caused by infectious entities and / or protein deficiencies).

[0009] Various formulas are disclosed below, including, for example, ionizable lipids of Formula (I), (IA-1), (IA-2), (IIA)-(IIC), (IIA-1), (IIIA)-(IIIE), (IIIC-1), (IVA-1)-(IVA-3), (IVC-1)-(IVC-2), (VC-1)-(VC-6).

[0010] One aspect of the present invention relates to a compound of formula (I):

[0011] A pharmaceutically acceptable salt thereof or a stereoisomer of any one of the foregoing, wherein:

[0012] is a cyclic or heterocyclic moiety;

[0013] Y is alkyl, hydroxy, hydroxyalkyl or

[0014] A does not exist, it is -O-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-、-N(R 7 )C(O)N(R 7 )-, -S-, -SS- or a divalent heterocycle;

[0015] Each of X and Z is independently absent and is -O-, -CO-, -N(R 7 )-, -O-alkylene-; -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-or-S-;

[0016] Each R 7 is independently H, alkyl, alkenyl, cycloalkyl, hydroxy, hydroxyalkyl, or aminoalkyl;

[0017] Each M is independently a biodegradable moiety;

[0018] R 30 、R 40 、R 50 、R 60 、R 70 、R 80 、R 90 、R 100 、R 110 and R 120Each of the C1-C ... 16 Branched or unbranched alkyl or C1-C 16 branched or unbranched alkenyl, or cycloalkyl or substituted cycloalkyl;

[0019] Each of l and m is an integer from 1 to 10;

[0020] t1 is an integer from 0 to 10; and

[0021] W is hydroxy, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted amino, substituted or unsubstituted aminocarbonyl, or substituted or unsubstituted heterocyclyl or heteroaryl.

[0022] In some embodiments, disclosed are ionizable lipids of formula (I):

[0023] A pharmaceutically acceptable salt thereof or a stereoisomer of any one of the foregoing, wherein:

[0024] is a cyclic or heterocyclic moiety;

[0025] Y is alkyl, hydroxy, hydroxyalkyl,

[0026] A does not exist, it is -O-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-、-N(R 7 )C(O)N(R 7 )-, -S-, -SS- or a divalent heterocycle;

[0027] Each of X and Z is independently absent, -O-, -N(R 7 )-, -O-alkylene-; -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-or-S-;

[0028] Each R 7 is independently H, alkyl, alkenyl, cycloalkyl, hydroxy, hydroxyalkyl, or aminoalkyl;

[0029] Each M is independently a biodegradable moiety;

[0030] R 30 、R 40 、R50 、R 60 、R 70 、R 80 、R 90 、R 100 、R 110 and R 120 Each of the C1-C ... 16 Branched or unbranched alkyl or C1-C 16 branched or unbranched alkenyl, or cycloalkyl or substituted cycloalkyl;

[0031] Each of l and m is an integer from 1 to 10;

[0032] t is 0, 1, 2, or 3;

[0033] t1 is an integer from 0 to 10; and

[0034] W is hydroxy, hydroxyalkyl, or one of the following moieties:

[0035]

[0036] in

[0037] Each Q is independently absent and is -O-, -C(O)-, -C(S)-, -C(O)O-, -C(R 7 )2-、-C(O)N(R 7 )-、-C(S)N(R 7 )-or-N(R 7 );

[0038] R 6 are independently H, alkyl, hydroxy, hydroxyalkyl, alkoxy, amino, aminoalkyl, alkylamino, thiol, thiolalkyl, or N + (R 7 )3-alkylene-Q-;

[0039] Each R 8 are independently H, alkyl, hydroxyalkyl, amino, aminoalkyl, thiol or thiolalkyl, or two R 8 Together with nitrogen atoms, they can form a ring;

[0040] q is 0, 1, 2, 3, 4, or 5; and

[0041] p is 0, 1, 2, 3, 4 or 5.

[0042] In some embodiments, Y is hydroxy,

[0043] In some embodiments, ionizable lipids of formula (IA-1) or (IA-2) are disclosed:

[0044] a pharmaceutically acceptable salt thereof or a stereoisomer of any of the foregoing,

[0045] in

[0046] is a cyclic or heterocyclic moiety;

[0047] A does not exist, it is -O-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-、N(R 7 )C(O)NH-, -S-, -SS- or a divalent heterocycle;

[0048] X does not exist, it is -O-, -C(O), -N(R 7 )-, -O-alkylene-; -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-or-S-;

[0049] Z does not exist, it is -O-, -N(R 7 )-, -O-alkylene-; -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-or-S-;

[0050] Each R 7 is independently H, alkyl, alkenyl, cycloalkyl, hydroxyalkyl, or aminoalkyl;

[0051] Each M is independently a biodegradable moiety;

[0052] R 30 、R 40 、R 50 、R 60 、R 100 、R 110 and R 120 Each of the C1-C ... 16 Branched or unbranched alkyl or C1-C 16 branched or unbranched alkenyl;

[0053] R 90 It is C1-C15 Branched or unbranched alkyl, C1-C 15 branched or unbranched alkenyl or cycloalkyl or substituted cycloalkyl; and

[0054] t is 0, 1, 2, or 3;

[0055] t1 is an integer from 0 to 10;

[0056] l is an integer from 1 to 10;

[0057] m is an integer from 1 to 10; and

[0058] W is hydroxy, hydroxyalkyl, or one of the following moieties:

[0059]

[0060] in

[0061] Q is -O-, -C(O)-, -C(S)-, -C(O)O-, -C(R 7 )2-、-C(O)N(R 7 )-、-C(S)N(R 7 )-or-N(R 7 );

[0062] Each R 6 are independently H, alkyl, hydroxy, hydroxyalkyl, alkoxy, amino, aminoalkyl, alkylamino, thiol, thiolalkyl, or N + (R 7 )3-alkylene-Q-;

[0063] Each R 8 are independently H, alkyl, hydroxyalkyl, amino, aminoalkyl, thiol or thiolalkyl, or two R 8 Together with nitrogen atoms, they can form a ring;

[0064] q is 0, 1, 2, 3, 4, or 5; and

[0065] p is 0, 1, 2, 3, 4 or 5.

[0066] In some embodiments, With formula structure, where:

[0067] each of G1, G2, G3, G4, G5, G6, and G7 is independently C(R′)(R″), O, or N, provided that no more than two of G1-G7 are O or N;

[0068] R' and R" are each independently absent and are H, alkyl, or two R's from two adjacent G's that together form a second 5- to 7-membered cyclic ring or heterocycle; and

[0069] n1 and n2 are each independently 0 or 1.

[0070] In some embodiments, Selected from pyrrolidine, piperidine, piperazine, cyclohexane, cyclopentane, tetrahydrofuran, tetrahydropyran, morpholine and dioxane.

[0071] In some embodiments, Is a 5 to 7 membered monocyclic ring. In some embodiments, is a 5- to 7-membered monocyclic, cycloalkane ring. In some embodiments, It is a 5- to 7-membered monocyclic or heterocyclic ring.

[0072] In some embodiments, It is bicyclic or tricyclic, ie, contains two or more rings, such as fused rings.

[0073] In some embodiments, X is absent, -O-, or -C(O)-.

[0074] In some embodiments, Z is —O—, —C(O)O—, or —OC(O)—.

[0075] In some embodiments, R 30 、R 40 、R 50 and R 60 Each of is H or a C1-C4 branched or unbranched alkyl group.

[0076] In some embodiments, R 30 、R 40 、R 50 and R 60 Each of is H.

[0077] In some embodiments, R 70 and R 80 Each of is H; and R 90 It is C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 90 It is C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 90 It is C1-C 15 In some embodiments, R 90 It is C1-C12 Branched or unbranched alkyl groups.

[0078] In some embodiments, R 70 is H; and R 80 and R 90 Each of C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 80 and R 90 Each of C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 80 and R 90 Each of C1-C 15 In some embodiments, R 80 and R 90 Each of C1-C 12 In some embodiments, R 80 and R 90 Each of the groups is independently a C1-C8 branched or unbranched alkyl group.

[0079] In some embodiments, R 100 is H; and R 110 and R 120 Each of C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 110 and R 120 Each of C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 110 and R 120 Each of C1-C 15 In some embodiments, R 110 and R 120 Each of C1-C 12 In some embodiments, R 110 and R 120 Each of the groups is independently a C1-C8 branched or unbranched alkyl group.

[0080] In some embodiments, l is 3 to 10, 3 to 7, or 4 to 7. In some embodiments, l is 4, 5, 6, 7, 8, 9, or 10. In some embodiments, l is 4, 5, 6, or 7.

[0081] In some embodiments, m is 4 to 10, 5 to 8, 1 to 7, 3 to 7, or 1 to 5. In some embodiments, m is 4, 5, 6, 7, 8, 9, or 10. In some embodiments, m is 3, 4, or 5. In some embodiments, m is 5, 6, 7, or 8.

[0082] In some embodiments, M is -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-、-C(OR 13 )-O-、-C(O)O(CH2) r -、-C(O)N(R 7 )(CH2) r -OR-C(OR 13 )-O-(CH2) r -, where each R 7 R is independently H, alkyl, alkenyl, cycloalkyl, hydroxyalkyl or aminoalkyl; 13 Is it a branched or unbranched C3-C 10 alkyl; and r is 1, 2, 3, 4 or 5.

[0083] Another aspect of the present invention relates to a lipid composition comprising a lipid compound of any of the formulas disclosed herein, e.g., Formula (I), (IA-1), (IA-2), (IIA)-(IIC), (IIA-1), (IIIA)-(IIIE), (IIIC-1), (IVA-1)-(IVA-3), (IVC-1)-(IVC-2), and (VC-1)-(VC-6), wherein the lipid composition is a lipid nanoparticle (LNP). In some embodiments, the lipid composition further comprises a second lipid. In some embodiments, the lipid composition comprises the compound and the second lipid at a ratio of about 1:1. In some embodiments, the second lipid is a cationic, anionic, ionizable, or zwitterionic lipid.

[0084] Also disclosed herein are pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a lipid composition as described herein, wherein the lipid composition comprises one or more lipid compounds selected from the group consisting of ionizable lipids of Formula (I), (IA-1), (IA-2), (IIA)-(IIC), (IIA-1), (IIIA)-(IIIE), (IIIC-1), (IVA-1)-(IVA-3), (IVC-1)-(IVC-2), and (VC-1)-(VC-6). The pharmaceutical composition may further comprise a therapeutic agent. In some embodiments, the pharmaceutical composition further comprises one or more components selected from the group consisting of neutral lipids, charged lipids, steroids, and polymer-conjugated lipids. Such compositions can be used to form lipid nanoparticles for delivery of therapeutic agents.

[0085] Another aspect of the present disclosure provides a method for delivering a therapeutic agent to a subject (e.g., a patient) in need thereof, the method comprising administering to the subject (e.g., a patient) a pharmaceutical composition comprising a lipid nanoparticle composition and the therapeutic agent, the lipid nanoparticle composition comprising a lipid compound of Formula (I), (IA-1), (IA-2), (IIA)-(IIC), (IIA-1), (IIIA)-(IIIE), (IVA-1)-(IVA-3), (IVC-1)-(IVC-2), and (VC-1)-(VC-6), pharmaceutically acceptable salts thereof, and / or stereoisomers of any one of the foregoing. In some embodiments, the method further comprises preparing a lipid nanoparticle composition comprising a lipid compound of Formula (I), (IA-1), (IA-2), (IIA)-(IIC), (IIA-1) and (IIIA)-(IIIIC), (IVA-1)-(IVA-3), (IVC-1)-(IVC-2), and (VC-1)-(VC-6), a pharmaceutically acceptable salt thereof, and / or a stereoisomer of any of the foregoing, and a therapeutic agent.

[0086] Another aspect of the present disclosure provides extrahepatic delivery of a therapeutic agent to a subject (e.g., to the pancreas, spleen, or lung), comprising administering to the subject a pharmaceutical composition comprising a lipid nanoparticle composition comprising a lipid compound of Formula (I), (IA-1), (IA-2), (IIA)-(IIC), (IIA-1), (IIIA)-(IIIE), (IVA-1)-(IVA-3), (IVC-1)-(IVC-2), and (VC-1)-(VC-6), pharmaceutically acceptable salts thereof, and / or stereoisomers of any of the foregoing, and the therapeutic agent. In some embodiments, the spleen to liver ratio of the total therapeutic agent administered to the subject is at least 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, the spleen to liver ratio of the total therapeutic agent administered to the subject is at least 1. In some embodiments, the spleen to liver ratio of the total therapeutic agent administered to the subject is at least 5.

[0087] These and other aspects of the disclosure will be apparent upon reference to the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0088] Figure 1 Figure 5 represents the mean spleen:liver radiance ratio (p / s / cm2) for various exemplary lipid nanoparticle compositions containing exemplary lipid compounds (LNP 2230, LNP 2231) compared to comparative lipid nanoparticle compositions containing C12-200 and MC3, respectively, based on EPO levels determined by in vivo bioluminescent imaging of each lipid nanoparticle composition, as described in Example 7. 2 / sr). DETAILED DESCRIPTION

[0089] definition

[0090] As used herein, the following terms have the meanings ascribed to them unless otherwise specified.

[0091] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0092] As used in this specification and claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0093] Throughout this specification and claims, unless the context requires otherwise, the word "comprise" and variations such as "comprises" and "comprising" are to be interpreted in an open and inclusive sense, i.e., "including, but not limited to."

[0094] The phrase "induces expression of a desired protein" refers to the ability of a nucleic acid to increase the expression of a desired protein. To examine the extent of protein expression, a test sample (e.g., a cell sample in culture expressing the desired protein) or a test mammal (e.g., a mammal, such as a human or animal) model, such as a rodent (e.g., mouse) or non-human primate (e.g., monkey) model, is contacted with a nucleic acid (e.g., a nucleic acid in combination with a lipid of the present disclosure). The expression of the desired protein in the test sample or test animal is compared to the expression of the desired protein in a control sample (e.g., a cell sample in culture expressing the desired protein) or a control mammal (e.g., a mammal, such as a human or animal) model (e.g., a rodent (e.g., mouse) or non-human primate (e.g., monkey) model) that is not contacted with or administered with the nucleic acid. When the desired protein is present in the control sample or control mammal, the expression of the desired protein in the control sample or control mammal can be assigned a value of 1.0. In certain embodiments, when the ratio of the protein expression level of the desired protein in the test sample or test mammal to the control sample or control mammal is greater than 1 (e.g., about 1.1, 1.5, 2.0, 5.0, or 10.0), the expression of the desired protein is induced. When there is no desired protein in the control sample or control mammal, when any measurable level of the protein desired in the test sample or test mammal is detected, the expression of the desired protein is induced. One of ordinary skill in the art will appreciate that it is suitable for determining the protein expression level in the sample, such as dot blots, northern blotting, in situ hybridization, ELISA, immunoprecipitation, enzyme function, and phenotypic assays or based on assays that can produce fluorescence or luminous reporter proteins under appropriate conditions.

[0095] The phrase "inhibits the expression of a target gene" refers to the ability of a nucleic acid to silence, reduce, or inhibit the expression of a target gene. To examine the extent of gene silencing, a test sample (e.g., a cell sample in culture expressing the target gene) or a test mammalian (e.g., mammalian, such as a human or animal) model, such as a rodent (e.g., mouse) or non-human primate (e.g., monkey) model, is contacted with a nucleic acid that silences, reduces, or inhibits the expression of the target gene. The expression of the target gene in the test sample or test animal is compared to the expression of the target gene in a control sample (e.g., a cell sample in culture expressing the target gene) or a control mammalian (e.g., mammalian, such as a human or animal) model (e.g., rodent (e.g., mouse) or non-human primate (e.g., monkey) model) that is not contacted with or administered with the nucleic acid. The expression of the target gene in the control sample or control mammal can be assigned a value of 100%. In some embodiments, silencing, inhibition or reduction of target gene expression is achieved when the level of target gene expression in the test sample or test mammal is about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5% or 0% relative to the level of target gene expression in a control sample or control mammal. In other words, the nucleic acid is capable of silencing, reducing or inhibiting the expression of the target gene in the test sample or test mammal by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% relative to the level of target gene expression in a control sample or control mammal that has not been contacted with or administered the nucleic acid. Suitable assays for determining target gene expression levels include, but are not limited to, examining protein or mRNA levels using techniques known to those of skill in the art, such as dot blots, Northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, and phenotypic assays known to those of skill in the art.

[0096] An "effective amount" or "therapeutically effective amount" of an active or therapeutic agent, such as a therapeutic nucleic acid, is an amount sufficient to produce a desired effect, e.g., an increase or inhibition of target sequence expression compared to normal expression levels detected in the absence of the nucleic acid. An increase in target sequence expression is achieved when any measurable level is detected in the absence of expression product that is not present in the absence of the nucleic acid. An increase in expression is achieved when the fold increase in the value obtained with the nucleic acid, such as mRNA, relative to a control, is about 1.05, 1.1, 1.2, 1.3, 1.4, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, 250, 500, 750, 1000, 5000, 10000 or greater, where the expression product is present at a certain level prior to contact with the nucleic acid. Inhibition of target gene or target sequence expression is achieved when the value obtained relative to a control nucleic acid, such as an antisense oligonucleotide, is about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%), 15%), 10%), 5%) or 0%. Suitable assays for measuring the expression of a target gene or target sequence include, for example, examining protein or RNA levels using techniques known to those skilled in the art, such as dot blots, northern blotting, in situ hybridization, ELISA, immunoprecipitation, enzyme function, fluorescence or luminescence of a suitable reporter protein, and phenotypic assays known to those skilled in the art.

[0097] As used herein, the term "nucleic acid" refers to a polymer of deoxyribonucleotides or ribonucleotides containing at least two single-stranded or double-stranded forms, and includes DNA, RNA, and hybrids thereof. DNA can be in the form of antisense molecules, plasmid DNA, cDNA, PCR products, or vectors. RNA can be in the form of small hairpin RNA (shRNA), messenger RNA (mRNA), antisense RNA, miRNA, micRNA, multivalent RNA, Dicer substrate RNA, or viral RNA (vRNA), and combinations thereof. Nucleic acid includes nucleic acids containing known nucleotide analogs or modified backbone residues or bonds, which are synthetic, naturally occurring, and non-naturally occurring, and have binding properties similar to reference nucleic acids. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methylphosphonates, chiral-methylphosphonates, 2'-O-methyl ribonucleotides, and peptide-nucleic acids (PNAs). Unless otherwise specifically limited, the term encompasses nucleic acids with binding properties similar to reference nucleic acids, containing known analogs of natural nucleotides. Unless otherwise indicated, specific nucleic acid sequence also implicitly encompasses variants (e.g., degenerate codon substitutions), alleles, orthologs, single nucleotide polymorphisms, and complementary sequences of its conservative modifications, as well as sequences clearly indicated. Specifically, degenerate codon substitutions can be achieved by generating a sequence in which the third position of one or more selected (or all) codons is replaced by mixed bases and / or deoxyinosine residues (Batzer et al., Nucleic Acids Res., 19:5081 (1991); Ohtsuka et al., J. Biol. Chem., 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes, 8:91-98 (1994)). "Nucleotide" contains sugar deoxyribose (DNA) or ribose (RNA), bases, and phosphate groups. Nucleotides are linked together by phosphate groups.

[0098] "Bases" include purines and pyrimidines, which further include the natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs; as well as synthetic derivatives of purines and pyrimidines, which include but are not limited to modifications that place new reactive groups such as but not limited to amines, alcohols, thiols, carboxylates, and alkyl halides.

[0099] The term "gene" refers to a nucleic acid (eg, DNA or RNA) sequence that includes a partial-length or full-length coding sequence necessary for producing a polypeptide or precursor polypeptide.

[0100] As used herein, "gene product" refers to the product of a gene, such as an RNA transcript or a polypeptide.

[0101] The term "lipid" refers to a group of organic compounds that include, but are not limited to, esters of fatty acids and are generally characterized by being poorly soluble in water but soluble in many organic solvents. They are generally divided into at least three categories: (1) "simple lipids," which include fats and oils as well as waxes; (2) "compound lipids," which include phospholipids and glycolipids; and (3) "derivative lipids," such as steroids.

[0102] "Steroids" are compounds that contain the following carbon skeleton: A non-limiting example of a steroid is cholesterol.

[0103] As used herein, the term "compound" is meant to encompass all isomers and isotopes of the depicted structure, all pharmaceutically acceptable salts, solvates, or hydrates thereof, and all crystal forms (e.g., crystal polymorphs), mixtures of crystal forms, or anhydrides or hydrates thereof.

[0104] "Isotopes" are atoms with the same atomic number but different mass numbers (caused by the different number of neutrons in the nucleus). For example, isotopes of hydrogen include tritium (3H) and deuterium (2H).

[0105] "Isomers". The compounds described herein, or pharmaceutically acceptable salts thereof, may include all isomers, such as geometric isomers, optical isomers based on asymmetric carbons, stereoisomers, tautomers, and the like. For example, a compound may contain one or more stereocenters and thus may give rise to geometric isomers (e.g., a double bond gives rise to geometric E / Z isomers), enantiomers, diastereomers (e.g., enantiomers (i.e., (+) or (-)) or cis / trans isomers), and other stereoisomeric configurations that may be defined in terms of absolute stereochemistry as (R)- or (S)-, such as sugar isomers, or as (D)- or (L)-, such as amino acids, and the like. The present disclosure is intended to encompass all such possible isomers and their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques (e.g., chromatography and fractional crystallization). Conventional techniques for preparing / isolating individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). Enantiomeric and stereoisomeric mixtures of compounds and methods of resolving them into their component enantiomers or stereoisomers are well known. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise indicated, it is intended that the compounds encompass both E and Z geometric isomers. Likewise, all tautomeric forms are intended to be encompassed.

[0106] The terms "crystalline polymorph," "polymorph," or "crystal form" refer to crystal structures in which a compound (or a salt or solvate thereof) can crystallize under different crystal packing arrangements, all of which have the same elemental composition. Different crystal forms typically have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvent, crystallization rate, storage temperature, and other factors may cause one crystal form to dominate. Crystal polymorphs of a compound can be prepared by crystallization under different conditions. Crystallization of the compounds disclosed herein may produce solvates.

[0107] As used herein, the term "solvate" refers to an aggregate comprising one or more molecules of an ionizable lipid of the present disclosure and one or more molecules of a solvent. The solvent may be water, in which case the solvate may be a hydrate, including monohydrates, dihydrates, hemihydrates, sesquihydrates, trihydrates, tetrahydrates, and the like. Alternatively, the solvent may be an organic solvent.

[0108] As used herein, " ionizable lipid " refers to lipid that can be charged. In certain embodiments, ionizable lipid comprises one or more positively charged amine groups. In certain embodiments, ionizable lipid is ionizable so that it can exist in a positively charged or neutral form according to pH. The ionization of ionizable lipid affects the surface charge of the lipid nanoparticles including the ionizable lipid under different pH conditions. The surface charge of lipid nanoparticles may affect its plasma protein absorption, blood clearance and tissue distribution (Semple, SC et al., " Advanced Drug Delivery Review (Adv.Drug Deliv Rev) " 32:3-17 (1998)) and its ability to form a non-double-layer structure of endosome dissolution (Hafez, IM et al., " Gene Ther (Gene Ther) " 8:1188-1196 (2001)), which may affect the intracellular delivery of nucleic acid.

[0109] The term "polymer-conjugated lipid" refers to a molecule that includes both a lipid portion and a polymer portion. A non-limiting example of a polymer-conjugated lipid is a PEGylated lipid. The term "PEGylated lipid" refers to a molecule that includes both a lipid portion and a polyethylene glycol portion. PEGylated lipids are known in the art and include, for example, 1-(monomethoxy-polyethylene glycol)-2,3-dimyristoylglycerol (PEG-DMG) and the like. As used herein, the terms "PEG-lipid" or "PEGylated lipid" are interchangeable and refer to a lipid that includes a polyethylene glycol component.

[0110] The term "neutral lipid" refers to any lipid that exists in an uncharged or neutral zwitterionic form at a selected pH. At physiological pH, such lipids include, but are not limited to, phosphatidylcholines such as 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-5n-glycero-3-phosphocholine (DPPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC); phosphatidylethanolamines such as 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE); sphingomyelin (SM); ceramides; and steroids such as sterols; and their derivatives. Neutral lipids can be of synthetic or natural origin.

[0111] As used herein, "phospholipid" is a lipid comprising a phosphoric acid moiety and one or more carbon chains (such as unsaturated fatty acid chains). Phospholipids can comprise one or more multiple bonds (e.g., double bonds or triple bonds) (one or more unsaturated groups). Specific phospholipids can promote fusion with membranes. For example, cationic phospholipids can interact with one or more negatively charged phospholipids of membranes (e.g., cell membranes or intracellular membranes). The fusion of phospholipids with membranes can allow one or more elements containing lipid compositions to pass through the membrane, thereby allowing, for example, one or more elements to be delivered to cells.

[0112] As used herein, the term "liposome" refers to a composition comprising an outer lipid layer membrane (e.g., a single lipid bilayer referred to as a unilamellar liposome or a plurality of lipid bilayers referred to as a multilamellar liposome) around an internal water space that may contain cargo. See, for example, Cullis et al., Biochim. Biophys Acta, 559: 399-420 (1987), which is incorporated herein by reference in its entirety. The diameter of unilamellar liposomes is typically in the range of about 20 to about 400 nanometers (nm), about 50 to about 300 nm, about 100 to about 200 nm, or about 300 to about 400 nm. The diameter of multilamellar liposomes is typically in the range of about 1 to about 10 μm, and can include 2 to hundreds of concentric lipid bilayers alternating with aqueous layers.

[0113] The term "lipid nanoparticle" refers to a particle having at least one dimension of nanometer order (e.g., 1-1,000 nm) and comprising one or more compounds of formula (I). In some embodiments, lipid nanoparticles comprising one or more compounds of formula (I), pharmaceutically acceptable salts thereof, and / or stereoisomers of any of the foregoing are contained in a composition that can be used to deliver therapeutic agents such as nucleic acids (e.g., mRNA) to target sites of interest (e.g., cells, tissues, organs, tumors, etc.). In some embodiments, lipid nanoparticles comprise one or more compounds of formula (I), pharmaceutically acceptable salts thereof, and / or stereoisomers of any of the foregoing, and nucleic acids. In some embodiments, lipid nanoparticles comprise one or more compounds of formula (I), pharmaceutically acceptable salts thereof, and / or stereoisomers of any of the foregoing, and nucleic acids and one or more other lipids selected from neutral lipids, charged lipids, steroids, and polymer-conjugated lipids. In some embodiments, therapeutic agents such as nucleic acids can be encapsulated in the lipid portion of the lipid nanoparticle or in the aqueous space enclosed by some or all of the lipid portion of the lipid nanoparticle, thereby protecting them from enzymatic degradation or other undesirable effects induced by the mechanisms of the host organism or cell, such as an adverse immune response.

[0114] In some embodiments, the lipid nanoparticles have an average diameter of about 30 nm to about 150 nm, about 40 nm to about 150 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, about 70 nm to about 100 nm, about 80 nm to about 100 nm, about 90 nm to about 100 nm, about 70 to about 90 nm, about 80 nm to about 90 nm, about 70 nm to about 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm and are substantially non-toxic. In some embodiments, the nucleic acid is resistant to degradation by nucleases in aqueous solution when present in the lipid nanoparticle.Lipid nanoparticles comprising nucleic acids and methods for preparing the same are disclosed, for example, in U.S. Patent Publication Nos. 2004 / 0142025, 2007 / 0042031 and PCT Publication Nos. WO 2013 / 016058 and WO 2013 / 086373, 8,569,256, 5,965,542 and U.S. Patent Publication Nos. 2016 / 0199485, 2016 / 0009637, 2015 / 0273068, 2015 / 0265708, 2015 / 0203446, 2015 / 0005363, 2014 / 0308304, 2014 / 0200257, 2013 / 0 No. 086373, No. 2013 / 0338210, No. 2013 / 0323269, No. 2013 / 0245107, No. 2013 / 0195920, No. 2013 / 0123338, No. 2013 / 0022649, No. 2013 / 0017223, No. 2012 / 0295832, No. 2012 / 0183581, No. 2012 / 0172411, No. 2012 / 00278 03, 2012 / 0058188, 2011 / 0311583, 2011 / 0311582, 2011 / 0262527, 2011 / 0216622, 2011 / 0117125, 2011 / 0091525, 2011 / 0076335, 2011 / 0060032, 2010 / 0130588, 2007 / 0042031, Nos. 2006 / 0240093, 2006 / 0083780, 2006 / 0008910, 2005 / 0175682, 2005 / 017054, 2005 / 0118253, 2005 / 0064595, 2004 / 0142025, 2007 / 0042031, 1999 / 009076, and PCT Publication Nos. WO99 / 39741, WO 2017 / 117528, WO 2017 / 004143, WO 2017 / 075531, WO 2015 / 199952, WO 2014 / 008334, WO 2013 / 086373, WO 2013 / 086322, WO 2013 / 016058, WO 2013 / 086373, WO 2011 / 141705, and WO 2001 / 07548, the entire disclosures of which are incorporated herein by reference in their entirety for all purposes.

[0115] As used herein, the term "size" refers to the hydrodynamic diameter of a population of lipid nanoparticles. Measurement of the size of a lipid nanoformulation can be used to indicate the size and population distribution (polydispersity index, PDI) of the composition.

[0116] As used herein, the "polydispersity index" is the ratio between the weight average molar mass and Mn, which is the number average molar mass, and describes the uniformity of the particle size distribution of a system. Small values, such as less than 0.3, indicate a narrow particle size distribution.

[0117] In some embodiments, the polydispersity index of lipid composition can be about 0 to about 0.25, such as 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24 or 0.25. In some embodiments, the polydispersity index of lipid composition can be about 0.10 to about 0.20.

[0118] As used herein, the term "apparent pKa" refers to the pH at which 50% of a lipid nanoformulation (e.g., LNP) is protonated. This can be used as an indicator of the pH range at which a lipid nanoformulation (e.g., LNP) will be protonated and thereby initiate the endosomal escape process during nucleotide delivery.

[0119] As used herein, the term "zeta potential" refers to the electrokinetic potential of lipids, for example, in lipid nanoformulations (e.g., LNP compositions). The zeta potential can describe the surface charge of the LNP composition. The zeta potential can be used to predict organ tropism and potential interactions with serum proteins.

[0120] The zeta potential of lipid composition (for example, liposome or LNP) can be used for the zeta potential of indicator composition.In certain embodiments, zeta potential can describe the surface charge of liposome or LNP.Lipid composition (for example, liposome or LNP) with relatively low electric charge (positive charge or negative charge) is normally desired, because the material of higher electric charge may have undesirable interaction with other element in cell, tissue and body. In some embodiments, the zeta potential of the liposomes or LNPs can be about -10 mV to about +20 mV, about -10 mV to about +15 mV, about -10 mV to about +10 mV, about -10 mV to about +5 mV, about -10 mV to about 0 mV, about -10 mV to about -5 mV, about -5 mV to about +20 mV, about -5 mV to about +15 mV, about -5 mV to about +10 mV, about -5 mV to about +5 mV, about -5 mV to about 0 mV, about 0 mV to about +20 mV, about 0 mV to about +15 mV, about 0 mV to about +10 mV, about 0 mV to about +5 mV, about +5 mV to about +20 mV, about +5 mV to about +15 mV, or about +5 mV to about +10 mV.

[0121] As used herein, "encapsulated" by lipids refers to that a therapeutic agent such as a nucleic acid (e.g., mRNA) is completely or partially encapsulated by lipid nanoparticles. In some embodiments, the nucleic acid (e.g., mRNA) is completely encapsulated in the lipid nanoparticles.

[0122] As used herein, " encapsulation efficiency " or " retention efficiency " refer to the percentage of encapsulated goods (for example, therapeutic agent and / or prophylactic agent) that is successfully incorporated (for example, be encapsulated or otherwise associated) into lipid composition (for example, LNP or liposome) relative to the initial total amount of the therapeutic agent and / or prophylactic agent provided. For example, if 97 mg of the therapeutic agent and / or prophylactic agent of the total 100 mg initially provided are encapsulated in the lipid composition, the encapsulation efficiency can be 97%. Encapsulation efficiency can be used to indicate the efficiency that encapsulated goods (for example, nucleic acid molecules) are loaded into the lipid composition using specific formulation and formulation.

[0123] The encapsulation efficiency of goods such as protein and / or nucleic acid describes relative to the initial amount provided, and is encapsulated after preparation or otherwise associated with lipid composition (for example, liposome or LNP) protein and / or the amount of nucleic acid. Encapsulation efficiency expectation is high (for example, at least 70%, 80%, 90%, 95%, nearly 100%). For example, the amount of protein or nucleic acid in the solution containing liposome or LNP before and after decomposing liposome or LNP with one or more organic solvents or detergents can be measured encapsulation efficiency. Anion exchange resin can be used for measuring the amount of free protein or nucleic acid (for example, RNA) in solution. Fluorescence can be used for measuring the amount of free protein and / or nucleic acid (for example, RNA) in solution. For liposomes or LNPs as described herein, the encapsulation efficiency of proteins and / or nucleic acids can be at least 50%, for example, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In some embodiments, the encapsulation efficiency can be at least 80%. In some embodiments, the encapsulation efficiency can be at least 90%. In some embodiments, the encapsulation efficiency can be at least 95%.

[0124] "Serum stable" with respect to nucleic acid-lipid nanoparticles means that the nucleic acid is not significantly degraded after exposure to serum or nuclease assays that would significantly degrade free DNA or RNA. Suitable assays include, for example, standard serum assays, DNase assays, or RNase assays.

[0125] Some administration techniques can enable systemic delivery of certain agents, but not other agents. "Systemic delivery" means that a useful (e.g., therapeutic) amount of an agent is delivered to most parts of the body. Systemic delivery of lipid nanoparticles can be performed by any means known in the art (including, for example, intravenous, intra-arterial, subcutaneous, and intraperitoneal delivery). In some embodiments, systemic delivery of lipid nanoparticles is by intravenous delivery.

[0126] As used herein, "local delivery" refers to the direct delivery of an agent to a target site within an organism. For example, an agent can be delivered locally by direct injection into a disease site (e.g., a tumor), other target sites (e.g., an inflammatory site), or a target organ (e.g., the liver, heart, pancreas, kidney, etc.). Local delivery can also include topical administration or local injection techniques, such as intramuscular, subcutaneous, or intradermal injection. Local delivery does not exclude systemic pharmacological effects.

[0127] As used herein, "method of administration" can include systemic delivery and local delivery. "Systemic delivery" means that the medicament of useful (such as treatment) amount is delivered to most parts of the body. The systemic delivery of liposomes or LNP can be carried out by any means known in the art (including, for example, intravenous, intraarterial, intramuscular, intradermal, subcutaneous and intraperitoneal delivery). In certain embodiments, the systemic delivery of lipid nanoparticles is by intravenous delivery. As used herein, "local delivery" refers to that the medicament is directly delivered to the target site in the organism. For example, the medicament can be delivered locally by direct injection into the disease site (such as tumor), other target sites (such as inflammation site) or target organs (such as liver, heart, pancreas, kidney, etc.). Local delivery can also include local application or local injection technology, such as intramuscular, subcutaneous or intradermal injection. Local delivery does not exclude systemic pharmacological effects.

[0128] As used herein, the term "polypeptide" or "polypeptide of interest" refers to a polymer of amino acid residues, typically joined by peptide bonds, which may be produced naturally (eg, isolated or purified) or synthetically.

[0129] " Nucleic acid " is intended to define oligonucleotide or polynucleotide sequence. Non-limiting examples of oligonucleotide or polynucleotide are DNA, plasmid DNA, self-amplification RNA, mRNA, siRNA and tRNA. The term also encompasses RNA / DNA hybrids. Nucleotide is typically connected in nucleic acid by a phosphodiester bond, but the term "nucleic acid" also encompasses nucleic acid analogs with other types of keys or backbones (e.g., phosphoramide, phosphorothioate, phosphorodithioate, O-methylphosphoramidite, morpholino, locked nucleic acid (LNA), glycerol nucleic acid (GNA), threose nucleic acid (TNA) and peptide nucleic acid (PNA) keys or backbones, etc.). Nucleic acid can be single-stranded, double-stranded or contain the part of both single-stranded and double-stranded sequences. Nucleic acids can contain any combination of deoxyribonucleotides and ribonucleotides, and any combination of bases, including, for example, adenine, thymine, cytosine, guanine, uracil, and modified or non-canonical bases (including, for example, hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5-methylcytosine, and 5-hydroxymethylcytosine).

[0130] As used herein, "RNA" refers to ribonucleic acid, which can be naturally occurring or non-naturally occurring. For example, RNA can contain modified and / or non-naturally occurring components, such as one or more nucleobases, nucleosides, nucleotides, or linkers. RNA can contain a cap structure, a chain-terminating nucleoside, a stem-loop, a polyA sequence, and / or a polyadenylation signal. RNA can have a nucleotide sequence that encodes a polypeptide of interest. For example, RNA can be messenger RNA (mRNA). Translation of an mRNA encoding a specific polypeptide, such as in vivo translation of an mRNA in a mammalian cell, can produce the encoded polypeptide. RNA can be selected from the non-limiting group consisting of small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA), mRNA, and mixtures thereof.

[0131] "Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, having, for example, one to twenty-four carbon atoms (C1-C 24 alkyl), four to twenty carbon atoms (C4-C 20 Alkyl), six to sixteen carbon atoms (C6-C 16 alkyl), six to nine carbon atoms (C6-C9 alkyl), one to fifteen carbon atoms (C1-C 15 alkyl), one to twelve carbon atoms (C1-C 12 The alkyl group may be a substituted alkyl group, a C1-C8 alkyl group, a C1-C6 ...

[0132] "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain connecting the rest of the molecule to a radical, consisting solely of carbon and hydrogen, having, for example, one to twenty-four carbon atoms (C1-C 24 Alkylene), one to fifteen carbon atoms (C1-C 15 Alkylene), one to twelve carbon atoms (C1-C 12The alkylene group may be a group consisting of one to eight carbon atoms (C1-C8 alkylene), one to six carbon atoms (C1-C6 alkylene), two to four carbon atoms (C2-C4 alkylene), or one to two carbon atoms (C1-C2 alkylene), such as methylene, ethylene, propylene, n-butylene, vinylene, propenyl, n-butenyl, propynylene, n-butynylene, and the like. The alkylene chain is attached to the rest of the molecule through a single or double bond and to the free radical through a single or double bond. The points of attachment of the alkylene chain to the rest of the molecule and to the free radical can be through one carbon or any two carbons within the chain.

[0133] The term "alkenyl" refers to a straight or branched hydrocarbon chain having one or more double bonds. Unless otherwise indicated, "alkenyl" generally refers to a C2-C8 alkenyl (e.g., C2-C6 alkenyl, C2-C4 alkenyl, or C2-C3 alkenyl). Typical examples of alkenyl include, but are not limited to, allyl, propenyl, 2-butenyl, 3-hexenyl, and 3-octenyl.

[0134] The term "alkynyl" refers to a straight or branched hydrocarbon chain containing 2 to 8 carbon atoms and is characterized by having one or more triple bonds. Unless otherwise indicated, "alkynyl" generally refers to a C2-C8 alkynyl (e.g., C2-C6 alkynyl, C2-C4 alkynyl, or C2-C3 alkynyl). Some examples of typical alkynyl groups are ethynyl, 2-propynyl, and 3-methylbutynyl, as well as propargyl. 2 and sp 3 The carbon can optionally serve as the point of attachment for alkenyl and alkynyl groups, respectively.

[0135] As used herein, the term "cycloalkyl" or "cyclyl" includes saturated and partially unsaturated, but not aromatic, cyclic hydrocarbon groups having 3 to 12 carbons, such as 3 to 8 carbons, and, for example, 3 to 6 carbons, wherein the cycloalkyl group may additionally be optionally substituted. Cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.

[0136] The term "heteroaryl" or "heteroar-" refers to an aromatic 5-8 membered monocyclic ring system, 8-12 membered bicyclic ring system, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, the heteroatoms being selected from O, N, or S (e.g., having carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted with substituents. The term also encompasses groups in which a heteroaromatic ring is fused to one or more aryl, cycloalkyl, or heterocyclyl rings, wherein the radical or point of attachment is on the heteroaromatic ring. Examples of heteroaryl groups include pyrrolyl, pyridinyl, pyridazinyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, pyrazinyl, indolizinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, isothiazolyl, thiadiazolyl, purinyl, naphthyridinyl, pteridinyl, isoindolyl, benzothiophenyl, benzofuranyl, dibenzofuranyl, indazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one, and the like.

[0137] The term "heterocyclyl," "heterocycle," "heterocyclic radical," or "heterocyclic ring" refers to a 5-8 membered monocyclic ring system, an 8-12 membered bicyclic ring system, or an 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, the heteroatoms being selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S, if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2, or 3 atoms of each ring may be substituted with substituents. As used herein, the term generally encompasses both non-aromatic rings and aromatic rings (e.g., typically covered by heteroaryl). The term also encompasses groups in which a heterocycle is fused to one or more aryl, cycloalkyl, or heterocyclyl rings. When used in reference to a ring atom of a heterocyclic ring, the term "nitrogen" includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur, or nitrogen, the nitrogen can be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or +NR (as in N-substituted pyrrolidinyl).

[0138] Examples of heterocyclic groups include triazolyl, tetrazolyl, piperazinyl, pyrrolidinyl, dioxanyl, dioxolanyl, diazacyclyl, oxazacyclyl, thiazacyclyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, quinuclidinyl, and the like.

[0139] Examples of heterocyclic groups also include those typical heteroaryl groups such as pyrrolyl, pyridyl, pyridazinyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, furyl, imidazolyl, benzimidazolyl, pyrimidinyl, pyrazinyl, indolizinyl, phenylthio or thienyl, quinolyl, indolyl, thiazolyl, isothiazolyl, thiadiazolyl, purinyl, naphthyridinyl, pteridinyl, isoindolyl, thiazolyl ... indole, benzothiophenyl, benzofuranyl, dibenzofuranyl, indazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolyl, tetrahydroisoquinolyl and pyrido[2,3-b]-1,4-oxazin-3(4H)-one, etc.

[0140] The divalent radicals of alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl are formed by removing one hydrogen atom from an alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl radical, respectively (or by removing two hydrogen atoms from an alkane, alkene, aromatic hydrocarbon, heteroaromatic hydrocarbon, cycloalkane, or heterocycle, respectively).

[0141] For example, the term "bivalent heterocycle" or "divalent heterocycle" refers to a divalent form of a heterocycle, i.e., a bivalent or divalent radical formed by removing one hydrogen atom from a heterocyclyl radical (or by removing two hydrogen atoms from a heterocycle). For example, a bivalent or divalent form of a heterocycle is formed by removing one hydrogen atom from each of two different atoms of the heterocycle. By way of example, a bivalent or divalent form of a 1,2,3, triazole is formed by removing one hydrogen atom from each of two different atoms of the triazole ring (from a carbon atom or a nitrogen atom) and may have structure.

[0142] The term "alkoxy" refers to an -O-alkyl radical.

[0143] The term "aminoalkyl" refers to an alkyl group substituted by an amino group. The term "alkylamino" refers to an amino group substituted by an alkyl group.

[0144] The term "aminocarbonyl" refers to a -C(O)-amino radical.

[0145] As used herein, the term "substituted" refers to any of the above groups (e.g., alkyl, hydroxyalkyl, alkylene, cycloalkyl, cycloalkylene, amino, aminocarbonyl, heterocyclyl, or heteroaryl) in which one or more hydrogen atoms are replaced by a bond with a non-hydrogen atom, such as, but not limited to, a halogen atom, such as F, CI, Br, or I; an oxo group (=O); a hydroxyl group (-OH); an alkoxy group, an alkoxyalkyl group, an aralkyloxy group, an alkyl group such as C1-C 12 Alkyl; cycloalkyl; alkenyl, alkynyl, aryl, aralkylheterocyclyl, heterocyclyl, heteroaryl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, aryloxy, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, aralkyloxycarbonyl, sulfonyl, alkylaminolactam, alkylaminoheteroaryl, alkylaminoheterocyclyl and aminosulfonamide. Exemplary substituents also include: -(C=O)OR; -O(C=O)R; -C(=O)R; -OR; -S(O) x R; -S-SR; -C(=O)SR; -SC(=O)R; -NRR'; -R'C(=O)R; -C(=O)RR'; -RC(=O)R'R"; -OC(=O)RR'; -RC(=O)OR'; -R'S(O) X R"R;-R'S(O) X R; and -S(O) x RR', wherein: R, R' and R" are independently each occurring H, C1-C 15 alkyl or cycloalkyl, heterocyclyl or heteroaryl, and x is 0, 1 or 2. In some embodiments, the substituent is C1-C 12In some embodiments, the substituent is a cycloalkyl group. In some embodiments, the substituent is a halo group, such as fluorine. In some embodiments, the substituent is an oxo group. In some embodiments, the substituent is a hydroxyl group. In some embodiments, the substituent is a hydroxyalkylene group (-R-OH). In some embodiments, the substituent is an alkoxy group (-OR). In some embodiments, the substituent is a carboxyl group. In some embodiments, the substituent is an amino group (-NRR'). Suitable substituents also include divalent substituents on saturated carbon atoms, including but not limited to: =O, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR*, =NOR*, -O(C(R*2))2-3O- or -S(C(R*2))2-3S-, wherein R* is independently selected at each occurrence from hydrogen, substituted or unsubstituted C1-6 alkyl, or an unsubstituted 5-6 membered saturated or partially unsaturated ring, or an aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0146] "Halo" or "halogen" refers to any radical of fluorine, chlorine, bromine or iodine.

[0147] "Optional" or "optionally" (e.g., optionally substituted) means that the subsequently described event or circumstances may or may not occur, and that the description includes instances where the event or circumstances occurs and instances where it does not. For example, "optionally substituted alkyl" means that the alkyl radical may or may not be substituted, and that the description includes both substituted and unsubstituted alkyl radicals.

[0148] The present disclosure is also intended to encompass all pharmaceutically acceptable compounds of all formulae identified herein that are isotopically labeled by replacing one or more atoms with an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 36 C1, 123 I and 125I. These isotopically labeled compounds can be used to help determine or measure the effectiveness of a compound by characterizing, for example, the site or mode of action or binding affinity for a pharmacologically important site of action. Certain isotopically labeled compounds of structure (I), (IA), or (IB), for example, compounds incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies. The radioactive isotope tritium (i.e., 3 H) and carbon 14 (i.e. 14 C) Given its ease of incorporation and readily available detection methods for this purpose.

[0149] Using heavier isotopes (such as deuterium, 2 H) substitutions may offer certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and therefore may be useful in some circumstances.

[0150] Use as 11 C. 18 F. 15 O and 13 Positron emitting isotope substitution such as N can be used in positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotope-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by methods analogous to those described in the preparations and examples shown below using appropriate isotope-labeled reagents in place of the unlabeled reagents previously employed.

[0151] The present disclosure is also intended to encompass the in vivo metabolites of the disclosed compounds. Such products may be produced primarily due to enzymatic processes by, for example, oxidation, reduction, hydrolysis, amidation, esterification, etc. of the administered compound. Therefore, embodiments of the present disclosure include compounds produced by methods comprising administering an ionizable lipid of the present disclosure to a mammal for a period of time sufficient to produce its metabolites. Such products are typically identified in the following manner: a radiolabeled compound of the present disclosure is administered to an animal (such as a rat, mouse, guinea pig, monkey, or human) with a detectable dose, allowing enough time for metabolism to occur, and separating its conversion products from urine, blood, or other biological samples.

[0152] "Pharmaceutically acceptable carriers, diluents or excipients" include, but are not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent or emulsifier that has been approved by the United States Food and Drug Administration as acceptable for use in humans or veterinary medicine.

[0153] "Pharmaceutically acceptable salts" encompass both acid addition salts and base addition salts.

[0154] "Pharmaceutically acceptable acid addition salts" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed from inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, decanoic acid, hexanoic acid, octanoic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, acid), dodecyl sulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactonic acid, gentisic acid, glucoheptanoic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.

[0155] "Pharmaceutically acceptable base addition salts" refer to those salts that retain the biological effectiveness and properties of the free acid and are not biologically or otherwise undesirable. These salts are prepared by adding an inorganic or organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Non-limiting examples of inorganic salts are ammonium salts, sodium salts, potassium salts, calcium salts, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines; substituted amines (including naturally occurring substituted amines); cyclic amines; and basic ion exchange resins such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, denanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, phenethylbenzylamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. Non-limiting examples of organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.

[0156] Crystallization of the ionizable lipids disclosed herein can produce solvates. As used herein, the term "solvate" refers to an aggregate comprising one or more molecules of the ionizable lipids disclosed herein and one or more molecules of a solvent. The solvent can be water, in which case the solvate can be a hydrate. Alternatively, the solvent can be an organic solvent. Therefore, the compounds of the present disclosure can exist as hydrates, including monohydrates, dihydrates, hemihydrates, sesquihydrates, trihydrates, tetrahydrates, etc., and corresponding solvated forms. The solvates of the compounds of the present disclosure can be true solvates, while in other cases, the compounds of the present disclosure can retain only exogenous water or a mixture of water plus some exogenous solvent.

[0157] A "pharmaceutical composition" refers to a composition that can include an ionizable lipid of the present disclosure and a medium generally accepted in the art for delivering a biologically active compound to a mammal (e.g., a human). Such a medium therefore contains a pharmaceutically acceptable carrier, diluent, or excipient.

[0158] An "effective amount" or "therapeutically effective amount" refers to an amount of the ionizable lipid of the present disclosure that is sufficient to achieve treatment of a mammal (e.g., a human) when administered to the mammal (e.g., a human). The amount of the lipid nanoparticles of the present disclosure that constitutes a "therapeutically effective amount" will vary depending on the compound, the condition and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by one of ordinary skill in the art based on their own knowledge and this disclosure.

[0159] As used herein, "treating" or "treatment" encompasses the treatment of a disease or condition of interest in a mammal, such as a human, suffering from the disease or condition of interest, and includes:

[0160] (i) preventing the occurrence of the disease or condition in a mammal, particularly where such mammal is susceptible to the condition but has not yet been diagnosed as having the condition;

[0161] (ii) inhibiting the disease or condition, i.e., preventing its development;

[0162] (iii) alleviate the disease or condition, i.e., cause regression of the disease or condition; or

[0163] (iv) relieving symptoms caused by the disease or condition, i.e., relieving pain without addressing the underlying disease or condition. As used herein, the terms "disease" and "condition" may be used interchangeably or may be different, as a particular disease or condition may not have a known etiology (and thus the etiology has not been determined), and therefore the particular disease or condition has not been identified as a disease, but only as an undesirable condition or syndrome in which clinicians have identified a more or less specific set of symptoms.

[0164] The compounds of the present disclosure, or their pharmaceutically acceptable salts, may contain one or more stereocenters and thus may produce enantiomers, diastereomers, and other stereoisomeric forms, which may be defined as (R)- or (S)-, or as (D)- or (L)- for amino acids, based on absolute stereochemistry. The present disclosure is intended to encompass all such possible isomers and their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques (e.g., chromatography and fractional crystallization). Conventional techniques for preparing / isolating individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise indicated, it is intended that the compounds comprise both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.

[0165] "Stereoisomers" refer to compounds made up of the same atoms bonded by the same bonds but with different three-dimensional structures, which are not interchangeable. This disclosure contemplates various stereoisomers and mixtures thereof, and encompasses "enantiomers," which refer to two stereoisomers whose molecules are non-superimposable mirror images of one another.

[0166] In the following description, certain specific details are set forth to provide a thorough understanding of various embodiments of the present disclosure. However, it will be understood by those skilled in the art that the present disclosure can be practiced without these details.

[0167] Ionizable lipid compounds

[0168] One aspect of the present invention relates to a compound of formula (I):

[0169] A pharmaceutically acceptable salt thereof or a stereoisomer of any one of the foregoing, wherein:

[0170] is a cyclic or heterocyclic moiety;

[0171] Y is alkyl, hydroxy, hydroxyalkyl or

[0172] A does not exist, it is -O-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-、-N(R 7 )C(O)N(R 7 )-, -S-, -SS- or a divalent heterocycle;

[0173] Each of X and Z is independently absent and is -O-, -CO-, -N(R 7 )-, -O-alkylene-; -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-or-S-;

[0174] Each R 7 is independently H, alkyl, alkenyl, cycloalkyl, hydroxy, hydroxyalkyl, or aminoalkyl;

[0175] Each M is independently a biodegradable moiety;

[0176] R 30 、R 40 、R 50 、R 60 、R 70 、R 80 、R 90 、R 100 、R 110 and R 120 Each of the C1-C ... 16 Branched or unbranched alkyl or C1-C 16 branched or unbranched alkenyl, or cycloalkyl or substituted cycloalkyl;

[0177] Each of l and m is an integer from 1 to 10;

[0178] t1 is an integer from 0 to 10; and

[0179] W is hydroxy, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted amino, substituted or unsubstituted aminocarbonyl, or substituted or unsubstituted heterocyclyl or heteroaryl.

[0180] In some embodiments, disclosed are ionizable lipids of formula (I):

[0181] A pharmaceutically acceptable salt thereof or a stereoisomer of any one of the foregoing, wherein:

[0182] is a cyclic or heterocyclic moiety;

[0183] Y is alkyl, hydroxy, hydroxyalkyl or

[0184] A does not exist, it is -O-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-、-N(R 7 )C(O)N(R 7 )-, -S-, -SS-;

[0185] Each of X and Z is independently absent, -O-, -N(R 7 )-, -O-alkylene-; -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-or-S-;

[0186] Each R 7 is independently H, alkyl, alkenyl, cycloalkyl, hydroxy, hydroxyalkyl, or aminoalkyl;

[0187] Each M is independently a biodegradable moiety;

[0188] R 30 、R 40 、R 50 、R 60 、R 70 、R 80 、R 90 、R 100 、R 110 and R 120 Each of the C1-C ... 16 Branched or unbranched alkyl or C1-C 16 branched or unbranched alkenyl, or cycloalkyl or substituted cycloalkyl;

[0189] Each of l and m is an integer from 1 to 10;

[0190] t is 0, 1, 2, or 3; and

[0191] W is hydroxy, hydroxyalkyl, or one of the following moieties:

[0192]

[0193] in

[0194] Q is -O- or -N(R 7 );

[0195] R 6 are independently H, alkyl, hydroxyalkyl, amino, aminoalkyl, thiol, or thiolalkyl;

[0196] Each R 8 are independently H, alkyl, hydroxyalkyl, amino, aminoalkyl, thiol or thiolalkyl, or two R 8 Can form rings;

[0197] q is 0, 1, 2, 3, 4, or 5; and

[0198] p is 0, 1, 2, 3, 4 or 5.

[0199] In some embodiments, in any of the formulae described herein, Y is hydroxy, or

[0200] In some embodiments, R 70 and R 80 Each of is H; and R 90 It is C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 90 It is C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 90 It is C1-C 15 In some embodiments, R 90 It is C1-C 12 Branched or unbranched alkyl groups.

[0201] In some embodiments, R 70 is H; and R 80 and R 90 Each of C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 80 and R 90 Each of C1-C15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 80 and R 90 Each of C1-C 15 In some embodiments, R 80 and R 90 Each of C1-C 12 In some embodiments, R 80 and R 90 Each of the groups is independently a C1-C8 branched or unbranched alkyl group.

[0202] In some embodiments, R 100 is H; and R 110 and R 120 Each of C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 110 and R 120 Each of C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 110 and R 120 Each of C1-C 15 In some embodiments, R 110 and R 120 Each of C1-C 12 In some embodiments, R 110 and R 120 Each of the groups is independently a C1-C8 branched or unbranched alkyl group.

[0203] In some embodiments, ionizable lipids of formula (IA-1) or (IA-2) are disclosed:

[0204] A pharmaceutically acceptable salt thereof or a stereoisomer of any one of the foregoing, wherein:

[0205] is a cyclic or heterocyclic moiety;

[0206] A does not exist, it is -O-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R7 )-、-N(R 7 )C(O)N(R 7 )-, -S-, -SS- or a divalent heterocycle;

[0207] X does not exist, it is -O-, -CO-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-or-S-;

[0208] Z does not exist, it is -O-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-or-S-;

[0209] Each R 7 is independently H, alkyl, alkenyl, cycloalkyl, hydroxy, hydroxyalkyl, or aminoalkyl;

[0210] Each M is independently a biodegradable moiety;

[0211] R 30 、R 40 、R 50 、R 60 、R 100 、R 110 and R 120 Each of the C1-C ... 16 Branched or unbranched alkyl or C1-C 16 branched or unbranched alkenyl;

[0212] R 90 It is C1-C 15 Branched or unbranched alkyl, C1-C 15 branched or unbranched alkenyl or cycloalkyl or substituted cycloalkyl;

[0213] t is 0, 1, 2, or 3;

[0214] t1 is an integer from 0 to 10;

[0215] l is an integer from 1 to 10;

[0216] m is an integer from 1 to 10; and

[0217] W is hydroxy, hydroxyalkyl, or one of the following moieties:

[0218]

[0219]

[0220] in

[0221] Each Q is independently absent and is -O-, -C(O)-, -C(S)-, -C(O)O-, -C(R 7 )2-、-C(O)N(R 7 )-、-C(S)N(R 7 )-or-N(R 7 );

[0222] Each R 6 are independently H, alkyl, hydroxy, hydroxyalkyl, alkoxy, amino, aminoalkyl, alkylamino, thiol, thiolalkyl, or N + (R 7 )3-alkylene-Q-;

[0223] Each R 8 are independently H, alkyl, hydroxyalkyl, amino, aminoalkyl, thiol or thiolalkyl, or two R 8 Together with nitrogen atoms, they can form a ring;

[0224] Each q is independently 0, 1, 2, 3, 4 or 5; and

[0225] Each p is independently 0, 1, 2, 3, 4 or 5.

[0226] Examples of various variables in Formulas (I) and (IA-1) and (IA-2) are discussed further below.

[0227] In some embodiments, in any of the formulae described herein, With formula structure, where:

[0228] Each of G1, G2, G3, G4, G5, and G6 is independently C(R')(R"), O, or N, provided that no more than two of G1-G6 are O or N;

[0229] R' and R" are each independently absent and are H, alkyl, or two R's from two adjacent G's that together form a second 5- to 7-membered cyclic ring or heterocycle; and

[0230] n1 and n2 are each independently 0 or 1.

[0231] In some embodiments, in any of the formulae described herein, Selected from pyrrolidine, piperidine, piperazine, cyclohexane, cyclopentane, tetrahydrofuran, tetrahydropyran, morpholine and dioxane.

[0232] In any of the formulae described herein, in some embodiments, Is a 5 to 7 membered monocyclic ring. In some embodiments, is a 5- to 7-membered monocyclic, cycloalkane ring. In some embodiments, It is a 5- to 7-membered monocyclic or heterocyclic ring.

[0233] In any of the formulae described herein, in some embodiments, It is bicyclic or tricyclic, ie, contains two or more rings, such as fused rings.

[0234] In any of the formulae described herein, in some embodiments, Selected from the group consisting of:

[0235] In some embodiments, Selected from the group consisting of:

[0236] In some embodiments, have In one embodiment, have structure.

[0237] In some embodiments, have In one embodiment, With formula In one embodiment, have In one embodiment, have structure.

[0238] In some embodiments, have In one embodiment, have structure.

[0239] In some embodiments, have In one embodiment, have structure.

[0240] In some embodiments, have In one embodiment, have structure.

[0241] In some embodiments, have In one embodiment, have structure.

[0242] In some embodiments, have In one embodiment, have structure.

[0243] In some embodiments, in any of the formulae described herein, for Y, A does not exist, it is -O-, -N(R 7 )-、N(R 7 )C(O)-、

[0244] -OC(O)- or -C(O)O-, where R 6 are independently H, alkyl, hydroxy, hydroxyalkyl, amino, aminoalkyl, thiol, thiolalkyl or N + (R 7 )3-alkylene-Q-; and R 7 Is H or C1-C3 alkyl. In one embodiment, A is absent. In one embodiment, A is -O-. In one embodiment, A is -N(R 7 )-, where R 7 Is H or C1-C3 alkyl. In one embodiment, A is -OC(O)- or -C(O)O-. In one embodiment, A is

[0245] In some embodiments, in any of the formulae described herein, t1 is 0, 1, 2, 3, or 4; and t is 0, 1, or 2.

[0246] In some embodiments, in any of the formulae described herein, W is hydroxy, hydroxyalkyl, or one of the following moieties:

[0247]

[0248]

[0249] in:

[0250] Each Q is independently absent and is -O-, -C(O)-, -C(S)-, -C(O)O-, -C(R 7 )2-、-C(O)N(R 7 )-、-C(S)N(R 7 )-or-N(R 7 )-;

[0251] Each R 6 are independently H, alkyl, hydroxy, hydroxyalkyl, alkoxy, amino, aminoalkyl, alkylamino, thiol, thiolalkyl, or N + (R 7 )3-alkylene-Q-;

[0252] Each R 8 are independently H, alkyl, hydroxyalkyl, amino, aminoalkyl, thiol or thiolalkyl, or two R 8 Together with nitrogen atoms, they can form a ring;

[0253] Each q is independently 0, 1, 2, 3, 4 or 5; and

[0254] Each p is independently 0, 1, 2, 3, 4 or 5.

[0255] In some embodiments, in any of the formulae described herein, W is OH,

[0256]

[0257]

[0258] in:

[0259] q is 0,

[0260] Each R 8 are independently H, C1-C3 alkyl or hydroxyalkyl, or two R 8 Together with the nitrogen atom, it forms a 5-membered ring optionally substituted with one or more alkyl groups,

[0261] Each R 6 are independently H, hydroxy, C1-C3 alkyl or -Q-alkylene-N + (R 7 )3,

[0262] Each Q independently does not exist and is -O-, -C(O)-, -N(R 7 )-、-C(R 7 )2-、-C(O)O-、-C(O)N(R 7 )-or-C(S)N(R 7 )-,and

[0263] Each R 7 are independently H, C1-C3 alkyl or hydroxyalkyl.

[0264] In some embodiments, in any of the formulae described herein, W is OH,

[0265] In some embodiments, W is OH.

[0266] In some embodiments, W is where q is 0 and each R 8 is independently H, C1-C3 alkyl or hydroxyalkyl. In one embodiment, W is In one embodiment, W is

[0267] In some embodiments, W is Each R 8 are independently H, C1-C3 alkyl or hydroxyalkyl, Q is -N(R 7 )-、-C(R 7 )2-、-C(O)O-、-C(O)N(R 7 )-or-C(S)N(R 7 )-; and each R 7 is independently H, C1-C3 alkyl or hydroxyalkyl. In one embodiment, W is In one embodiment, W is

[0268] In some embodiments, W is Each R 6 are independently H, C1-C3 alkyl, hydroxy, hydroxyalkyl, alkoxy, amino, aminoalkyl, alkylamino, C1-C3 alkyl or -Q-alkylene-N + (R 7 )3. In one embodiment, W is In one embodiment, W is In one embodiment, W is

[0269] In some embodiments, W is Where each Q is independently absent, is -N(R 7 )-、-C(R 7 )2-、-C(O)O-、-C(O)N(R 7 )-or-C(S)N(R 7 )-; Each R 6are independently H, alkyl, hydroxy, hydroxyalkyl, alkoxy, amino, aminoalkyl, alkylamino, thiol, thiolalkyl, or N + (R 7 )3-alkylene-Q-; and each R 7 In one embodiment, W is In one embodiment, W is In one embodiment, W is

[0270] In some embodiments, W is Where each Q is independently absent, is -N(R 7 )-、-C(R 7 )2-、-C(O)O-、-C(O)N(R 7 )-or-C(S)N(R 7 )-; Each R 6 are independently H, alkyl, hydroxy, hydroxyalkyl, alkoxy, amino, aminoalkyl, alkylamino, thiol, thiolalkyl, or N + (R 7 )3-alkylene-Q-; and each R 7 are independently H, C1-C3 alkyl, hydroxy or hydroxyalkyl.

[0271] In some embodiments, W is Where each Q is independently absent, is -N(R 7 )-、-C(R 7 )2-、-C(O)O-、-C(O)N(R 7 )-or-C(S)N(R 7 )-; Each R 6 are independently H, alkyl, hydroxy, hydroxyalkyl, alkoxy, amino, aminoalkyl, alkylamino, thiol, thiolalkyl, or N + (R 7 )3-alkylene-Q-; and each R 7 are independently H, C1-C3 alkyl, hydroxy or hydroxyalkyl.

[0272] In some embodiments, where q is 0 or 1, and each R 7 In one embodiment, W is

[0273] In some embodiments, W is wherein each Q is independently -N(R 7 )-、-C(R 7)2-、-C(O)O-、-C(O)N(R 7 )-or-C(S)N(R 7 )-; Each R 6 are independently H or C1-C3 alkyl, each Q is independently -O-, -C(O)-, -N(R 7 ), and R 7 Is H, C1-C3 alkyl, hydroxyl or hydroxyalkyl. In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is

[0274] In one embodiment, W is In one embodiment, W is

[0275] In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is

[0276] In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is

[0277] In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is

[0278] In one embodiment, W is In one embodiment, W is In one embodiment, W is In one embodiment, W is

[0279] In some embodiments, in any of the formulae described herein, Y or Yes: OH,

[0280]

[0281] Each R c is independently H or C1-C3 alkyl, and each t1 is independently 1, 2, 3 or 4.

[0282] In some embodiments, in any of the formulae described herein, Y or Yes: OH,

[0283]

[0284] In some embodiments, in any of the formulae described herein, X is absent, -O-, or -C(O)-.

[0285] In some embodiments, in any of the formulae described herein, Z is —O—, —C(O)O—, or —OC(O)—.

[0286] In some embodiments, in any of the formulae described herein, R 30 、R 40 、R 50 and R 60 Each of is H or a C1-C4 branched or unbranched alkyl group.

[0287] In some embodiments, in any of the formulae described herein, R 30 、R 40 、R 50 and R 60 Each of is H.

[0288] In any of the formulae described herein, in some embodiments, R 70 and R 80 Each of is H; and R 90 It is C1-C 15 Branched or unbranched alkyl, C1-C15 In some embodiments, R 90 It is C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 90 It is C1-C 15 In some embodiments, R 90 It is C1-C 12 In some embodiments, R 90 It is a C1-C8 branched or unbranched alkyl group.

[0289] In any of the formulae described herein, in some embodiments, R 70 is H; and R 80 and R 90 Each of which is independently H, Cl-C 15 Branched or unbranched alkyl, C1-C 15 branched or unbranched alkenyl, or cycloalkyl or substituted cycloalkyl, provided that R 80 and R 90 At least one of is not H. In some embodiments, R 80 and R 90 Each of which is independently H, Cl-C 15 Branched or unbranched alkyl or C1-C 15 In some embodiments, R 80 and R 90 Each of which is independently H or C1-C 15 In some embodiments, R 80 and R 90 Each of which is independently H or C1-C 12 In some embodiments, R 80 and R 90 Each of is independently H or a C1-C8 branched or unbranched alkyl group.

[0290] In any of the formulae described herein, in some embodiments, R 100 is H; and R 110 and R 120 Each of which is independently H, Cl-C 15 Branched or unbranched alkyl, C1-C 15 branched or unbranched alkenyl, or cycloalkyl or substituted cycloalkyl, provided that R 110 and R 120 At least one of is not H. In some embodiments, R 110and R 120 Each of which is independently H or C1-C 15 Branched or unbranched alkyl or C1-C 15 In some embodiments, R 110 and R 120 Each of which is independently H or C1-C 15 In some embodiments, R 110 and R 120 Each of which is independently H or C1-C 12 In some embodiments, R 110 and R 120 Each of is independently H or a C1-C8 branched or unbranched alkyl group.

[0291] In any of the formulae described herein, in some embodiments, l is 3 to 10, 3 to 7, or 4 to 7. In some embodiments, l is 4, 5, 6, 7, 8, 9, or 10. In some embodiments, l is 3, 4, 5, 6, or 7. In some embodiments, l is 4, 5, 6, or 7.

[0292] In any of the formulae described herein, in some embodiments, m is 4 to 10, 5 to 8, 1 to 7, 3 to 7, or 1 to 5. In some embodiments, m is 4, 5, 6, 7, 8, 9, or 10. In some embodiments, m is 1, 2, 3, 4, or 5. In some embodiments, m is 3, 4, or 5. In some embodiments, m is 5, 6, 7, or 8.

[0293] In any of the formulae described herein, in some embodiments, R 70 is H. In some embodiments, R 100 It’s H.

[0294] In any of the formulae described herein, in some embodiments, Independently selected from:

[0295]

[0296] where t is 0, 1, 2, 3, 4, or 5.

[0297] In any of the formulae described herein, in some embodiments, M is -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-、-C(OR 13 )-O-、-C(O)O(CH2) r -、-C(O)N(R 7)(CH2) r -OR-C(OR 13 )-O-(CH2) r -, where each R 7 R is independently H, alkyl, alkenyl, cycloalkyl, hydroxyalkyl or aminoalkyl; 13 Is it a branched or unbranched C3-C 10 alkyl, and r is 1, 2, 3, 4, or 5. In some embodiments, M is -OC(O)- or -C(O)O-.

[0298] In any of the formulae described herein, in some embodiments, X is absent, -O-, or -C(O)-;

[0299] Z is –O-, –C(O)O-, or –OC(O)-; M is –OC(O)- or –C(O)O-; Y or yes:

[0300] OH,

[0301] Each R c are independently H or C1-C3 alkyl; each t1 is independently 1, 2, 3 or 4; R 30 、R 40 、R 50 and R 60 Each of R is H or C1-C4 branched or unbranched alkyl; 70 is H; and R 80 and R 90 Each of which is independently H or C1-C 12 Branched or unbranched alkyl; R 100 is H; and R 110 and R 120 Each of which is independently H or C1-C 12 branched or unbranched alkyl, provided that R 80 and R 90 At least one of is not H, and R 110 and R 120 At least one of is not H; l is 3 to 7; and m is 1 to 5.

[0302] In some embodiments, disclosed herein include lipid compounds having the formula:

[0303] All variables in this formula are defined and exemplified as those described in the above Examples.

[0304] In some embodiments, disclosed herein include lipid compounds having the formula:

[0305]

[0306] in:

[0307] Each m1 is independently an integer from 3 to 6,

[0308] Each l1 is independently an integer from 4 to 8,

[0309] m2 and l2 are each independently an integer from 0 to 3;

[0310] R 80 and R 90 are each independently an unsubstituted C5-C8 alkyl group; or R 80 is H or unsubstituted C1-C4 alkyl, and R 90 Is an unsubstituted C5-C 11 alkyl; and

[0311] R 110 and R 120 are each independently an unsubstituted C5-C8 alkyl group; or R 110 is H or unsubstituted C1-C4 alkyl, and R 120 Is an unsubstituted C5-C 11 All other variables in these formulae are defined and exemplified as those described in the above Examples.

[0312] In some embodiments, in these formulas, R 80 is H or unsubstituted C1-C2 alkyl, and R 90 Is an unsubstituted C6-C 10 alkyl; and R 110 and R 120 Each independently is an unsubstituted C5-C8 alkyl. In some embodiments, R 80 、R 90 、R 110 and R 120 Each is independently an unsubstituted C5-C8 alkyl group.

[0313] In some embodiments, disclosed herein include lipid compounds having the formula:

[0314]

[0315]

[0316] All variables in these formulae are defined and exemplified as those described in the above embodiments. In some embodiments, in these formulae, R 80 is H or unsubstituted C1-C2 alkyl, and R 90 Is an unsubstituted C6-C 10 alkyl; and R 110 and R 120 Each independently is an unsubstituted C5-C8 alkyl. In some embodiments, R 80 、R 90 、R 110 and R 120 Each is independently an unsubstituted C5-C8 alkyl. In some embodiments, Yes: OH,

[0317]

[0318] In some embodiments, disclosed herein include lipid compounds having the formula: All variables in this formula are defined and exemplified as those described in the above Examples.

[0319] In some embodiments, disclosed herein include lipid compounds having the formula:

[0320] in:

[0321] Each m1 is independently an integer from 3 to 6,

[0322] Each l1 is independently an integer from 4 to 8,

[0323] m2 and l2 are each independently an integer from 0 to 3;

[0324] R 80 and R 90 are each independently an unsubstituted C5-C8 alkyl group; or R 80 is H or unsubstituted C1-C4 alkyl, and R 90 Is an unsubstituted C5-C 11 alkyl; and

[0325] R 110 and R 120 are each independently an unsubstituted C5-C8 alkyl group; or R 110 is H or unsubstituted C1-C4 alkyl, and R 120 Is an unsubstituted C5-C 11All other variables in these formulae are defined and exemplified as those described in the above examples. In some embodiments, in these formulae, R 80 is H or unsubstituted C1-C2 alkyl, and R 90 Is an unsubstituted C6-C 10 alkyl; and R 110 and R 120 Each independently is an unsubstituted C5-C8 alkyl. In some embodiments, R 80 、R 90 、R 110 and R 120 Each is independently an unsubstituted C5-C8 alkyl group.

[0326] In some embodiments, disclosed herein include lipid compounds having the formula:

[0327]

[0328] All variables in these formulae are defined and exemplified as those described in the above embodiments. In some embodiments, in these formulae, R 80 is H or unsubstituted C1-C2 alkyl, and R 90 Is an unsubstituted C6-C 10 alkyl; and R 110 and R 120 Each independently is an unsubstituted C5-C8 alkyl. In some embodiments, R 80 、R 90 、R 110 and R 120 Each is independently an unsubstituted C5-C8 alkyl. In some embodiments, Yes: OH,

[0329] In some embodiments, the present disclosure relates to ionizable lipids of formula (IIA):

[0330] Pharmaceutically acceptable salts thereof and stereoisomers of any of the foregoing, wherein:

[0331] A does not exist, it is -O-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -NHC(O)-, -C(O)N(R 7 )-、-N(R 7 )C(O)N(R 7 )-, -S-, -SS-;

[0332] X does not exist, it is -O-, -CO-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -NHC(O)-, -C(O)N(R 7 )-or-S-;

[0333] Z does not exist, it is -O-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -NHC(O)-, -C(O)NH-, or -S-;

[0334] Each R 7 are independently H, C1-C3 branched or unbranched alkyl, C2-C3 branched or unbranched alkenyl, cycloalkyl, hydroxyalkyl or aminoalkyl;

[0335] Each M is independently a biodegradable moiety;

[0336] R 30 、R 40 、R 50 、R 60 、R 100 、R 110 and R 120 Each of the C1-C ... 16 Branched or unbranched alkyl or C1-C 16 branched or unbranched alkenyl;

[0337] R 90 It is C1-C 15 Branched or unbranched alkyl, C1-C 15 branched or unbranched alkenyl or cycloalkyl or substituted cycloalkyl;

[0338] t is 0, 1, 2, or 3;

[0339] l is an integer from 1 to 10;

[0340] m is an integer from 1 to 10; and

[0341] W is hydroxy, hydroxyalkyl, or one of the following moieties:

[0342]

[0343] in

[0344] Q is -O- or -N(R 7 );

[0345] R 6are independently H, alkyl, hydroxyalkyl, amino, aminoalkyl, thiol, or thiolalkyl;

[0346] Each R 8 are independently H, alkyl, hydroxyalkyl, amino, aminoalkyl, thiol or thiolalkyl, or two R 8 Can form rings;

[0347] q is 0, 1, 2, 3, 4, or 5; and

[0348] p is 0, 1, 2, 3, 4 or 5.

[0349] In some embodiments, the present disclosure relates to ionizable lipids of formula (IIIA):

[0350] Pharmaceutically acceptable salts thereof and stereoisomers of any of the foregoing, wherein the variables in (IIIA) are defined the same as those in (IIA).

[0351] In some embodiments, the present disclosure relates to ionizable lipids of formula (IIB):

[0352] Pharmaceutically acceptable salts thereof and stereoisomers of any of the foregoing, wherein:

[0353] A does not exist, it is -O-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -NHC(O)-, -C(O)N(R 7 )-、-N(R 7 )C(O)N(R 7 )-, -S-, -SS-;

[0354] X does not exist, it is -O-, -CO-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -NHC(O)-, -C(O)N(R 7 )-or-S-;

[0355] Z does not exist, it is -O-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -NHC(O)-, -C(O)NH-, or -S-;

[0356] Each R 7 are independently H, C1-C3 branched or unbranched alkyl, C2-C3 branched or unbranched alkenyl, cycloalkyl, hydroxyalkyl or aminoalkyl;

[0357] Each M is independently a biodegradable moiety;

[0358] R 30 、R 40 、R 50 、R 60 、R 70 、R 80 、R 90 、R 100 、R 110 and R 120 Each of the C1-C ... 16 Branched or unbranched alkyl or C1-C 16 branched or unbranched alkenyl;

[0359] t is 0, 1, 2, or 3;

[0360] l is an integer from 1 to 10;

[0361] m is an integer from 1 to 10; and

[0362] W is hydroxy, hydroxyalkyl, or one of the following moieties:

[0363]

[0364] in

[0365] Q is -O- or -N(R 7 );

[0366] R 6 are independently H, alkyl, hydroxyalkyl, amino, aminoalkyl, thiol, or thiolalkyl;

[0367] Each R 8 are independently H, alkyl, hydroxyalkyl, amino, aminoalkyl, thiol or thiolalkyl, or two R 8 Can form rings;

[0368] q is 0, 1, 2, 3, 4, or 5; and

[0369] p is 0, 1, 2, 3, 4 or 5.

[0370] In some embodiments, the present disclosure relates to ionizable lipids of formula (IIIB):

[0371] Pharmaceutically acceptable salts thereof and stereoisomers of any of the foregoing, wherein the variables in (IIIB) are defined the same as those in (IIB).

[0372] In some embodiments, the present disclosure relates to ionizable lipids of formula (IIC):

[0373] Pharmaceutically acceptable salts thereof and stereoisomers of any of the foregoing, wherein:

[0374] A does not exist, it is -O-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R')-、N(R 7 )C(O)N(R 7 )-, -S-, -SS-;

[0375] R 30 、R 40 、R 50 、R 60 、R 100 、R 110 and R 120 Each of the C1-C ... 16 Branched or unbranched alkyl or C1-C 16 branched or unbranched alkenyl;

[0376] R 90 It is C1-C 15 Branched or unbranched alkyl, C1-C 15 branched or unbranched alkenyl, cycloalkyl or substituted cycloalkyl;

[0377] Each R 7 are independently H, C1-C3 branched or unbranched alkyl, C2-C3 branched or unbranched alkenyl, cycloalkyl, hydroxyalkyl or aminoalkyl;

[0378] Each M is independently a biodegradable moiety;

[0379] t is 0, 1, 2, or 3;

[0380] l is an integer from 1 to 10;

[0381] m is an integer from 1 to 10; and

[0382] W is hydroxy, hydroxyalkyl, or one of the following moieties:

[0383]

[0384] in

[0385] Q is -O- or -N(R 7 )-;

[0386] R 6are independently H, alkyl, hydroxyalkyl, amino, aminoalkyl, thiol, or thiolalkyl;

[0387] Each R 8 are independently H, alkyl, hydroxyalkyl, amino, aminoalkyl, thiol or thiolalkyl, or two R 8 Can form rings;

[0388] q is 0, 1, 2, 3, 4, or 5; and

[0389] p is 0, 1, 2, 3, 4 or 5.

[0390] In some embodiments, the present disclosure relates to ionizable lipids of formula (IIIC):

[0391] Pharmaceutically acceptable salts thereof and stereoisomers of any of the foregoing, wherein the variables in (IIIA) are defined the same as those in (IIC).

[0392] In some embodiments, the present disclosure relates to ionizable lipids of formula (IIID):

[0393] Pharmaceutically acceptable salts thereof and stereoisomers of any of the foregoing, wherein the variables in (IID) are defined the same as those defined above.

[0394] In some embodiments, the present disclosure relates to ionizable lipids of formula (IIIE):

[0395] Pharmaceutically acceptable salts thereof and stereoisomers of any of the foregoing, wherein the variables in (IID) are defined the same as those defined above.

[0396] Examples for various variables within Formula (IIA), (IIB), (IIC), (IIIA), (IIIB), (IIIC), (IIID), or (IIIE) are discussed further below.

[0397] In some embodiments, X is absent, -O- or -C(O)-. In one embodiment, X is absent. In one embodiment, X is -O-. In one embodiment, X is -C(O)-.

[0398] In some embodiments, Z is -O-, -C(O)O-, or -OC(O)-. In one embodiment, Z is -O-. In one embodiment, Z is -C(O)O-, or -OC(O)-.

[0399] In some embodiments, R 30 、R 40、R 50 and R 60 Each of is H or a C1-C4 branched or unbranched alkyl group.

[0400] In some embodiments, R 30 、R 40 、R 50 and R 60 Each of is H.

[0401] In some embodiments, R 70 and R 80 Each of is H; and R 90 It is C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 90 It is C1-C 15 In some embodiments, R 90 It is C1-C 12 Branched or unbranched alkyl groups.

[0402] In some embodiments, R 70 is H; and R 80 and R 90 Each of C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 80 and R 90 Each of C1-C 15 In some embodiments, R 80 and R 90 Each of C1-C 12 In some embodiments, R 80 and R 90 Each of the groups is independently a C1-C8 branched or unbranched alkyl group.

[0403] In some embodiments, R 100 is H; and R 110 and R 120 Each of C1-C 15 Branched or unbranched alkyl, C1-C 15 In some embodiments, R 110 and R 120 Each of C1-C 15 In some embodiments, R 110 and R 120Each of C1-C 12 In some embodiments, R 110 and R 120 Each of the groups is independently a C1-C8 branched or unbranched alkyl group.

[0404] In some embodiments, l is 3 to 10, 3 to 7, or 4 to 7. In some embodiments, l is 4, 5, 6, 7, 8, 9, or 10. In some embodiments, l is 4, 5, 6, or 7.

[0405] In some embodiments, m is 4-10, 5-8, 1-7, 3-7, or 1-5.

[0406] In some embodiments, m is 4, 5, 6, 7, 8, 9, or 10. In some embodiments, m is 3, 4, or 5. In some embodiments, m is 5, 6, 7, or 8.

[0407] In some embodiments, M is -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-、-C(OR 13 )-O-、

[0408] -C(O)O(CH2) r -、-C(O)N(R 7 )(CH2) r -OR-C(OR 13 )-O-(CH2) r -, where each R 7 R is independently H, alkyl, alkenyl, cycloalkyl, hydroxyalkyl or aminoalkyl; 13 Is it a branched or unbranched C3-C 10 alkyl, and r is 1, 2, 3, 4, or 5. In some embodiments, M is -OC(O)- or -C(O)O-.

[0409] In some embodiments, the pKa of the protonated form of the ionizable lipid compound described herein is about 4.5 to about 8.0, for example, about 4.6 to about 7.8, about 4.6 to about 7.3, about 4.6 to about 6.8, about 4.6 to about 6.2, about 4.6 to about 6.0, about 4.6 to about 5.9, about 4.6 to about 5.8, about 4.6 to about 5.6, about 4.6 to 5.5, about 5.7 to about 6.5, about 5.7 to about 6.4, or about 5.8 to about 6.2. In some embodiments, the pKa of the protonated form of the ionizable lipid compound is about 4.6 to about 7.8. In some embodiments, the pKa of the protonated form of the ionizable lipid compound is about 4.6 to about 5.6. In some embodiments, the pKa of the protonated form of the ionizable lipid compound is about 5.5 to about 6.0. In some embodiments, the pKa of the protonated form of the ionizable lipid compound is about 6.1 to about 6.3. In some embodiments, the pKa of the protonated form of the ionizable lipid compound is about 4.7 to about 5.1.

[0410] Non-limiting examples of ionizable lipid compounds disclosed herein are shown in Table 1 below.

[0411] Table 1: Exemplary ionizable lipid compounds.

[0412]

[0413]

[0414]

[0415]

[0416]

[0417]

[0418]

[0419]

[0420]

[0421]

[0422]

[0423]

[0424]

[0425]

[0426] Additional non-limiting examples of ionizable lipid compounds disclosed herein are shown in Table 2 below.

[0427] Table 2: Exemplary ionizable lipid compounds.

[0428]

[0429]

[0430]

[0431]

[0432]

[0433]

[0434]

[0435]

[0436]

[0437]

[0438]

[0439]

[0440]

[0441]

[0442] Lipid composition

[0443] The ionizable lipids disclosed herein can be used to form lipid compositions.Thus, another aspect of the present invention relates to a lipid composition comprising a lipid compound as described in the above aspects of the invention relating to novel ionizable lipid compounds.

[0444] All of the above descriptions relating to lipid compounds, including compounds covered by Formula (I), (IA-1), (IA-2), (IIA)-(IIC), (IIA-1), (IIIA)-(IIIE), (IIIC-1), (IVA-1)-(IVA-3), (IVC-1)-(IVC-2), and (VC-1)-(VC-6), and all of the embodiments discussed in the above aspects apply to these aspects of the invention relating to lipid compositions.

[0445] As described herein, suitable lipid compounds to be used in the lipid compositions include all isomers and isotopes of the above-mentioned compounds and all pharmaceutically acceptable salts, solvates or hydrates thereof, as well as all crystal forms, mixtures of crystal forms and anhydrides or hydrates.

[0446] In certain embodiments, the lipid composition contains one or more compounds as described herein or a pharmaceutically acceptable salt thereof. In certain embodiments, the lipid composition is a liposome or lipid nanoparticle (LNP). In one embodiment, the lipid composition is an LNP.

[0447] In addition to one or more compounds described herein, the lipid composition may further comprise a second lipid. In some embodiments, the present disclosure relates to a lipid composition comprising (i) one or more ionizable lipids selected from Formula (I), (IA-1), (IA-2), (IIA)-(IIC), (IIA-1), (IIIA)-(IIIE), (IIIC-1), (IVA-1)-(IVA-3), (IVC-1)-(IVC-2) and (VC-1)-(VC-6), a lipid compound of a stereoisomer of any one thereof, a pharmaceutically acceptable salt thereof, and (ii) a second lipid. In some embodiments, the lipid composition comprises 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of the one or more lipid compounds.

[0448] In certain embodiments, the second lipid is cationic, non-cationic (e.g., neutral, anionic or zwitterionic) or ionizable. In certain embodiments, the lipid composition comprises a lipid compound and a second lipid (e.g., helper lipid) in a ratio of about 1:1.

[0449] In some embodiments, the second lipid is a cationic lipid, an anionic lipid, another ionizable lipid, or a zwitterionic lipid.

[0450] In some embodiments, the present disclosure relates to a lipid nanoparticle composition comprising (i) one or more ionizable lipid compounds as described herein and (ii) one or more lipid components.

[0451] In certain embodiments, the one or more lipid components in the lipid composition include one or more helper lipids and one or more PEG lipids. In certain embodiments, the lipid component includes one or more helper lipids, one or more PEG lipids and one or more neutral lipids. In certain embodiments, the lipid composition can further include sterol and PEG lipid. In certain embodiments, the lipid composition can further include sterol, PEGylated lipid, phospholipid and / or neutral lipid.

[0452] In some embodiments, one or more naturally occurring and / or synthetic lipid compounds can be used to prepare the lipid composition.The lipid composition can contain negatively charged lipids, positively charged lipids, or a combination thereof.

[0453] Non-ionizable lipid components

[0454] Charged and neutral lipids

[0455] Examples of suitable negatively charged (anionic) lipids include, but are not limited to, dimyristoyl-, dipalmitoyl-, and distearoyl-phosphatidylglycerol; dimyristoyl-, dipalmitoyl-, and dipalmitoyl-phosphatidic acid; dimyristoyl-, dipalmitoyl-, and dipalmitoyl-phosphatidylethanolamine; and their unsaturated diacyl and mixed acyl chain counterparts, as well as cardiolipin.

[0456] Examples of positively charged (cationic) lipids include, but are not limited to, N,N'-dimethyl-N,N'-dioctadecyl ammonium bromide (DDAB) and chloride (DDAC), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), 3β-[N-(N',N'-dimethylaminoethyl)carbamoyl]cholesterol (DC-chol), 1,2-dioleoyloxy-3-[trimethylammonium]-propane (DOTAP), 1,2-dioctadecyloxy-3-[trimethylammonium]-propane (DSTAP), and 1,2-dioleoyloxypropyl-3-dimethyl-hydroxyethylammonium chloride (DORI), as well as the cationic lipids described, for example, in Martin et al., Current Pharmaceutical Design, pp. 1-394, which is incorporated herein by reference in its entirety.

[0457] Additional exemplary cationic lipids include, but are not limited to, N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-(2,3-dioleoyloxy)propylamine (DODMA), 1,2-dioleoyl-3-dimethylammonium-propane (DODMAP), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-(2,3-dioleoyloxy)propylamine (DODMA), N,N-dimethyl-(2,3-dioleoyloxy)propylamine (DODMAP ... DAP), 1,2-dioleoylcarbamoyl-3-dimethylammonium-propane (DOCDAP), 1,2-dilinoleic acid-3-dimethylammonium-propane (DLINDAP), 3-dimethylamino-2-(cholest-5-en-3-β-oxybut-4-oxy)-1-(cis,cis-9,12-octadecadienyloxy)propane (CLinDMA), 2-[5'-(cholest-5-en-3-β-oxy)-3'-(oxopentyloxy)-3-dimethyl-1-(cis,cis-9',12'-octadecadienyloxy)propane (CpLinDMA), N,N-dimethyl-3,4-dioleoyloxybenzylamine (DMOBA) and / or mixtures thereof. The neutral lipids may include dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), egg phosphatidylcholine (EPC), distearoylphosphatidylcholine (DSPC), and / or mixtures thereof.

[0458] In some embodiments, the lipid component includes one or more neutral lipids. The neutral lipids can be one or more phospholipids, such as one or more (poly)unsaturated lipids. The phospholipids can be assembled into one or more lipid bilayers. Generally speaking, the phospholipids can include a phospholipid portion and one or more fatty acid portions. For example, the phospholipids can be lipids according to the formula: where R p represents the phospholipid portion, and R A and R BRepresents an unsaturated or saturated fatty acid moiety that may be the same or different. The phospholipid moiety may be phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, 2-lysophosphatidylcholine or sphingomyelin. The fatty acid moiety may be lauric acid, myristic acid, myristoleic acid (myristoleic acid), palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, erucic acid, phytanic acid (phytanic acid), arachidic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid or docosahexaenoic acid. Non-natural substances are also envisioned, including natural substances with modifications and substitutions (including branching, oxidation, cyclization and alkynes). For example, phospholipids can be functionalized or cross-linked with one or more alkynes (e.g., alkenyl groups in which one or more double bonds are replaced by triple bonds). Under appropriate reaction conditions, alkynes can undergo copper-catalyzed cycloaddition when exposed to azide. Such reactions can be used to functionalize the lipid bilayer of lipid nanoparticles to facilitate membrane penetration or cellular recognition, or to conjugate lipid nanoparticles with useful components such as targeting moieties or imaging moieties (eg, dyes).

[0459] In some embodiments, the neutral lipid can be a phospholipid, such as distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero 1-oleoyl-3-phosphocholine (DPPC), 1,2-heneicosanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholestyryl hemisuccinyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dialinolenoyl-sn-glycero-3-phosphocholine, 1,2-diacardonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (MEPC) 16.0PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoyl phosphatidylethanolamine (POPE), distearoyl-phosphatidyl-ethanolamine (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), 1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE), or a mixture thereof.

[0460] Additional non-limiting examples of neutral lipids include phospholipids such as phosphatidylcholine, phosphatidylethanolamine, lysolecithin, lysolecithin, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidic acid, cerebrosides, dihexadecyl phosphate, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoyl-phosphatidylcholine (POPC), palmitoyloleoylphosphatidylcholine (DPPC), and palmitoyloleoylphosphatidylglycerol (DPPG). Acyl-phosphatidylethanolamine (POPE), palmitoyloleoyl-phosphatidylglycerol (POPG), dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), monomethyl-phosphatidylethanolamine, dimethyl-phosphatidylethanolamine, di-elaidoyl-phosphatidylethanolamine (DEPE), stearoyloleoyl-phosphatidylethanolamine (SOPE), lysophosphatidylcholine, dilinoleoylphosphatidylcholine and mixtures thereof. Other diacylphosphatidylcholine and diacylphosphatidylethanolamine phospholipids may also be used. The acyl groups in these lipids may be derived from C 10 -C 24 Acyl groups of carbon-chain fatty acids, such as lauroyl, myristoyl, palmitoyl, stearoyl or oleoyl.

[0461] Steroids and other non-ionizable lipid components

[0462] In some embodiments, the lipid component of the lipid composition includes one or more steroids or analogs thereof.

[0463] In some embodiments, the lipid components in the lipid composition include sterols, such as cholesterol, sitosterol and derivatives thereof. Non-limiting examples of cholesterol derivatives include: polar analogs, such as 5a-cholestanol, 5a-coprolol, cholesteryl-(2'-hydroxy)-ethyl ether, cholesteryl-(4'-hydroxy)-butyl ether and 6-ketocholestanol; non-polar analogs, such as 5a-cholestane, cholesterenone, 5a-cholestol, 5a-cholestol and cholesterol decanoate; and mixtures thereof. In some embodiments, the cholesterol derivative is a polar analog, such as cholesteryl-(4'-hydroxy)-butyl ether.

[0464] In certain embodiments, the non-ionizable lipid component comprises a mixture of one or more phospholipids and cholesterol or derivatives thereof, or is composed of the mixture. In certain embodiments, the non-ionizable lipid component present in the lipid composition comprises one or more phospholipids, such as cholesterol-free lipid particle formulations or is composed of the one or more phospholipids. In certain embodiments, the non-ionizable lipid component present in the lipid composition comprises cholesterol or derivatives thereof, such as phospholipid-free lipid particle formulations or is composed of the cholesterol or derivatives thereof.

[0465] In certain embodiments, the lipid component in the lipid composition (e.g., LNP composition) includes a combination of phytosterols or phytosterols and cholesterol. In certain embodiments, the phytosterols are selected from the group consisting of: b-sitosterol, stigmasterol, b-sitostanol, campesterol, rapeseed sterol (brassicasterol) and combinations thereof. In certain embodiments, the phytosterols are selected from the group consisting of: b-sitosterol, b-sitostanol, campesterol, rapeseed sterol, compound S-140, compound S-151, compound S-156, compound S-157, compound S-159, compound S-160, compound S-164, compound S-165, compound S-170, compound S-173, compound S-175 and combinations thereof. In some embodiments, the phytosterol is selected from the group consisting of: compound S-140, compound S-151, compound S-156, compound S-157, compound S-159, compound S-160, compound S-164, compound S-165, compound S-170, compound S-173, compound S-175, and combinations thereof. In some embodiments, the phytosterol is a combination of compound S-141, compound S-140, compound S-143, and compound S-148. In some embodiments, the phytosterol includes sitosterol or a salt or ester thereof. In some embodiments, the phytosterol includes stigmasterol or a salt or ester thereof.

[0466] In some embodiments, the plant sterol is β-sitosterol its salts or esters.

[0467] In some embodiments, the lipid composition (eg, LNP composition) includes phytosterol or a salt or ester thereof, and cholesterol or a salt thereof.

[0468] In certain embodiments, the targeted delivery cell of the lipid composition is a cell as described herein (e.g., a hepatocyte or a splenocyte), and the phytosterol or its salt or ester is selected from the group consisting of: b-sitosterol, b-sitostanol, campesterol and rapeseed sterol and combinations thereof. In certain embodiments, the phytosterol is b-sitosterol. In certain embodiments, the phytosterol is b-sitostanol. In certain embodiments, the phytosterol is campesterol. In certain embodiments, the phytosterol is rapeseed sterol.

[0469] In some embodiments, the targeted delivery cell of the lipid composition is a cell as described herein (e.g., a hepatocyte or a splenocyte), and the phytosterol or its salt or ester is selected from the group consisting of: b-sitosterol and stigmasterol and combinations thereof. In some embodiments, the phytosterol is b-sitosterol. In some embodiments, the phytosterol is stigmasterol.

[0470] Other examples of non-ionizable lipid components include phosphorus-free lipids such as stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glyceryl ricinoleate, cetyl stearate, isopropyl myristate, amphoteric acrylic acid polymers, triethanolamine-lauryl sulfate, alkyl-aryl sulfate polyethoxylated fatty acid amides, dioctadecyldimethylammonium bromide, ceramides, and sphingomyelin.

[0471] In some embodiments, the non-ionizable lipid component is present at 10 mol% to 60 mol%, 20 mol% to 55 mol%, 20 mol% to 45 mol%, 20 mol% to 40 mol%, 25 mol% to 50 mol%, 25 mol% to 45 mol%, 30 mol% to 50 mol%, 30 mol% to 45 mol%, 30 mol% to 40 mol%, 35 mol% to 45 mol%, 37 mol% to 42 mol%, or 35 mol%, 36 mol%, 37 mol%, 38 mol%, 39 mol%, 40 mol%, 41 mol%, 42 mol%, 43 mol%, 44 mol%, or 45 mol% (or any portion or range thereof) of the total lipids present in the lipid composition.

[0472] In embodiments where the lipid composition contains a mixture of phospholipids and cholesterol or a cholesterol derivative, the mixture may be present at up to 40 mol%, 45 mol%, 50 mol%, 55 mol% or 60 mol% of the total lipids present in the lipid composition.

[0473] In certain embodiments, the phospholipid component in the mixture can exist with 2mol% to 20mol%, 2mol% to 15mol%, 2mol% to 12mol%, 4mol% to 15mol% or 4mol% to 10mol% (or any part or scope therein) of the TL present in the lipid composition.In certain embodiments, the phospholipid component in the mixture exists with 5mol% to 10mol%, 5mol% to 9mol%, 5mol% to 8mol%, 6mol% to 9mol%, 6mol% to 8mol% or 5mol%, 6mol%, 7mol%, 8mol%, 9mol% or 10mol% (or any part or scope therein) of the TL present in the lipid composition.

[0474] In certain embodiments, the sterol component (for example, cholesterol component) in the mixture can exist with 25mol% to 45mol%, 25mol% to 40mol%, 30mol% to 45mol%, 30mol% to 40mol%, 27mol% to 37mol%, 25mol% to 30mol% or 35mol% to 40mol% (or any part or scope therein) of the TL present in the lipid composition. In certain embodiments, the cholesterol component in the mixture exists with 25mol% to 35mol%, 27mol% to 35mol%, 29mol% to 35mol%, 30mol% to 35mol%, 30mol% to 34mol%, 31mol% to 33mol% or 30mol%, 31mol%, 32mol%, 33mol%, 34mol% or 35mol% (or any part or scope therein) of the TL present in the lipid composition.

[0475] In embodiments where the lipid composition does not contain phospholipids, cholesterol or a derivative thereof may be present at up to 25 mol%, 30 mol%, 35 mol%, 40 mol%, 45 mol%, 50 mol%, 55 mol% or 60 mol% of the total lipids present in the lipid composition.

[0476] In some embodiments, the sterol component (e.g., cholesterol or a derivative thereof) in the phospholipid-free lipid particle formulation may be present at 25 mol% to 45 mol%, 25 mol% to 40 mol%, 30 mol% to 45 mol%, 30 mol% to 40 mol%, 31 mol% to 39 mol%, 32 mol% to 38 mol%, 33 mol% to 37 mol%, 35 mol% to 45 mol%, 30 mol% to 35 mol%, 35 mol% to 40 mol%, or 30 mol%, 31 mol%, 32 mol%, 33 mol%, 34 mol%, 35 mol%, 36 mol%, 37 mol%, 38 mol%, 39 mol% or 40 mol% (or any portion or range thereof) of the total lipid present in the lipid composition.

[0477] In some embodiments, the non-ionizable lipid component may be present at 5 mol% to 90 mol%, 10 mol% to 85 mol%, 20 mol% to 80 mol%, 10 mol% (e.g., phospholipids only), or 60 mol% (e.g., phospholipids and cholesterol or derivatives thereof) of the total lipids present in the lipid composition (or any portion or range therein).

[0478] The percentage of non-ionizable lipid present in the lipid composition is a target amount, and the actual amount of non-ionizable lipid present in the particle can vary, for example, by ±5 mol%.

[0479] Lipid conjugates

[0480] The lipid compositions described herein can further include one or more lipid conjugates. Conjugated lipids can prevent the aggregation of particles. Non-limiting examples of conjugated lipids include PEG-lipid conjugates, cationic polymer-lipid conjugates, and mixtures thereof.

[0481] In some embodiments, the lipid conjugate is a PEG-lipid or a PEG-modified lipid (alternatively referred to as a PEGylated lipid). PEG lipids are lipids modified with polyethylene glycol. Examples of PEG-lipids include, but are not limited to, PEG coupled to a dialkoxypropyl group (PEG-DAA), PEG coupled to diacylglycerol (PEG-DAG), PEG-modified dialkylamines, PEG-modified diacylglycerols (PEG-DEG), PEG coupled to phospholipids such as phosphatidylethanolamine (PEG-PE), PEG-modified phosphatidic acid, PEG conjugated to ceramide (PEG-CER), PEG conjugated to cholesterol or its derivatives, and mixtures thereof.

[0482] For example, the PEG lipid can be a PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or PEG-DSPE lipid.

[0483] In some embodiments, the PEG-lipid is selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol.

[0484] In some embodiments, the PEG-lipid is selected from the group consisting of 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-disterylglycerol (PEG-DSG), PEG-dipalmitoyl, PEG-dioleyl, PEG-distearoyl, PEG-diacylglycinamide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE), or PEG-1,2-dimyristyloxypropyl-3-amine (PEG-c-DMA).

[0485] PEG is a linear, water-soluble polymer of ethylene PEG repeating units with two terminal hydroxyl groups. PEG is classified by its molecular weight and includes the following: monomethoxypolyethylene glycol (MePEG-OH), monomethoxypolyethylene glycol-succinate (MePEG-S), monomethoxypolyethylene glycol-succinimidyl succinate (MePEG-S-NHS), monomethoxypolyethylene glycol-amine (MePEG-NH2), monomethoxypolyethylene glycol-trifluoroethanesulfonate (MePEG-TRES), monomethoxypolyethylene glycol-imidazolyl-carbonyl (MePEG-IM), and compounds containing terminal hydroxyl groups instead of terminal methoxy groups (e.g., HO-PEG-S, HO-PEG-S-NHS, HO-PEG-NH2).

[0486] The PEG portion of the PEG-lipid conjugates described herein can include an average molecular weight ranging from 550 to 10,000 Daltons. In some cases, the average molecular weight of the PEG portion is from 750 to 5,000 Daltons (e.g., from 1,000 to 5,000 Daltons, from 1,500 to 3,000 Daltons, from 750 to 3,000 Daltons, from 750 to 2,000 Daltons). In some embodiments, the average molecular weight of the PEG portion is 2,000 Daltons or 750 Daltons.

[0487] In some cases, PEG can be optionally substituted by alkyl, alkoxy, acyl or aryl. PEG can be directly conjugated to lipid, or can be connected to lipid via a linker moiety. Any linker moiety suitable for making PEG and lipid coupling can be used, including, for example, a linker moiety without ester and a linker moiety containing ester. In certain embodiments, the linker moiety is a linker moiety without ester. Suitable linkers without ester include, but are not limited to, amides (-C (O) NH-), amino (-NR-), carbonyl (-C (O)-), carbamates (-NHC (O) O-), urea (-NHC (O) NH-), disulfides (-SS-), ethers (-O-), succinyl (-(O) CCH2CH2C (O)-), succinyl (-NHC (O) CH2CH2C (O) NH-), ethers, disulfides and combinations thereof (such as joints containing carbamate linker moieties and amide linker moieties). In certain embodiments, a carbamate linker is used to make PEG and lipid coupling.

[0488] In some embodiments, an ester-containing linker moiety is used to couple PEG to a lipid. Suitable ester-containing linker moieties include, for example, carbonate (—OC(O)O—), succinyl, phosphate (—O—(O)POH—O—), sulfonate, and combinations thereof.

[0489] Phosphatidylethanolamines of various acyl chain groups with different chain lengths and degrees of saturation can be conjugated to PEG to form lipid conjugates. Such phosphatidylethanolamines are commercially available or can be isolated or synthesized using conventional techniques known to those skilled in the art.

[0490] In some embodiments, the phosphatidylethanolamine contains saturated or unsaturated fatty acids with carbon chain lengths ranging from C10 to C20. Phosphatidylethanolamines with monounsaturated or diunsaturated fatty acids and mixtures of saturated and unsaturated fatty acids can also be used. Suitable phosphatidylethanolamines include, but are not limited to, dimyristoyl-phosphatidylethanolamine (DMPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dioleoyl-phosphatidylethanolamine (DOPE), and distearoyl-phosphatidylethanolamine (DSPE).

[0491] The term "diacylglycerol" or "DAG" includes compounds having two fatty acyl chains, R1 and R2, both independently having 2 to 30 carbon atoms bonded to the 1- and 2-positions of glycerol via ester bonds. The acyl groups can be saturated or have varying degrees of unsaturation. Suitable acyl groups include, but are not limited to, lauroyl (C12), myristoyl (C16), palmitoyl (C16), stearoyl (C18), and icosoyl (C20). In some embodiments, R1 and R2 are the same, i.e., both R1 and R2 are myristoyl (i.e., dimyristoyl) and both R1 and R2 are stearoyl (i.e., distearoyl).

[0492] The term "dialkoxypropyl" or "DAA" encompasses compounds having two alkyl chains, R and R', both independently having from 2 to 30 carbons. The alkyl groups can be saturated or have varying degrees of unsaturation.

[0493] In some embodiments, the PEG-DAA conjugate is a PEG-didecyloxypropyl (C10) conjugate, a PEG-dilauryloxypropyl (C12) conjugate, a PEG-dimyristyloxypropyl (C14) conjugate, a PEG-dipalmityloxypropyl (C16) conjugate, or a PEG-distearyloxypropyl (C18) conjugate. In some embodiments, the PEG has an average molecular weight of 750 or 2,000 Daltons. In some embodiments, the terminal hydroxyl group of the PEG is substituted with a methyl group.

[0494] In addition to the foregoing, other hydrophilic polymers can be used instead of PEG. Examples of suitable polymers that can be used to replace PEG include, but are not limited to, polyvinyl pyrrolidone, polymethyl oxazoline, polyethyl oxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide and polydimethylacrylamide, polylactic acid, polyglycolic acid and derivatized cellulose (such as hydroxymethyl cellulose or hydroxyethyl cellulose).

[0495] In some embodiments, the PEG-lipid is of the formula A compound or a salt thereof, wherein:

[0496] R 3PL1 Yes–OR OPL1 ;

[0497] R OPL1 is hydrogen, optionally substituted alkyl, or an oxygen protecting group;

[0498] r PL1 an integer between 1 and 100 (inclusive);

[0499] L 1 is an optionally substituted C 1-10Alkylene, wherein the optionally substituted C 1-10 At least one methylene group of the alkylene group is independently optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, O, N(R NPL1 )、S、C(O)、C(O)N(R NPL1 ),NR NPL1 C(O), -C(O)O, OC(O), OC(O)O, OC(O)N(R NPL1 ),NR NPL1 C(O)O or NR NPL1 C(O)N(R NPL1 )replace;

[0500] D is a moiety obtained by click chemistry or a moiety cleavable under physiological conditions; m PL1 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0501] A is the following formula:

[0502] L 2 Each instance of is independently a bond or an optionally substituted C 1-6 Alkylene, wherein the optionally substituted C 1-6 A methylene unit of the alkylene group is optionally replaced by O, N(R NPL1 )、S、C(O)、C(O)N(R NPL1 ),NR NPL1 C(O), C(O)O, OC(O), OC(O)O, -OC(O)N(R NPL1 ),NR NPL1 C(O)O or NR NPL1 C(O)N(R NPL1 )replace;

[0503] R 2SL Each instance of is independently optionally substituted C 1-30 Alkyl, optionally substituted C 1-30 Alkenyl or optionally substituted C 1-30 Alkynyl; optionally wherein R 2SL The one or more methylene units are independently optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, N(R NPL1 )、O、S、C(O)、C(O)N(R NPL1 ),NR NPL1 C(O),-NR NPL1 C(O)N(R NPL1 ), C(O)O, OC(O), OC(O)O, OC(O)N(RNPL1 ),NR NPL1 C(O)O, C(O)S, -SC(O), C(=NR NPL1 ), C(=NR NPL1 )N(R NPL1 ),NR NPL1 C(=NR NPL1 ),-NR NPL1 C(=NR NPL1 )N(R NPL1 )、C(S)、C(S)N(R NPL1 ),NR NPL1 C(S),NR NPL1 C(S)N(R NPL1 ), S(O), OS(O), S(O)O, OS(O)O, OS(O)2, S(O)2O, OS(O)2O, N(R NPL1 )S(O), S(O)N(R NPL1 )、-N(R NPL1 )S(O)N(R NPL1 )、OS(O)N(R NPL1 )、N(R NPL1 )S(O)O、S(O)2、N(R NPL1 )S(O)2、-S(O)2N(R NPL1 )、N(R NPL1 )S(O)2N(R NPL1 )、OS(O)2N(R NPL1 ) or N(R NPL1 )S(O)2O replacement;

[0504] R NPL1 Each instance of is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group;

[0505] Ring B is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and

[0506] p SL It is 1 or 2.

[0507] In some embodiments, the PEG-lipid is of the formula A compound or a salt thereof, wherein r PL1 , L 1 ,D,m PL1 and A are as defined above.

[0508] In some embodiments, the PEG-lipid is of the formula A compound or a salt or isomer thereof, wherein:

[0509] R 3PEGYes–OR O ;

[0510] R O It is hydrogen, C 1-6 alkyl or oxygen protecting groups;

[0511] r PEG is an integer from 1 to 100 (e.g., 40 to 50, e.g., 45);

[0512] R 5PEG It is C 10-40 Alkyl (e.g., C 17 Alkyl), C 10-40 Alkenyl or C 10-40 Alkynyl; and R 5PEG Optionally, one or more methylene groups are independently replaced by C 3-10 Carbocyclylene, 4- to 10-membered heterocyclylene, C 6-10 Arylene, 4- to 10-membered heteroarylene, –N(R NPEG )–, –O–, –S–, –C(O)–, –C(O)N(R NPEG )–、–NR NPEG C(O)–,–NR NPEG C(O)N(R NPEG )–, –C(O)O–, –OC(O)–, –OC(O)O–, –OC(O)N(R NPEG )–、–NR NPEG C(O)O–, –C(O)S–, –SC(O)–, –C(=NR NPEG )–、–C(=NR NPEG )N(R NPEG )–、–NR NPEG C(=NR NPEG )–、–NR NPEG C(=NR NPEG )N(R NPEG )–, –C(S)–, –C(S)N(R NPEG )–、–NR NPEG C(S)–,–NR NPEG C(S)N(R NPEG )–, –S(O)–, –OS(O)–, –S(O)O–, –OS(O)O–, –OS(O)2–, –S(O)2O–, –OS(O)2O–, –N(R NPEG )S(O)–、–S(O)N(R NPEG )–、–N(R NPEG )S(O)N(R NPEG )–、–OS(O)N(R NPEG )–、–N(R NPEG)S(O)O–, –S(O)2–, –N(R NPEG )S(O)2–、–S(O)2N(R NPEG )–、–N(R NPEG )S(O)2N(R NPEG )–、–OS(O)2N(R NPEG )–or–N(R NPEG )S(O)2O–substituted; and

[0513] R NPEG Each instance of is independently hydrogen, C 1-6 Alkyl or nitrogen protecting group.

[0514] In some embodiments, the PEG-lipid is of the formula Compounds where r PEG is an integer from 1 to 100 (eg, 40 to 50, for example, 45).

[0515] In some embodiments, the PEG-lipid is of the formula A compound or a salt or isomer thereof, wherein s PL1 is an integer from 1 to 100 (eg, 40 to 50, for example, 45).

[0516] In some embodiments, the PEG-lipid has the formula or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:

[0517] R 8 and R 9 are each independently a linear or branched, saturated or unsaturated alkyl chain containing 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds (e.g., R 8 and R 9 are each independently a straight chain, saturated alkyl chain containing 12 to 16 carbon atoms); and

[0518] w has an average value ranging from 30 to 60 (eg, an average w of about 49).

[0519] In certain embodiments, in lipid compositions, incorporating any one of the above-mentioned PEG-lipids can improve the pharmacokinetics and / or biodistribution of the lipid compositions. For example, in lipid compositions, incorporating any one of the above-mentioned PEG-lipids can reduce accelerated blood clearance (ABC) effect.

[0520] Other ionizable lipids

[0521] In some embodiments, the lipid composition may include one or more additional ionizable lipids other than the ionizable lipids described herein. Exemplary ionizable lipids include, but are not limited to,

[0522] LP01

[0523] SM-86

[0524] SM-102

[0525] ALC-0315

[0526] Lipid 10

[0527] MC3 Acuitas lipid 9 and Acuitas lipid 10 (see WO 2017 / 004143A1, herein incorporated by reference in its entirety).

[0528] In one embodiment, the additional ionizable lipid is heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecanoxy)hexyl)amino)octanoate (SM-102); e.g., as described in Example 1 of U.S. Patent No. 9,867,888, which is herein incorporated by reference in its entirety.

[0529] In one embodiment, the additional ionizable lipid is octadec-9,12-dienoic acid 9Z,12Z)-3-((4,4-bis(octyloxy)butyryl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl ester (LP01), e.g., as synthesized in Example 13 of WO 2015 / 095340, which is herein incorporated by reference in its entirety.

[0530] In one embodiment, the additional ionizable lipid is di((Z)-non-2-en-1-yl) 9-((4-dimethylamino)butanoyl)oxy)heptadecanedioate (L319); for example, as synthesized in Example 7, 8 or 9 of US2012 / 0027803 (which is herein incorporated by reference in its entirety).

[0531] In one embodiment, the additional ionizable lipid is 1,1′-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), e.g., as synthesized in Examples 14 and 16 of WO 2010 / 053572, herein incorporated by reference in its entirety.

[0532] In one embodiment, the additional ionizable lipid is the imidazolyl cholesterol ester (ICE) lipid (3S,10R,13R,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3-yl 3-(1H-imidazol-4-yl)propanoate, for example, structure (I) from WO 2020 / 106946, which is incorporated herein by reference in its entirety.

[0533] In one embodiment, the additional ionizable lipid is MC3 (6Z, 9Z, 28Z, 31Z)-triacontac-6, 9, 28, 31-tetraen-19-yl-4-(dimethylamino) butyrate (DLin-MC3-DMA or MC3), for example, as described in Example 9 of WO 2019 / 051289A9, which is incorporated herein by reference in its entirety.

[0534] In one embodiment, the additional ionizable lipid is lipid ATX-002, e.g., as described in Example 10 of WO 2019 / 051289A9, which is incorporated herein by reference in its entirety.

[0535] In one embodiment, the additional ionizable lipid is (13Z,16Z)-A,A-dimethyl-3-nonyldocosa-13,16-dien-1-amine (Compound 32), for example, as described in Example 11 of WO 2019 / 051289A9, which is incorporated herein by reference in its entirety.

[0536] In one embodiment, the additional ionizable lipid is Compound 6 or Compound 22, for example, as described in Example 12 of WO2019 / 051289A9 (which is incorporated herein by reference in its entirety).

[0537] Examples of additional ionizable lipids that can be used in the lipid composition include the ionizable lipids listed in Table 1 of WO 2019 / 051289, which is incorporated herein by reference.

[0538] Additional lipid components

[0539] Some non-limiting examples of additional lipid compounds that can be used (e.g., in combination with the ionizable lipid compounds and other lipid components described herein) to form lipid compositions include:

[0540]

[0541]

[0542] In some embodiments, the lipid composition further comprises a lipid of formula (i), (ii), (iii), (iv), (v), (vi), (vii), (viii), or (ix).

[0543] In some embodiments, the lipid composition further comprises the following compound having the following structure: in:

[0544] X 1 It is O, NR 1 Or direct key, X 2 It is C 2-5 Alkylene, and X 3 is C(=O) or a direct bond;

[0545] R 1 is H or Me, R 3 It is C 1-3 Alkyl, R 2 It is C 1-3 Alkyl, or R 2 The nitrogen atom and X 2 1-3 carbon atoms of the amine group together form a 4-membered, 5-membered or 6-membered ring; or

[0546] X 1 It is NR 1 , R 1 and R 2 Together with the nitrogen atom to which it is attached, it forms a 5-membered or 6-membered ring, or R 2 and R 3 Together with the nitrogen atom to which it is attached, it forms a 5-, 6-, or 7-membered ring;

[0547] Y 1 It is C 2-12 Alkylene, and Y 2 Selected from

[0548]

[0549] (either direction), (either direction), (either direction),

[0550] n is 0 to 3;

[0551] R 4 It is C 1-15 alkyl;

[0552] Z 1 It is C 1-6 alkylene or a direct bond, and Z 2 yes (either direction) or not present, if Z 1 is a direct key, then Z 2 does not exist;

[0553] R 5 It is C 5-9 Alkyl or C 6-10 Alkoxy, R 6 It is C 5-9 Alkyl or C 6-10 alkoxy;

[0554] W is a methylene group or a direct bond; and

[0555] R 7 is H or Me, or a salt thereof;

[0556] The condition is that if R 3 and R 2 is a C2 alkyl group, X 1 It's O, X 2 is a linear C3 alkylene group, X 3 is C(=O), Y 1 is a linear C5 alkylene group, (Y 2 )nR 4 yes R 4 is a linear C5 alkyl group, Z 1 is C2 alkylene, Z 2 Not present, W is methylene and R 7 is H, then R 5 and R 6 Not a C2 alkoxy group.

[0557] In some embodiments, the lipid composition further comprises one or more compounds of formula (x).

[0558] Additional non-limiting examples of lipid compounds that may be further included in the lipid composition further include (e.g., in combination with the lipid compounds and other lipid components described herein):

[0559]

[0560]

[0561] In some embodiments, the lipid composition further comprises one or more compounds of Formula (xi), (xii), (xiii), (xiv), (xv), (xvi), (xvii), (xviii) (e.g., (xviii)a, (xviii)b), or (xix).

[0562] In some embodiments, the lipid composition further comprises a lipid formed by one of the following reactions:

[0563]

[0564] In some embodiments, the lipid composition further comprises a lipid having formula (xxi) (e.g., in combination with the lipid compounds and other lipid components described herein): in:

[0565] Each n is independently an integer from 2 to 15;

[0566] L1 and L3 are each independently -OC(O)-* or -C(O)O-*, where "*" indicates the point of attachment to R1 or R3;

[0567] R1 and R3 are each independently a linear or branched C9-C 20 Alkyl or C9-C 20 alkenyl: oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocycloalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkynyl, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocycloalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclocarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; and

[0568] R2 is selected from the group consisting of:

[0569]

[0570] In some embodiments, the lipid composition further includes one or more compounds of formula (xxi). In some embodiments, the compound of formula (xxi) includes a lipid described in WO 2021 / 113777 (e.g., a lipid of formula (1), such as the lipid of Table 1 of WO 2021 / 113777), which is incorporated herein by reference in its entirety.

[0571] In some embodiments, the lipid composition further comprises a lipid having formula (xxii) (e.g., in combination with a lipid compound and other lipid components described herein): in:

[0572] Each n is independently an integer from 1 to 15;

[0573] R1 and R2 are each independently selected from the group consisting of:

[0574]

[0575] R3 is selected from the group consisting of:

[0576]

[0577] In some embodiments, the lipid composition further includes one or more compounds of formula (xxii). In some embodiments, the compound of formula (xxii) includes a lipid described in WO 2021 / 113777 (e.g., a lipid of formula (2), such as the lipid of Table 2 of WO 2021 / 113777), which is incorporated herein by reference in its entirety.

[0578] In some embodiments, the lipid composition further comprises a lipid having formula (xxiii) (e.g., in combination with the lipid compounds and other lipid components described herein):

[0579] in

[0580] X is selected from -O-, -S- or -OC(O)-*, where * indicates the point of attachment to R1;

[0581] R1 is selected from the group consisting of:

[0582] and

[0583] R2 is selected from the group consisting of:

[0584]

[0585] In some embodiments, the lipid composition further includes one or more compounds of formula (xxiii). In some embodiments, the compound of formula (xxiii) includes a lipid described in WO 2021 / 113777 (e.g., a lipid of formula (3), such as the lipid of Table 3 of WO 2021 / 113777), which is incorporated herein by reference in its entirety.

[0586] Examples of additional lipids that can be used in the lipid composition include, but are not limited to, one or more of the following formulae: X of US2016 / 0311759; I of US20150376115 or US2016 / 0376224; I, II, or III of US2016 / 0151284; I, IA, II, or IIA of US2017 / 0210967; Ic of US2015 / 0140070; A of US2013 / 0178541; I of US2013 / 0303587 or US 2013 / 0123338; ​​I of US2015 / 0141678; II, III, IV, or V of US2015 / 0239926; I of US2017 / 0119904; I or II of US2017 / 117528; A of US2012 / 0149894; A of US2015 / 0057373; A of WO 2013 / 116126; A of US2013 / 0090372; A of US2013 / 0274523; A of US2013 / 0274504; A of US2013 / 0053572; A of WO 2013 / 016058; A of WO 2012 / 162210; I of US2008 / 042973; US I, II, III or IV of US2012 / 01287670; I or II of US2014 / 0200257; I, II or III of US2015 / 0203446; I or III of US2015 / 0005363; I, IA, IB, IC, ID, II, IIA, IIB, IIC, IID or III-XXIV of US2014 / 0308304; of US2013 / 0338210; I, II, III or IV of WO 2009 / 132131; A of US2012 / 01011478; I or XXXV of US2012 / 0027796; XIV or XVII of US2012 / 0058144; of US2013 / 0323269; I of US2011 / 0117125; I, II or III of US2011 / 0256175; I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII of US2012 / 0202871; I, II, III, IV, V, VI, VII, VIII, X, XII, XIII, XIV, XV or XVI of US2011 / 0076335; I or II of US2006 / 008378; I of US2013 / 0123338; ​​I or XAYZ of US2015 / 0064242; XVI, XVII or XVIII of US2013 / 0022649; I, II or III of US2013 / 0116307;I, II, or III of US 2013 / 0116307; I or II of US 2010 / 0062967; IX of US 2013 / 0189351; I of US 2014 / 0039032; V of US 2018 / 0028664; I of US 2016 / 0317458; I of US 2013 / 0195920; 5, 6, or 10 of US 10,221,127; III-3 of WO 2018 / 081480; I-5 or I-8 of WO 2020 / 081938; 18 or 25 of US 9,867,888; A of US 2019 / 0136231; WO II of 2020 / 219876; 1 of US2012 / 0027803; OF-02 of US2019 / 0240349; 23 of US10,086,013; cKK-E12 / A6 of Miao et al. (2020); C12-200 of WO 2010 / 053572; 7C1 of Dahlman et al. (2017); 304-O13 or 503-O13 of Whitehead et al.; TS-P4C2 of U S9,708,628; I of WO 2020 / 106946; I of WO 2020 / 106946; (1), (2), (3) or (4) of WO 2021 / 113777; and WO Any of Tables 1-16 of 2021 / 113777, all of which are incorporated herein by reference in their entirety. ;

[0587] In some embodiments, the lipid conjugate (e.g., PEG-lipid) is present at 0.1 mol% to 2 mol%, 0.5 mol% to 2 mol%, 1 mol% to 2 mol%, 0.6 mol% to 1.9 mol%, 0.7 mol% to 1.8 mol%, 0.8 mol% to 1.7 mol%, 0.9 mol% to 1.6 mol%, 0.9 mol% to 1.8 mol%, 1 mol% to 1.8 mol%, 1 mol% to 1.7 mol%, 1.2 mol% to 1.8 mol%, 1.2 mol% to 1.7 mol%, 1.3 mol% to 1.6 mol%, or 1.4 mol% to 1.5 mol% (or any portion or range thereof) of the total lipid present in the lipid composition. In some embodiments, the lipid conjugate (e.g., PEG-lipid) is present at 0 mol% to 20 mol%, 0.5 mol% to 20 mol%, 2 mol% to 20 mol%, 1.5 mol% to 18 mol%, 2 mol% to 15 mol%, 4 mol% to 15 mol%, 2 mol% to 12 mol%, 5 mol% to 12 mol%, or 2 mol% (or any portion or range thereof) of the total lipid present in the lipid composition.

[0588] In some embodiments, the lipid conjugate (e.g., PEG-lipid) lipid composition is 4 mol% to 10 mol%, 5 mol% to 10 mol%, 5 mol% to 9 mol%, 5 mol% to 8 mol%, 6 mol% to 9 mol%, 6 mol% to 8 mol%, or 5 mol%, 6 mol%, 7 mol%, 8 mol%, 9 mol%, or 10 mol% (or any portion or range thereof) of the total lipid present in the lipid composition.

[0589] The percentage of lipid conjugate (e.g., PEG-lipid) present in the lipid compositions of the present disclosure is a target amount, and the actual amount of lipid conjugate present in the composition can vary, for example, by ±2 mol%. One of ordinary skill in the art will understand that the concentration of the lipid conjugate can vary depending on the lipid conjugate used and the rate at which the lipid particles fuse.

[0590] By controlling the composition and concentration of the lipid conjugates, the rate at which the lipid conjugates are exchanged out of the lipid composition can be controlled, and the rate at which the lipid composition becomes fused can be controlled. In addition, other variables comprising, for example, pH, temperature, or ionic strength can be used to change and / or control the rate at which the lipid composition becomes fused. After reading this disclosure, other methods that can be used to control the rate at which the lipid composition becomes fused will become apparent to those skilled in the art. Similarly, by controlling the composition and concentration of the lipid conjugates, the lipid particle size can be controlled.

[0591] In certain embodiments, the lipid composition containing ionizable lipid compounds can include 30-70% ionizable lipid compounds, 0-60% cholesterol, 0-30% phospholipids and 1-10% polyethylene glycol (PEG). In certain embodiments, the lipid composition includes 30-40% ionizable lipid compounds, 40-50% cholesterol and 10-20% PEG. In certain embodiments, the lipid composition includes 50-75% ionizable lipid compounds, 20-40% cholesterol and 5-10% phospholipids and 1-10% PEG. The lipid composition can contain 60-70% ionizable lipid compounds, 25-35% cholesterol and 5-10% PEG-lipid.

[0592] In some embodiments, the lipid component of the lipid composition comprises about 30 mol% to about 60 mol% (e.g., about 35-55 mol% or about 40-50 mol%) of an ionizable lipid compound as described herein, about 0 mol% to about 30 mol% (e.g., 5-25 mol% or 10-20 mol%) of a phospholipid, about 15 mol% to about 50 mol% (e.g., 18.5-48.5 mol% or 30-40 mol%) of a sterol, and about 0 mol% to about 10 mol% (e.g., 1-5 mol% or 1.5-2.5 mol%) of a PEGylated lipid, with the proviso that the total mol% of the lipid component does not exceed 100%.

[0593] In some embodiments, the lipid composition may contain up to 90% ionizable lipid compounds and 2-15% helper lipids.

[0594] In some embodiments, the lipid composition can be a lipid particle composition, for example, containing 8-30% ionizable lipid compounds, 5-30% helper lipids and 0-20% cholesterol. In some embodiments, the lipid nanoparticle composition contains 4-25% ionizable lipids, 4-25% helper lipids, 2-25% cholesterol, 10-35% cholesterol-PEG and 5% cholesterol-amine. In some embodiments, the lipid nanoparticle composition contains 2-30% ionizable lipids, 2-30% helper lipids, 1-15% cholesterol, 2-35% cholesterol-PEG and 1-20% cholesterol-amine. In some embodiments, the lipid nanoparticle composition contains up to 90% ionizable lipids and 2-10% helper lipids. In some embodiments, the lipid nanoparticle composition contains 100% ionizable lipids.

[0595] Other components of LNP compositions

[0596] In addition to the components described above, the lipid nanoparticle composition may further comprise one or more components. For example, the LNP composition may comprise one or more small hydrophobic molecules, such as vitamins (e.g., vitamin A or vitamin E) or sterols.

[0597] The lipid nanoparticle compositions may also comprise one or more penetration enhancer molecules, carbohydrates, polymers, surface altering agents, or other components.

[0598] Suitable carbohydrates can include monosaccharides (eg, glucose) and polysaccharides (eg, glycogen and its derivatives and analogs).

[0599] Polymers can be used to encapsulate or partially encapsulate nanoparticle compositions. Polymers can be biodegradable and / or biocompatible. Suitable polymers include, but are not limited to, polyamines, polyethers, polyamides, polyesters, polyurethanes, polyureas, polycarbonates, polystyrenes, polyimides, polysulfones, polyurethanes, polyacetylene, polyethylene, polyethyleneimine, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitrile, and polyarylates.For example, the polymer can include poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L-lactide-co-PEO-co-D,L-lactide). D,L-lactide-co-PPO-co-D,L-lactide), polyalkyl cyanoacrylates, polyurethanes, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA), polyethylene glycol, poly-L-glutamic acid, poly(hydroxy acids), polyanhydrides, polyorthoesters, poly(esteramides), polyamides, poly(ester ethers), polycarbonates, polyolefins (such as polyethylene and polypropylene), polyalkylene glycols (such as poly(ethylene glycol) (PEG)), polyalkylene oxides (PEO), polyalkylene terephthalates (such as poly(ethylene terephthalate)), polyvinyl alcohol (PVA), polyethylene ethers, polyethylene esters (such as poly(vinyl acetate)) ), polyvinyl halides (such as poly(vinyl chloride) (PVC)), polyvinyl pyrrolidone (PVP), polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses (such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitrocellulose, hydroxypropyl cellulose, carboxymethyl cellulose), acrylic acid polymers (such as poly(methyl (meth)acrylate) (PMMA), poly(ethyl (meth)acrylate), poly(butyl (meth)acrylate), poly(isobutyl (meth)acrylate), poly(hexyl (meth)acrylate), poly(isodecyl (meth)acrylate), poly(lauryl (meth)acrylate), and mixtures thereof), poly(phenyl (meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), and copolymers and mixtures thereof), polydioxanones and copolymers thereof, polyhydroxyalkanoates, polypropylene fumarate, polyoxymethylenes, poloxamers, polyamine oxides, poly(ortho)esters, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), trimethylene carbonate, poly(N-acryloylmorpholine) (PAcM), poly(2-methyl-2-oxazoline) (PMOX), poly(2-ethyl-2-oxazoline) (PEOZ), and polyglycerol.

[0600] Suitable surface-altering agents include, but are not limited to, anionic proteins (e.g., bovine serum albumin), surfactants (e.g., cationic surfactants such as dimethyldioctadecyl-ammonium bromide), sugars or sugar derivatives (e.g., cyclodextrins), nucleic acids, polymers (e.g., heparin, polyethylene glycol, and poloxamer), mucolytics (e.g., acetylcysteine, artemisia, bromelain, papain, zedoaria, bromhexine, carbocisteine, eprazinone, mesna, ambroxol, sobrerol, domiodol, letosteine, stepronin, tiopronin, gelsolin, thymosin beta 4, dornase alfa, neltenexine, and erdosteine), and DNA enzymes (e.g., rhDNA enzyme). The surface-altering agent can be disposed within and / or on the surface of the lipid nanoparticle (eg, by coating, adsorption, covalent attachment, or other methods).

[0601] The lipid nanoparticle composition can also include one or more functionalized lipids. For example, the lipid can be functionalized with an alkyne that undergoes a cycloaddition reaction when exposed to an azide under appropriate reaction conditions. Specifically, the lipid bilayer can be functionalized in this manner with one or more groups that can be used to promote membrane penetration, cell recognition, or imaging. The surface of the lipid nanoparticle can also be conjugated with one or more useful antibodies. Functional groups and conjugates that can be used for targeted cell delivery, imaging, and membrane penetration are well known in the art.

[0602] The lipid nanoparticle composition can include any substance useful in a pharmaceutical composition. For example, the lipid nanoparticle composition can include one or more pharmaceutically acceptable excipients or auxiliary ingredients, such as, but not limited to, one or more solvents, dispersion media, diluents, dispersing aids, suspending aids, granulation aids, disintegrants, fillers, glidants, liquid vehicles, binders, surfactants, isotonicity agents, thickeners or emulsifiers, buffers, lubricants, oils, preservatives, and other substances. Excipients such as waxes, butters, colorants, coating agents, flavorings, and fragrances may also be included.

[0603] Suitable diluents may include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and / or combinations thereof. Granulating and dispersing agents may be selected from a non-limiting list consisting of potato starch, corn starch, tapioca starch, sodium starch glycolate, clay, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methyl cellulose, pregelatinized starch (starch 1500), microcrystalline starch, water-insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate Sodium lauryl sulfate, quaternary ammonium compounds and / or combinations thereof.

[0604] Suitable surfactants and / or emulsifiers may include, but are not limited to, natural emulsifiers (e.g., gum arabic, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan gum, pectin, gelatin, egg yolk, casein, lanolin, cholesterol, waxes, and lecithin), colloidal clays (e.g., bentonite [aluminum silicate] and [magnesium aluminum silicate]), long-chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxypolymethylene, polyacrylic acid, acrylic acid polymers, and carboxyvinyl polymers), carrageenan, cellulose derivatives (e.g., sodium carboxymethylcellulose, powdered cellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate [ 20], polyoxyethylene sorbitan[ 60], polyoxyethylene sorbitan monooleate[ 80], Sorbitan monopalmitate[ 40], Sorbitan monostearate[ 60], Sorbitan tristearate[ 65], monoolein, sorbitan monooleate[ 80]), polyoxyethylene esters (e.g., polyoxyethylene monostearate [ 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate and ), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., ), polyoxyethylene ethers (e.g., polyoxyethylene lauryl ether [ 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, F 68, 188. Cetrimide bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium and / or a combination thereof.

[0605] Suitable binders may be starches (e.g., corn starch and starch paste); gelatin; sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol); natural and synthetic gums (e.g., gum arabic, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husk, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate and larch arabinogalactan); alginate; polyethylene oxide; polyethylene glycol; inorganic calcium salt; silicic acid; polymethacrylate; wax; water; alcohol; and combinations thereof or any other suitable binder.

[0606] Suitable preservatives can include but are not limited to antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives and / or other preservatives. The example of antioxidant includes but is not limited to alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite and / or sodium sulfite. The example of chelating agent includes ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate, edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid and / or trisodium edetate. Examples of antimicrobial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethanol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and / or thimerosal. Examples of antifungal preservatives include, but are not limited to, butylparaben, methylparaben, ethylparaben, propylparaben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and / or sorbic acid. Examples of alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, benzyl alcohol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoates and / or phenylethyl alcohol. Examples of acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroascorbic acid, ascorbic acid, sorbic acid and / or phytic acid. Other preservatives include, but are not limited to, tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, GLYDANT Methyl paraben, 115. II. NEOLONE TM KATHON TM and / or

[0607] Suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, silicon dioxide, talc, malt, glyceryl behenate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and combinations thereof.

[0608] Suitable oils include, but are not limited to, almond oil, apricot kernel oil, avocado oil, babassu oil, bergamot oil, black currant seed oil, borage oil, juniper oil, chamomile oil, rapeseed oil, caraway oil, babassu oil, castor oil, cinnamon oil, cocoa butter oil, coconut oil, cod liver oil, coffee oil, corn oil, cottonseed oil, emu oil, eucalyptus oil, evening primrose oil, fish oil, linseed oil, geraniol oil, gourd oil, grape seed oil, hazelnut oil, hyssop oil, isopropyl myristate, jojoba oil, macadamia oil, lavender oil, lavender oil, lemon oil, litsea cubeba oil, macadamia nut oil, mallow oil, mango seed oil, meadowfoam seed oil, mink oil, nutmeg oil, olive oil, sweet orange oil, deep sea fish oil (orange roughy oil), palm oil, palm kernel oil, peach kernel oil, peanut oil, poppy seed oil, pumpkin seed oil, rapeseed oil, rice bran oil, rosemary oil, safflower oil, sandalwood oil, sasquana oil, savory oil, sea buckthorn oil, sesame oil, shea butter, ketone oil, soybean oil, sunflower oil, tea tree oil, thistle oil, tsubaki oil, vetiver oil, walnut oil, and wheat germ oil, as well as butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, simethicone, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and / or combinations thereof.

[0609] In some embodiments, the lipid composition further includes one or more cryoprotectants. Suitable cryoprotectants include but are not limited to polyols (e.g., diols or triols, such as propylene glycol (i.e., 1,2-propylene glycol), 1,3-propylene glycol, glycerol, (+ / -)-2-methyl-2,4-pentanediol, 1,6-hexanediol, 1,2-butylene glycol, 2,3-butylene glycol, ethylene glycol or diethylene glycol), non-detergent sulfobetaines (e.g., NDSB-201 (3-(1-pyrido)-1-propanesulfonate)), permeates (e.g., L-proline or trimethylamine N-oxide dihydrate), polymers (e.g., polyethylene glycol 200 (PEG 200), PEG 400, PEG 600, PEG 1000, PEG 2k-DMG, PEG 3350, PEG 4000, PEG 8000, PEG 10000, PEG 20000, polyethylene glycol monomethyl ether 550 (mPEG 550), mPEG 600, mPEG 2000, mPEG 3350, mPEG 4000, mPEG 5000, polyvinylpyrrolidone (e.g., polyvinylpyrrolidone K15), pentaerythritol propoxylate or polypropylene glycol P400), an organic solvent (e.g., dimethyl sulfoxide (DMSO) or ethanol), a sugar (e.g., D-(+)-sucrose, D-sorbitol, trehalose, D-(+)-maltose monohydrate, m-erythritol, xylitol, inositol, D-(+)-raffinose pentahydrate, D-(+)-trehalose dihydrate or D-(+)-glucose monohydrate) or a salt (e.g., lithium acetate, lithium chloride, lithium formate, lithium nitrate, lithium sulfate, magnesium acetate, sodium acetate, sodium chloride, sodium formate, sodium malonate, sodium nitrate, sodium sulfate or any hydrate thereof), or any combination thereof.

[0610] In some embodiments, the cryoprotectant comprises sucrose. In some embodiments, the cryoprotectant and / or the excipient is sucrose. In some embodiments, the cryoprotectant comprises sodium acetate. In some embodiments, the cryoprotectant and / or the excipient is sodium acetate. In some embodiments, the cryoprotectant comprises sucrose and sodium acetate.

[0611] In some embodiments, the composition further comprises one or more buffers. Suitable buffers include, but are not limited to, citrate buffer solution, acetate buffer solution, phosphate buffer solution, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glucuronate, calcium glucoheptonate, calcium gluconate, d-gluconic acid, calcium glycerophosphate, calcium lactate, calcium lactobionate, propionic acid, calcium valerate, valeric acid, dibasic calcium phosphate, phosphoric acid, tricalcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixture, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, potassium phosphate mixture, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium phosphate mixture, tromethamine, sulfamate buffer (e.g., HEPES), magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethanol and / or combinations thereof.

[0612] In some embodiments, the buffer is acetate buffer, citrate buffer, phosphate buffer, tris buffer, or a combination thereof.

[0613] In some embodiments, the lipid composition further comprises one or more nucleic acids, ionizable lipids, amphiphiles, phospholipids, cholesterol, and / or PEG-linked cholesterol.

[0614] Pharmaceutical composition

[0615] Another aspect of the present disclosure also provides a pharmaceutical composition comprising a lipid composition as described herein and a pharmaceutically acceptable excipient, wherein the lipid composition comprises one or more lipid compounds selected from the ionizable lipid compounds described herein (e.g., lipid compounds having the structures of Formula (I), (IA-1), (IA-2), (IIA)-(IIC), (IIA-1), (IIIA)-(IIIE), (IIIC-1), (IVA-1)-(IVA-3), (IVC-1)-(IVC-2), and (VC-1)-(VC-6)). The pharmaceutical composition may further comprise a therapeutic agent.

[0616] All of the above descriptions of various aspects relating to lipid compounds, including compounds covered by Formula (I), (IA-1), (IA-2), (IIA)-(IIC), (IIA-1), (IIIA)-(IIIE), (IIIC-1), (IVA-1)-(IVA-3), (IVC-1)-(IVC-2), and (VC-1)-(VC-6), as well as exemplary variables and compounds, and all of the embodiments discussed in the above aspects apply to these aspects of the invention relating to pharmaceutical compositions.

[0617] All of the above descriptions of the various aspects relating to lipid compositions, including various other lipid components, and all of the embodiments discussed in the above aspects are applicable to these aspects of the invention relating to pharmaceutical compositions.

[0618] In the lipid composition containing therapeutic agents, the ratio of total lipid components to goods (e.g., encapsulated therapeutic agents, such as nucleic acids) can be varied as needed. For example, the ratio of total lipid components to goods (mass or weight) can be from about 10: 1 to about 30: 1. In certain embodiments, the ratio of total lipid components to goods (mass / mass ratio; w / w ratio) can be from about 1: 1 to about 25: 1, from about 10: 1 to about 14: 1, from about 3: 1 to about 15: 1, from about 4: 1 to about 10: 1, from about 5: 1 to about 9: 1 or from about 6: 1 to about 9: 1. The amount of total lipid components and goods can be adjusted to provide a desired N / P ratio, for example, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or higher N / P ratios. Typically, the total lipid content of the lipid composition can range from about 5 mg / ml to about 30 mg / mL.

[0619] therapeutic agents

[0620] Nucleic acid molecules

[0621] In some embodiments, the lipid composition further comprises one or more nucleic acid molecules. The nucleic acid molecules can be plasmids, immunostimulatory oligonucleotides, antisense oligonucleotides, antagomirs, aptamers, deoxyribozymes (DNA enzymes), and ribozymes.

[0622] In some embodiments, the lipid composition further comprises one or more RNA and / or DNA.

[0623] In some embodiments, the nucleic acid molecule is DNA. In some embodiments, the DNA is linear DNA, circular DNA, single-stranded DNA, or double-stranded DNA.

[0624] In some embodiments, the nucleic acid molecule is RNA. In some embodiments, the RNA is mRNA, miRNA, siRNA, RNA aptamer, linear RNA, circular RNA, single-stranded RNA, double-stranded RNA, tRNA, microRNA (miRNA) or miRNA precursor, Dicer substrate small interfering RNA (dsiRNA), short hairpin RNA (shRNA), asymmetric interfering RNA (aiRNA), guide RNA (gRNA), lncRNA, ncRNA, sncRNA, rRNA, snRNA, piRNA, snoRNA, snRNA, scaRNA, exRNA, scaRNA, gamma RNA or hnRNA. In some embodiments, the RNA is mRNA. In one embodiment, the mRNA is modified mRNA.

[0625] In certain embodiments, the nucleic acid molecule is an enzymatic nucleic acid molecule. The term "enzymatic nucleic acid molecule" refers to a nucleic acid molecule that is complementary to a specific gene target in the substrate binding region and also has enzymatic activity and is active in specifically cutting a target RNA. In other words, the enzymatic nucleic acid molecule is capable of cutting RNA between molecules and thereby inactivating the target RNA molecule. The term enzymatic nucleic acid can be used interchangeably with phrases such as ribozymes, catalytic RNA, enzymatic RNA, catalytic DNA, aptamers or aptamer-bound ribozymes, adjustable ribozymes, catalytic oligonucleotides, ribozymes, DNA enzymes, RNA enzymes, endoribonucleases, endonucleases, small ribozymes, leading enzymes, oligonucleotide enzymes or DNA enzymes. All of these terms describe nucleic acid molecules with enzymatic activity.

[0626] In some embodiments, the nucleic acid molecule is an antisense nucleic acid. The term "antisense nucleic acid" refers to a non-enzymatic nucleic acid molecule that binds to a target RNA through RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid) interactions and alters the activity of the target RNA.

[0627] In some embodiments, the nucleic acid molecule can be a 2-5A antisense chimera. The term "2-5A antisense chimera" refers to an antisense oligonucleotide containing a 5'-phosphorylated 2'-5' linked adenylate residue.

[0628] In some embodiments, the nucleic acid molecule may be a triplex-forming oligonucleotide. The term "triplex-forming oligonucleotide" refers to an oligonucleotide that can bind to double-stranded DNA in a sequence-specific manner to form a triple helix.

[0629] In some embodiments, the nucleic acid molecule can be a decoy RNA. The term "decoy RNA" refers to an RNA molecule or aptamer designed to preferentially bind to a predetermined ligand. Such binding can inhibit or activate the target molecule.

[0630] In some embodiments, the nucleic acid molecule (eg, RNA or DNA) encodes a therapeutic peptide or polypeptide that is operably linked to a promoter from the DNA. The therapeutic peptide or polypeptide can be, for example, a transcription factor; a chromatin remodeling factor; an antigen; a hormone; an enzyme (such as a nuclease, such as an endonuclease, such as the nuclease element of the CRISPR system, such as Cas9, dCas9, aCas9-nickase, Cpf / Cas12a); an enzyme connected via CRISPR, such as a base editor or a primer editor; a mobile genetic factor protein (e.g., a transposase, a retrotransposase, a recombinase, an integrase); a gene writer (GeneWriter); a polymerase; a methylase; a demethylase; an acetylase; a deacetylase; a kinase; a phosphatase; a ligase; a deubiquitinase; an integrase; a recombinase; a topoisomerase; a gyrase; a helicase; a lysosomal acid hydrolase; an antibody; a receptor ligand; a receptor; a coagulation factor; a membrane protein; a mitochondrial protein; a nuclear protein; an antibody or other protein scaffold binder, such as a centyrin, a darpin or an adnectin.

[0631] In some embodiments, the nucleic acid molecule is an RNA comprising a gRNA nucleic acid. In some embodiments, the gRNA nucleic acid is a gRNA. In some embodiments, the nucleic acid molecule is an RNA comprising 2 types of Cas nuclease mRNA and a gRNA. In some embodiments, the gRNA nucleic acid is or encodes a dual guide RNA (dgRNA). In some embodiments, the gRNA nucleic acid is or encodes a single guide RNA (sgRNA). In some embodiments, the gRNA is a modified gRNA. In some embodiments, the modified gRNA includes modifications of one or more of the first five nucleotides at the 5' end. In some embodiments, the modified gRNA includes modifications of one or more of the last five nucleotides at the 3' end.

[0632] In some embodiments, the nucleic acid molecule is an RNA comprising an mRNA. In some embodiments, the RNA component comprises an RNA-guided DNA binder, such as a Cas nuclease mRNA (such as a class 2 Cas nuclease mRNA) or a Cas9 nuclease mRNA.

[0633] All nucleic acid molecules described herein can be chemically modified. Various modification strategies for nucleic acid molecules are well known to those skilled in the art. In certain embodiments, the nucleic acid molecules include one or more modifications selected from the group consisting of: pseudouridine, 5-bromouracil, 5-methylcytosine, peptide nucleic acid, heterologous nucleic acid, morpholino, locked nucleic acid, glycerol nucleic acid, threose nucleic acid, dideoxynucleotide, cordycepin, 7-deaza-GTP, fluorophore (e.g., rhodamine or fluorescein connected to sugar), thiol-containing nucleotides, nucleotides connected through biotin, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudouridine, dihydrouridine, braided glycosides and wyoside. In certain embodiments, the antisense oligonucleotide can be a locked nucleic acid oligonucleotide (LNA). The term "locked nucleic acid (LNA)" refers to an oligonucleotide containing one or more nucleotide building blocks in which an additional methylene bridge fixes the ribose moiety in a C3'-endo (β-D-LNA) or C2'-endo (α-L-LNA) conformation (Grunweller A, Hartmann RK, BioDrugs, 21(4):235-243 (2007)).

[0634] In some embodiments, the composition further comprises one or more template nucleic acids.

[0635] Additional examples of nucleic acid molecules (comprising tumor suppressor genes, antisense oligonucleotides, siRNA, miRNA, or shRNA) can be found in U.S. Published Patent Application No. 2007 / 0065499 and U.S. Patent No. 7,780,882, which are incorporated herein by reference in their entireties.

[0636] In some embodiments, the pharmaceutical composition may comprise a plurality of nucleic acid molecules, which may be of the same or different types.

[0637] The nucleic acids used in the embodiments of the present disclosure can be prepared according to any available technology. For mRNA, the main method of preparation is, but is not limited to, enzymatic synthesis (also known as in vitro transcription), which currently represents the most effective method for producing long sequence-specific mRNA. In vitro transcription describes a method for template-directed synthesis of RNA molecules from an engineered DNA template comprising an upstream phage promoter sequence (e.g., including but not limited to sequences from T7, T3, and SP6 E. coli phages) linked to a downstream sequence encoding a gene of interest. Template DNA for in vitro transcription can be prepared from a number of sources using appropriate techniques well known in the art, including but not limited to plasmid DNA and polymerase chain reaction amplification (see Linpinsel, JL and Conn, GL, General protocols for preparation of plasmid DNA template and Bowman, JC, Azizi, B., Lenz, TK, Ray, P. and Williams, LD, RNA in vitro transcription and RNA purification by denaturing PAGE. In Recombinant and in vitro RNA syntheses Methods, Vol. 941. Conn GL (ed.), New York, NY Humana Press, 2012).

[0638] Under the conditions that the potential degradation of the obtained mRNA transcript is minimized while supporting polymerase activity, in the presence of corresponding RNA polymerase and adenosine, guanosine, uridine and cytidine triphosphate ribonucleoside (rNTP), RNA transcription is carried out in vitro using a linearized DNA template. In vitro transcription can be carried out using various commercially available test kits and commercially available reagents, including but not limited to RiboMax large-scale RNA production system (Promega), MegaScript transcription kit (Life Technologies), which includes RNA polymerase and rNTP. Methods for in vitro transcription of mRNA are well known in the art. (See, e.g., Losick, R., 1972, In vitro transcription. Ann Rev Biochem, 41:409-46; Kamakaka, R.T. and Kraus, W.L. 2001. In vitro transcription. Current Protocols in Cell Biology, 2:11.6:11.6.1-11.6.17; Beckert, B. and Masquida, B. (2010). Synthesis of RNA by In Vitro Transcription in RNA. In Methods in Molecular Biology, Vol. 703 (Neilson, H. ed.), Humana Press, New York, NY, 2010; Brunelle, J.L. and Green, R., 2013, Chapter Five - In vitro transcription from plasmid or PCR-amplified DNA.) PCR-amplified DNA), Methods in Enzymology, Vol. 530, 101-114; all references in said reference are incorporated herein by reference).

[0639] The desired in vitro transcribed mRNA can be purified from undesirable components of the transcription or related reactions (including unincorporated rNTPs, protein enzymes, salts, short RNA oligonucleotides, etc.). Techniques for isolating mRNA transcripts are well known in the art. For non-limiting examples, well-known procedures include extraction with alcohols (ethanol, isopropanol) or precipitation with phenol / chloroform in the presence of monovalent cations or lithium chloride.

[0640] Other non-limiting examples of purification procedures that can be used include size exclusion chromatography (Lukavsky, PJ and Puglisi, JD, 2004, Large-scale preparation and purification of polyacrylamide-free RNA oligonucleotides, RNA Vol. 10, 889-893); silica-based affinity chromatography and polyacrylamide gel electrophoresis (Bowman, JC, Azizi, B., Lenz, TK, Ray, P. and Williams, L.D. In RNA in vitro transcription and RNA purification by denaturing PAGE. In Methods of Recombinant and In Vitro RNA Synthesis, Vol. 941, Conn GL (ed.), Humana Press, New York, NY, 2012). Purification can be performed using various commercially available kits, including but not limited to the SV Total Isolation System (Promega) and the In Vitro Transcription Cleanup and Concentration Kit (NorgenBiotek).

[0641] In addition, although reverse transcription can produce a large amount of mRNA, product can contain many abnormal RNA impurities related to the undesirable polymerase activity that may need to be removed from full-length mRNA preparation. These comprise the short RNA produced by terminating transcription initiation and the double-stranded RNA (dsRNA) produced by RNA-dependent RNA polymerase activity, the transcription and self-complementary 3 ' extension caused by RNA template. It has been confirmed that these pollutants with dsRNA structure can produce undesirable immunostimulatory activity by interacting with the various innate immune sensors in eukaryotic cells, which are used to identify specific nucleic acid structures and induce effective immune responses. This then can significantly reduce mRNA translation because protein synthesis reduces during the innate cellular immune response. Therefore, additional techniques for removing these dsRNA contaminants have been developed and are known in the art and include, but are not limited to, scalable HPLC purification (see, e.g., Kariko, K., Muramatsu, H., Ludwig, J., and Weissman, D., 2011, Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA, Nucleic Acids Research, Vol. 39, el42; Weissman, D., Pardi, N., Muramatsu, H., and Kariko, K., HPLC Purification of in vitro transcribed long RNA in Synthetic Messenger RNA and Cell Metabolism Modulation in Methods in Molecular Biology, Vol. 969 (Rabinovich, PH ed., 2013). It was reported that HPLC-purified mRNA was translated at much higher levels, particularly in primary cells and in vivo.

[0642] Various modifications have been described in the art that are used to change the specific characteristics of in vitro transcribed mRNA and can improve its effectiveness. These include, but are not limited to, modifications to the 5' and 3' ends of the mRNA. Endogenous eukaryotic mRNAs typically contain a cap structure on the 5' end of the mature molecule, which plays an important role in mediating the binding of mRNA cap binding protein (CBP), which is then responsible for enhancing the efficiency of mRNA stability and mRNA translation in the cell. Therefore, the highest level of protein expression is achieved with capped mRNA transcripts. The 5' cap contains a 5'-5' triphosphate bond between the 5' nucleotide and the guanine nucleotide. The conjugated guanine nucleotide is methylated at the N7 position. Additional modifications include methylation of the last and penultimate 5' nucleotide on the 2'-hydroxyl.

[0643] A variety of different cap structures can be used to generate 5'-caps for synthetic mRNAs transcribed in vitro. 5'-capping of synthetic mRNAs can be performed co-transcriptionally with chemical cap analogs (i.e., capping during in vitro transcription). For example, the anti-reverse cap analog (ARC A) cap contains a 5'-5'-triphosphate guanine-guanine bond, in which one guanine contains an N7 methyl group and a 3'-O-methyl group. However, during this co-transcriptional process, up to 20% of the transcripts remain uncapped, and synthetic cap analogs differ from the 5'-cap structure of real cellular mRNAs, thereby potentially reducing translatability and cellular stability. Alternatively, synthetic mRNA molecules can also be enzymatically capped after transcription. These can produce more realistic 5'-cap structures that more closely mimic endogenous 5'-caps in structure or function, with enhanced cap-binding protein binding, increased half-life, and reduced sensitivity to 5' endonucleases and / or reduced 5' decapping. Many synthetic 5' cap analogs have been developed and are known in the art to enhance mRNA stability and translatability (see, e.g., Grudzien-Nogalska, E., Kowalska, J., Su, W., Kuhn, AN, Slepenkov, SV, Darynkiewicz, E., Sahin, U., Jemielity, J., and Rhoads, RE, Synthetic mRNAs with superior translation and stability properties in Synthetic Messenger RNA and Cell Metabolism Modulation. In Methods in Molecular Biology, Vol. 969 (Rabinovich, PH ed.), 2013).

[0644] During RNA processing, a long chain of adenine nucleotides (poly-A tail) is typically added to the 3' end of the mRNA molecule. Immediately after transcription, the 3' end of the transcript is cleaved to release a 3' hydroxyl group to which poly A polymerase adds a chain of adenine nucleotides to the RNA in a process called polyadenylation. The poly-A tail has been widely shown to enhance both the translation efficiency and stability of mRNA (see Bernstein, P. and Ross, J., 1989, Poly(A), poly(A) binding protein and the regulation of mRNA stability, Trends Bio Sci, 14, 373-377; Guhaniyogi, J. and Brewer, G., 2001, Regulation of mRNA stability in mammalian cells, Gene, 265, 11-23; Dreyfus, M. and Regnier, P., 2002, The poly(A) tail of mRNAs: Bodyguard ineukaryotes, scavenger inbacteria), Cell, Vol. I1, 611-613).

[0645] Poly(A) tailing of in vitro transcribed mRNA can be achieved using a variety of methods, including but not limited to cloning a poly(T) tract into a DNA template or by post-transcriptional addition using a poly(A) polymerase. The first approach allows in vitro transcription of mRNA with a poly(A) tail of defined length, depending on the size of the poly(T) tract, but requires additional manipulation of the template. The latter approach involves enzymatic addition of a poly(A) tail to in vitro transcribed mRNA using a poly(A) polymerase, which catalyzes the incorporation of an adenine residue onto the 3' end of the RNA, does not require additional manipulation of the DNA template, but produces mRNA with poly(A) tails of varying lengths. 5' capping and 3'-poly (A) tailing can be performed using various commercially available kits (including but not limited to Poly (A) polymerase tailing kit (EpiCenter), mMESSAGE mMACHINE T7 Ultra kit and Poly (A) tailing kit (Life Technologies)), as well as commercially available reagents, various ARCA caps, Poly (A) polymerase, etc.

[0646] In addition to 5' caps and 3' polyadenylation, other modifications of in vitro transcripts have been reported to provide benefits related to translation efficiency and stability. It is well known in the art that pathogenic DNA and RNA can be recognized by various sensors within eukaryotes and trigger an effective innate immune response. The ability to distinguish pathogenic and autologous DNA and RNA has been shown to be based at least in part on structure and nucleoside modifications, as most nucleic acids from natural sources contain modified nucleosides. In contrast, in vitro synthesized RNA lacks these modifications, thus making it immunostimulatory, which in turn can inhibit effective mRNA translation as outlined above.The introduction of modified nucleosides into in vitro transcribed mRNA can be used to prevent recognition and activation of RNA sensors, thereby mitigating this undesirable immunostimulatory activity and enhancing translational capacity (see, e.g., Kariko, K. and Weissman, D. 2007, Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development, Curr Opin Drug Discov Devel, vol. 10, pp. 523-532; Pardi, N., Muramatsu, H., Weissman, D., Kariko, K., Invitro transcription of long RNA containing modified nucleosides in Synthetic Messenger RNA and Cell Metabolism Modulation in Methods in Molecular Biology, Vol. 969 (Rabinovich, PH ed.), 2013; Kariko, K., Muramatsu, H., Welsh, FA, Ludwig, J., Kato, H., Akira, S., Weissman, D., 2008, Incorporation of Pseudouridine Intom RNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability, Mol Ther, Vol. 16, 1833-1840. Modified nucleosides and nucleotides used in the synthesis of modified RNA can be prepared, monitored, and utilized using general methods and procedures known in the art. A variety of nucleoside modifications are available that can be incorporated into in vitro transcribed mRNA alone or in some combination with other modified nucleosides (see, eg, US 2012 / 0251618).In vitro synthesis of nucleoside-modified mRNA has been reported to have reduced ability to activate immune sensors and enhanced translational capacity.

[0647] Other components of mRNA that can be modified to provide benefits in terms of translatability and stability include 5' and 3' untranslated regions (UTRs). Optimization of UTRs (good 5' and 3' UTRs can be obtained from cellular or viral RNAs), either together or independently, has been shown to increase mRNA stability and translation efficiency of in vitro transcribed mRNAs (see, e.g., Pardi, N., Muramatsu, H., Weissman, D., Kariko, K., In vitro transcription and cellular metabolic regulation of long RNAs containing modified nucleosides in synthetic messenger RNAs, in Methods in Molecular Biology, Vol. 969 (Rabinovich, PH ed.), 2013).

[0648] In addition to mRNA, other nucleic acid payloads can be used in the present disclosure. For oligonucleotides, preparation methods include but are not limited to chemical synthesis and enzymatic chemical cleavage of longer precursors, in vitro transcription as described above, etc. The method for synthesizing DNA and RNA nucleotides is widely used in the art and is well known (see, for example, Gait, MJ (ed.) Oligonucleotide synthesis: a practical approach, Oxford [Oxfordshire], Ishington, DC: IRL Press, 1984; and Herdewijn, P. (ed.) Oligonucleotide synthesis: methods and applications, Methods in Molecular Biology, Vol. 288 (Clifton, NJ) Humana Press, Totowa, NJ, 2005; Both of the documents are incorporated herein by reference).

[0649] For plasmid DNA, preparation for use with embodiments of the present disclosure typically utilizes, but is not limited to, in vitro amplification and isolation of the plasmid DNA in liquid culture of bacteria containing the plasmid of interest. The presence of a gene in the plasmid of interest that encodes resistance to a particular antibiotic (penicillin, kanamycin, etc.) allows those bacteria containing the plasmid of interest to selectively grow in cultures containing the antibiotic. Methods for isolating plasmid DNA are widely used and well known in the art (see, e.g., Heilig, J., Elbing, KL, and Brent, R., (2001), Large-Scale Preparation of Plasmid DNA, Current Protocols in Molecular Biology, 41: 11: 1.7: 1.7.1-1.7.16; Rozkov, A., Larsson, B., Gillstrom, S., Bjornestedt, R., and Schmidt, SR, (2008), Large-scale production of endotoxin-free plasmids for transient expression in mammalian cell culture, Biotechnol. Bioeng., 99: 557-566; and US 6,197,553 Bl). Plasmid isolation can be performed using a variety of commercially available kits, including but not limited to Plasmid Plus (Qiagen), GenJET Plasmid MaxiPrep (Thermo), and Pure Yield MaxiPrep (Promega) kits, as well as commercially available reagents.

[0650] In some embodiments, the lipid nanoparticle compositions can be used to express proteins encoded by mRNA. In some embodiments, provided herein are methods for expressing proteins encoded by mRNA.

[0651] In some embodiments, the N / P ratio of the lipid composition is from about 1:1 to about 30:1, for example, from about 3:1 to about 20:1, from about 3:1 to about 15:1, from about 3:1 to about 10:1, or from about 3:1 to about 6:1. For example, the N / P ratio of the lipid composition encapsulated by the nucleic acid molecule can be 6±1, or the N / P ratio of the lipid composition encapsulated by the nucleic acid molecule can be 6±0.5. In some embodiments, the N / P ratio of the lipid composition encapsulated by the nucleic acid molecule is in the range of from about 3:1 to about 15:1. In some embodiments, the N / P ratio of the lipid composition encapsulated by the nucleic acid molecule is about 6. The N:P ratio refers to the molar ratio of amines present in the lipid composition or lipid nanoformulation (e.g., amines in ionizable lipids) to phosphates present in the nucleic acid molecule. This is a factor for effective packaging and efficacy.

[0652] Other therapeutic agents

[0653] The therapeutic agent can be a peptide or protein, a small molecule drug encapsulated in the lipid composition. The pharmaceutical composition can contain two or more therapeutic agents different from the nucleic acid molecule, peptide or protein and small molecule drug.

[0654] In some embodiments, the protein can be a peptide or polypeptide, such as a transcription factor; a chromatin remodeling factor; an antigen; a hormone; an enzyme (such as a nuclease, such as an endonuclease, such as the nuclease element of a CRISPR system, such as Cas9, dCas9, aCas9-nickase, Cpf / Cas12a); an enzyme linked by CRISPR, such as a base editor or a primer editor; a mobile genetic element protein (e.g., a transposase, a retrotransposase, a recombinase, an integrase); a gene writer; a polymerase; a methylase; a demethylase; an acetylase; a deacetylase; a kinase; a phosphatase; a ligase; a deubiquitinase; an integrase; a recombinase; a topoisomerase; a gyrase; a helicase; a lysosomal acid hydrolase; an antibody; a receptor ligand; a receptor; a coagulation factor; a membrane protein; a mitochondrial protein; a nuclear protein; an antibody or other protein scaffold binder, such as a centyrin, a darpin, or an adnectin.

[0655] In some embodiments, the pharmaceutical composition may comprise a plurality of protein molecules which may be of the same or different types.

[0656] In some embodiments, the therapeutic agent is a small molecule drug, such as a small molecule drug approved for use in humans by an appropriate regulatory agency.

[0657] In some embodiments, the pharmaceutical composition may comprise multiple small molecule drugs, which may be of the same or different types.

[0658] In some embodiments, the therapeutic agent is a vaccine. In some embodiments, the vaccine is an RNA vaccine, such as an RNA cancer vaccine or an RNA vaccine for an infectious disease (e.g., an influenza virus vaccine or a coronavirus vaccine (e.g., a COVID-19 vaccine)).

[0659] Other ingredients

[0660] The pharmaceutical composition may contain one or more pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients are selected according to the mode of administration and route. Suitable pharmaceutical carriers or excipients for pharmaceutical formulations are described in Remington: The Science and Practice of Pharmacy, 21st edition, edited by Gennaro, Lippencott Williams and Wilkins (2005); Handbook of Pharmaceutical Excipients, 6th edition, edited by Rowe et al., Pharmaceutical Press (2009); and USP / NF (United States Pharmacopeia and the National Formulary), which are incorporated herein by reference in their entirety.

[0661] In some embodiments, the pharmaceutically acceptable excipients comprise one or more of the following: antioxidants, binders, anti-adherents, buffers, colorants, diluents (e.g., solid or liquid), disintegrants (e.g., coated disintegrants), dispersants, dyes, fillers, emulsifiers, flavorings, lubricants, pH adjusters, pigments, preservatives, stabilizers, solubilizers, solvents, suspending agents, sweeteners or wetting agents, or combinations thereof.

[0662] Examples of suitable excipients include, but are not limited to, gum acacia, alginate, calcium phosphate, calcium carbonate, calcium silicate, carbopol gel, carboxymethyl cellulose, carnauba wax, cellulose, crospovidone, dextrose, diacetylated monoglycerides, ethyl cellulose, gelatin, glyceryl monostearate 40-50, gum acacia, gum acacia, Arabic), hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hypromellose phthalate, hypromellose, lactose, lecithin, magnesium stearate, kaolin, C-methacrylic acid copolymer, mannitol, methylcellulose, methyl hydroxybenzoate, microcrystalline cellulose, povidone, polyethylene glycol, polysorbate 80, polyvinyl pyrrolidone, propyl hydroxybenzoate, sodium carboxymethylcellulose, sodium hydroxide, sodium stearyl fumarate, sodium starch glycolate, starch, sorbitan monooleate, sorbitol, sorbic acid, sucrose, talc, tragacanth gum, talc, triethyl citrate, titanium dioxide, yellow iron oxide, talc, oil medium (e.g., peanut oil, liquid paraffin, mineral oil, olive oil, almond oil, glycerin, propylene glycol) or water.

[0663] When excipient is used as diluent, it can be solid, semisolid or liquid material (for example, normal saline), and described material is used as vehicle, carrier or medium for active ingredient.As known in the art, the type of diluent can change according to expected route of administration.

[0664] The pharmaceutical composition may include a pharmaceutically acceptable carrier, excipient, or stabilizer in the form of a lyophilized formulation or aqueous solution. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations used and may include: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl alcohol, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues); (e.g., sucrose, mannitol, trehalose, or sorbitol); salt-forming counterions such as sodium; metal complexes (e.g., Zn protein complexes); and / or nonionic surfactants such as TWEEN®. TM 、PLURONICS TM or polyethylene glycol (PEG).

[0665] Suitable carriers or excipients for pharmaceutical compositions can also comprise materials that enhance individual body absorption LNP or liposome ability. Suitable carriers and / or excipients also comprise any material that can be used for filling formulations with LNP or liposomes, so that dosage is convenient and accurate. In addition, carriers and / or excipients can be used in manufacturing process, to help process LNP or liposomes. According to route of administration and pharmaceutical form, different carriers and / or excipients can be used.

[0666] The carrier and / or excipient may also include a vehicle and / or diluent. "Vehicle" refers to any of various media that typically serve as solvents or carriers; "diluent" refers to a diluent used to dilute the active ingredient of the composition; suitable diluents include any substance that can reduce the viscosity of the drug. The type and amount of the carrier and / or excipient are selected based on the selected pharmaceutical form; suitable pharmaceutical forms include liquid systems such as solutions, infusible solutions, suspensions; semi-solid systems such as colloids, gels, pastes, or creams; solid systems such as powders, granules, tablets, capsules, pellets, microgranules, minitablets, microcapsules, microgranules, suppositories, etc.

[0667] Each of the above systems can be appropriately formulated for normal, delayed or accelerated release using techniques well known in the art.

[0668] Formulations, dosages and routes of administration

[0669] The pharmaceutical compositions described herein can be prepared according to standard techniques and those described herein. For example, the pharmaceutical compositions can be prepared in a conventional manner, for example, by conventional mixing, dissolving, granulating, making dragees, grinding, emulsifying, encapsulating, embedding or lyophilizing methods. Methods for preparing formulations well known in the art are known in the art. See, for example, Remington: The Art and Practice of Pharmacy, 21st edition, edited by Gennaro, Lippincott Williams & Wilkins (2005) and Encyclopedia of Pharmaceutical Technology, edited by J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York.

[0670] Therapeutic agent can be encapsulated in the lipid composition, for example therapeutic agent can be positioned at the inner space of LNP wholly or in part, in lipid layer / film, or associate with the outer surface of lipid layer / film.A purpose that therapeutic agent is incorporated into LNP is to protect therapeutic agent from the influence of the system or the environment of acceptor that may contain enzyme or chemical substance or condition of degradation therapeutic agent and / or cause therapeutic agent to drain quickly.In addition, therapeutic agent is incorporated into and can promote the absorption of therapeutic agent among the LNP, and therefore can strengthen treatment effect.

[0671] In some embodiments, in the pharmaceutical composition, the ratio of the lipid component to the therapeutic agent (mass / mass ratio; w / w ratio) can be in the range of about 1:1 to about 25:1, 10:1 to about 14:1, about 3:1 to about 15:1, about 4:1 to about 10:1, about 5:1 to about 9:1, or about 6:1 to about 9:1.

[0672] Based on the weight of the lipid composition or pharmaceutical composition, the lipid composition or pharmaceutical composition can contain about 5 to about 95 weight % therapeutic agent. In some embodiments, based on the weight of the LNP or the pharmaceutical composition, the lipid composition or pharmaceutical composition contains about 5 weight %, about 10 weight %, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90 or about 95 weight % therapeutic agent. In some embodiments, the lipid composition or the pharmaceutical composition contains the following amount of therapeutic agent based on the weight of the lipid composition or the pharmaceutical composition: about 5-95%, about 5-90%, about 5-80%, about 5-70%, about 5-60%, about 5-50%, about 5-40%, about 5-30%, about 5-20%, about 5-10%, about 10-95%, about 10-90%, about 10-80%, about 10-70%, about 10-60%, about 10-50%, about 10-40%, about 10-30%, about 10-20%, about 20-95%, about 20-90%, about 20-80%, about 20-70%, about 20-60%, about 20-50 %, about 20-40%, about 20-30%, about 30-95%, about 30-90%, about 30-80%, about 30-70%, about 30-60%, about 30-50%, about 30-40%, about 40-95%, about 40-90%, about 40-80%, about 40-70%, about 40-60%, about 40-50%, about 50-95%, about 50-90%, about 50-80%, about 50-70%, about 50-60%, about 60-95%, about 60-90%, about 60-80%, about 60-70%, about 70-95%, about 70-90%, about 70-80%, about 80-95%, about 80-90%, or about 90-95%.

[0673] The lipid composition or pharmaceutical composition can contain total lipids in an amount of about 5 to about 95 wt %, based on the weight of the lipid composition or pharmaceutical composition. In some embodiments, the lipid composition or pharmaceutical composition contains total lipids in an amount of about 5-95%, about 5-90%, about 5-80%, about 5-70%, about 5-60%, about 5-50%, about 5-40%, about 5-30%, about 5-20%, about 5-10%, about 10-95%, about 10-90%, about 10-80%, about 10-70%, about 10-60%, about 10-50%, about 10-40%, about 10-30%, about 10-20%, about 20-95%, about 20-90%, about 20-80%, about 20-70%, about 20-60%, about 20-50 %, about 20-40%, about 20-30%, about 30-95%, about 30-90%, about 30-80%, about 30-70%, about 30-60%, about 30-50%, about 30-40%, about 40-95%, about 40-90%, about 40-80%, about 40-70%, about 40-60%, about 40-50%, about 50-95%, about 50-90%, about 50-80%, about 50-70%, about 50-60%, about 60-95%, about 60-90%, about 60-80%, about 60-70%, about 70-95%, about 70-90%, about 70-80%, about 80-95%, about 80-90%, or about 90-95%.

[0674] Lipid compositions of the present disclosure or pharmaceutical compositions can be used by various approaches, for example, by the systemic delivery carried out intravenously, parenterally, intraperitoneally, intramuscularly, intraductally or locally. In certain embodiments, siRNA can be delivered intracellularly, for example, in the cells of target tissues (such as lungs or liver) or in inflamed tissues. In certain embodiments, the disclosure provides methods for delivering siRNA in vivo. Nucleic acid-lipid compositions can be administered intravenously, subcutaneously or intraperitoneally to a subject.

[0675] As used herein, the term "parenteral" refers to a route of administration other than enteral administration. Examples of parenteral administration include, but are not limited to, buccal, epidermal, epidural, extra-amniotic, intra-arterial, intra-articular, intracardiac, intracavernous, intracerebral, intraventricular, intradermal, intralesional, intramuscular, intraocular, intraosseous infusion, intraperitoneal, intrapulmonary, intrathecal, intrauterine, intravaginal, intravenous, intravesical, intravitreal, nasal, perivascular, subcutaneous, sublingual, transdermal, topical, transepithelial, or transmucosal. Parenteral administration can be performed by continuous infusion over a selected period of time.

[0676] Compositions and methods of the present disclosure can be administered orally, rectally, vaginally, intranasally, intrapulmonaryly or transdermally or dermally, or administered to a subject by topical delivery to eyes, ears, skin or other mucosal surfaces. In some aspects of the present disclosure, the mucosal tissue layer comprises an epithelial cell layer. The epithelial cell can be a lung, trachea, bronchus, alveoli, nose, cheek, epidermis or gastrointestinal tract. Compositions of the present disclosure can be administered using conventional actuators (such as mechanical spray devices) and pressurization, electrical activation or other types of actuators.

[0677] The compositions of the present disclosure can be used as nasal spray or lung spray in aqueous solution, and can be distributed in spray form by various methods known to those skilled in the art. The lung delivery of the compositions of the present disclosure is achieved by applying the compositions in the form of drops, particles or sprays, and the drops, particles or sprays can be, for example, aerosolized, pulverized or atomized. The particles, sprays or aerosols of the compositions can be in liquid or solid form. Non-limiting examples of systems for distributing liquid as nasal sprays are disclosed in U.S. Patent No. 4,511,069. Such formulations can be easily prepared by dissolving the compositions according to the present disclosure in water to produce an aqueous solution and making the solution sterile. The formulations can be present in a multidose container, such as in a sealed distribution system disclosed in U.S. Patent No. 4,511,069. Other suitable nasal spray delivery systems are described in TRANSDERMAL SYSTEMIC MEDICATION, edited by YW Chien, Elsevier Publishers, New York, 1985; and U.S. Patent No. 4,778,810. Additional aerosol delivery forms can include, for example, compressed air jets, ultrasound, and piezoelectric nebulizers that deliver bioactive agents dissolved or suspended in pharmaceutical solvents (e.g., water, ethanol, or mixtures thereof).

[0678] The nasal and pulmonary spray solutions of the present disclosure generally include a drug or a drug to be delivered, optionally formulated with a surfactant such as a nonionic surfactant (e.g., polysorbate 80) and one or more buffers. In some embodiments of the present disclosure, the nasal spray solution further includes a propellant. The pH of the nasal spray solution can be pH 6.8 to 7.2. The pharmaceutical solvent employed can also be a slightly acidic aqueous buffer of pH 4-6. Other components can be added to enhance or maintain chemical stability, including preservatives, surfactants, dispersants, or gases.

[0679] In some embodiments, the present disclosure is a pharmaceutical product comprising a solution containing a composition of the present disclosure and an actuator for pulmonary, mucosal, or intranasal spray or aerosol.

[0680] The dosage form of the composition of the present disclosure may be a liquid, in the form of liquid droplets or emulsion or in the form of an aerosol.

[0681] The dosage form of the composition of the present disclosure can be a solid that can be reconstituted in a liquid before administration. The solid can be administered as a powder. The solid can be in the form of a capsule, tablet, or gel.

[0682] To prepare compositions within the present disclosure for pulmonary delivery, the bioactive agent may be combined with various pharmaceutically acceptable additives as well as a base or carrier for dispersing the active agent.

[0683] The example of additive includes pH control agent, such as arginine, sodium hydroxide, glycine, hydrochloric acid, citric acid and its mixture.Other additives include local anesthetic (for example, benzyl alcohol), isotonic agent (for example, sodium chloride, mannitol, sorbitol), adsorption inhibitor (for example, Tween 80), solubility enhancer (for example, cyclodextrin and its derivatives), stabilizer (for example, serum albumin) and reducing agent (for example, glutathione).When the composition for mucosal delivery is liquid, as measured by the tension of 0.9% (w / v) physiological saline solution as a whole, the tension of the composition is usually adjusted to a value that does not cause substantial, irreversible tissue damage in the mucosa at the application site.Usually, the tension of the solution is adjusted to a value of 1 / 3 to 3, more usually 1 / 2 to 2 and most usually 3 / 4 to 1.7.

[0684] Bioactive agent can be dispersed in substrate or vehicle, and described substrate or vehicle can include the hydrophilic compound and any desired additive with the ability of dispersing active agent.Substrate can be selected from the suitable carrier of wide range, including but not limited to polycarboxylic acid or its salt, copolymer of carboxylic anhydride (for example, maleic anhydride) and other monomers (for example, (methyl) methyl acrylate, acrylic acid etc.);Hydrophilic vinyl polymer, such as polyvinyl acetate, polyvinyl alcohol, polyvinyl pyrrolidone;Cellulose derivative, such as hydroxymethyl cellulose, hydroxypropyl cellulose etc.;And natural polymer, such as chitosan, collagen, sodium alginate, gelatin, hyaluronic acid and its non-toxic metal salt.Usually, select biodegradable polymer as substrate or carrier, such as polylactic acid, poly (lactic acid-glycolic acid) copolymer, polyhydroxybutyric acid, poly (hydroxybutyric acid-glycolic acid) copolymer and its mixture.Alternatively or additionally, synthetic fatty acid esters such as polyglycerol fatty acid ester, sucrose fatty acid ester can be used as carrier. Hydrophilic polymers and other carriers can be used alone or in combination and can impart enhanced structural integrity to the carrier through partial crystallization, ionic bonding, cross-linking, etc. Carriers can be provided in a variety of forms, including fluid or viscous solutions, gels, pastes, powders, microspheres, and films for direct application to the nasal mucosa. Use of the selected carrier in this context can promote absorption of the bioactive agent.

[0685] Compositions for mucosal, nasal or pulmonary delivery can contain hydrophilic low molecular weight compounds as substrates or excipients. Such hydrophilic low molecular weight compounds can provide a channel medium through which water-soluble active agents, such as physiologically active peptides or proteins, can diffuse through the substrate to reach the body surface where the active agent is absorbed. The hydrophilic low molecular weight compound can optionally absorb moisture from the mucosa or the atmosphere of application and can dissolve water-soluble active peptides. In some embodiments, the molecular weight of the hydrophilic low molecular weight compound is less than or equal to 10,000, such as no more than 3,000. Examples of hydrophilic low molecular weight compounds include polyol compounds, such as oligosaccharides, disaccharides and monosaccharides, including sucrose, mannitol, lactose, L-arabinose, D-erythrose, D-ribose, D-xylose, D-mannose, D-galactose, lactulose, cellobiose, gentiobiose, glycerol, polyethylene glycol and mixtures thereof. Additional examples of the hydrophilic low molecular weight compound include N-methylpyrrolidone, alcohols (eg, oligovinyl alcohol, ethanol, ethylene glycol, propylene glycol, etc.), and mixtures thereof.

[0686] The compositions of the present disclosure may alternatively contain pharmaceutically acceptable carrier substances required to approximate physiological conditions, such as pH adjusters and buffers, tonicity adjusters and wetting agents, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate and mixtures thereof. For solid compositions, conventional non-toxic pharmaceutically acceptable carriers may be used, which include, for example, pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate and the like.

[0687] In certain embodiments of the present disclosure, the bioactive agent can be administered in a delayed release formulation, for example, in a composition comprising a slow-release polymer. The active agent can be prepared with a carrier that will prevent rapid release (e.g., a controlled release vehicle, such as a polymer, a microencapsulated delivery system, or a bioadhesive gel). In various compositions of the present disclosure, extended delivery of the active agent can be achieved by being included in a composition medicament that delays absorption (e.g., aluminum monostearate hydrogel and gelatin).

[0688] In some embodiments, the lipid composition, the pharmaceutical composition, or the dosage unit contains about 0.01 to about 1000 mg of one or more lipid compounds described herein. In some embodiments, the lipid composition, the pharmaceutical composition, or the dosage unit contains about 0.01, about 0.1, about 0.5, about 1, about 5, about 10, about 25, about 50, about 75, about 100, about 125, about 150, about 175, about 200, about 225, 250, about 275, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, about 950, or about 1000 mg of one or more lipid compounds described herein.In some embodiments, the lipid composition, the pharmaceutical composition, or the dosage unit contains about 0.01 to about 750 mg, about 0.01 to about 500 mg, about 0.01 to about 250 mg, about 0.01 to about 100 mg, about 0.01 to about 50 mg, about 0.01 to about 25 mg, about 0.01 to about 10 mg, about 0.01 to about 5 mg, about 0.01 to about 0.1 mg, about 0.1 to about 1000 mg, about 0.1 to about 750 mg, about 0.1 to about 500 mg, about 0.1 to about 25 0 mg, about 0.1 to about 100 mg, about 0.1 to about 50 mg, about 0.1 to about 25, about 0.1 to about 10 mg, about 0.1 to about 5 mg, about 0.1 to about 1 mg, about 1 to about 1000 mg, about 1 to about 750 mg, about 1 to about 500 mg, about 1 to about 250 mg, about 1 to about 100 mg, about 1 to about 50 mg, about 1 to about 25 mg, about 1 to about 10 mg, about 1 to about 5 mg, about 5 to about 1000 mg, about 5 to about 750 mg, about 5 to about 500 mg, about 5 to about 2 50 mg, about 5 to about 100 mg, about 5 to about 50 mg, about 5 to about 25 mg, about 5 to about 10 mg, about 10 to about 1000 mg, about 10 to about 750 mg, about 10 to about 500, about 10 to about 250 mg, about 10 to about 100 mg, about 10 to about 50 mg, about 10 to about 25 mg, about 25 to about 1000 mg, about 25 to about 750 mg, about 25 to about 500 mg, about 25 to about 250 mg, about 25 to about 100 mg, about 25 to about 50 mg, about 50 to about 10 In some embodiments, the present invention provides an oral dosage of about 100 mg, about 50 to about 750 mg, about 50 to about 500 mg, about 50 to about 250 mg, about 50 to about 100 mg, about 100 to about 1000 mg, about 100 to about 750 mg, about 100 to about 500 mg, about 100 to about 250 mg, about 250 to about 1000 mg, about 250 to about 750 mg, about 250 to about 500 mg, about 500 to about 1000 mg, about 500 to about 750 mg, or about 750 to about 1000 mg of one or more lipid compounds described herein.

[0689] Methods of using lipid compositions

[0690] Another aspect of the present disclosure provides a method for delivering a therapeutic agent to a subject (e.g., a patient) in need thereof, the method comprising administering to the subject (e.g., a patient) a pharmaceutical composition comprising a lipid nanoparticle composition and the therapeutic agent, wherein the lipid nanoparticle composition comprises a lipid compound of Formula (I), (IA-1), (IA-2), (IIA)-(IIC), (IIA-1), (IIIA)-(IIIE), (IVA-1)-(IVA-3), (IVC-1)-(IVC-2), and (VC-1)-(VC-6), a pharmaceutically acceptable salt thereof, and / or a stereoisomer of any one of the foregoing.

[0691] Another aspect of the present disclosure relates to a method for extrahepatic delivery of a therapeutic agent to at least one organ other than the liver (e.g., pancreas, one or both lungs, or spleen) of a subject in need thereof, wherein the amount delivered to other parts of the subject's body (e.g., liver) is minimized. The method comprises administering to the subject a pharmaceutical composition comprising a lipid nanoparticle composition and a therapeutic agent, wherein the lipid nanoparticle composition comprises a lipid compound of Formula (I), (IA-1), (IA-2), (IIA)-(IIC), (IIA-1), (IIIA)-(IIIE), (IVA-1)-(IVA-3), (IVC-1)-(IVC-2), and (VC-1)-(VC-6), a pharmaceutically acceptable salt thereof, and / or a stereoisomer of any of the foregoing. In some embodiments, the method delivers the therapeutic agent to the pancreas and / or one or both lungs of a subject in need thereof, wherein the amount delivered to other parts of the subject's body (e.g., liver) is minimized.

[0692] In some embodiments, less than 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 1% of the total therapeutic agent administered to the subject is delivered to the subject's liver. In some embodiments, less than 6%, 7%, 8%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% of the total therapeutic agent administered to the subject is delivered to the subject's liver.

[0693] In some embodiments, more than 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15% or 10% of the total therapeutic agent administered to the subject is delivered to the pancreas, spleen and / or one or both lungs of the subject. In some embodiments, more than 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15% or 10% of the total therapeutic agent administered to the subject is delivered to the pancreas of the subject. In some embodiments, more than 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15% or 10% of the total therapeutic agent administered to the subject is delivered to the lungs of the subject. In some embodiments, more than 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15% or 10% of the total therapeutic agent administered to the subject is delivered to the spleen of the subject.

[0694] In some embodiments, the spleen to liver ratio of the total therapeutic agent administered to the subject is at least 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, the spleen to liver ratio of the total therapeutic agent administered to the subject is at least 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150. In some embodiments, the spleen to liver ratio of the total therapeutic agent administered to the subject is at least 1. In some embodiments, the spleen to liver ratio of the total therapeutic cargo administered to the subject is at least 5. In some embodiments, the spleen to liver ratio of the total therapeutic agent administered to the subject is at least 10. In some embodiments, the spleen to liver ratio of the total therapeutic agent administered to the subject is at least 25. In some embodiments, the spleen to liver ratio of the total therapeutic agent administered to the subject is at least 70. In some embodiments, the spleen to liver ratio of the total therapeutic agent administered to the subject is at least 75. In some embodiments, the spleen to liver ratio of the total therapeutic agent administered to the subject is at least 100. In some embodiments, the spleen to liver ratio of the total therapeutic agent administered to the subject is at least 110.

[0695] As used herein, the percentage amount of the total therapeutic agent administered to the subject and delivered to a location in the subject's body is measured by protein expression level or mRNA knockdown level.

[0696] In some embodiments, the methods of delivering therapeutic agents disclosed above comprise administering to a subject a lipid composition comprising a therapeutic agent. In some embodiments, the lipid nanoparticles in the lipid composition are formed by one or more ionizable lipids selected from Formula (I), (IA-1), (IA-2), (IIA)-(IIC), (IIA-1), (IIIA)-(IIIE), (IVA-1)-(IVA-3), (IVC-1)-(IVC-2), and (VC-1)-(VC-6), pharmaceutically acceptable salts thereof, and stereoisomers of any of the foregoing. In some embodiments, the lipid nanoparticles are formed by one or more ionizable lipids selected from Formula (I), (IA-1), (IA-2), pharmaceutically acceptable salts thereof, and stereoisomers of any of the foregoing. In some embodiments, the lipid nanoparticles are formed by one or more ionizable lipids selected from Formula (IIA)-(IIC), pharmaceutically acceptable salts thereof, and stereoisomers of any of the foregoing. In some embodiments, the lipid nanoparticles are formed from one or more ionizable lipids selected from the group consisting of formula (IIA-1), pharmaceutically acceptable salts thereof, and stereoisomers of any of the foregoing. In some embodiments, the lipid nanoparticles are formed from one or more ionizable lipids selected from the group consisting of formula (IIIA)-(IIIE), pharmaceutically acceptable salts thereof, and stereoisomers of any of the foregoing. In some embodiments, the lipid nanoparticles are formed from one or more ionizable lipids selected from the group consisting of formula (IVA-1)-(IVA-3), pharmaceutically acceptable salts thereof, and stereoisomers of any of the foregoing. In some embodiments, the lipid nanoparticles are formed from one or more ionizable lipids selected from the group consisting of formula (IVC-1)-(IVC-3), pharmaceutically acceptable salts thereof, and stereoisomers of any of the foregoing. In some embodiments, the lipid nanoparticles are formed from one or more ionizable lipids selected from the group consisting of formula (VC-1)-(VC-6), pharmaceutically acceptable salts thereof, and stereoisomers of any of the foregoing.

[0697] In some embodiments, the lipid compositions disclosed herein can be used for a variety of purposes, including delivering encapsulated or associated (e.g., complexed) therapeutic agents, such as nucleic acids, to cells in vitro and / or in vivo. Thus, in some embodiments, methods are provided for treating or preventing a disease or condition in a subject in need thereof, comprising administering a lipid composition to the subject. In some embodiments, the lipid composition encapsulates or associates with a suitable therapeutic agent, wherein the lipid composition comprises one or more of the novel ionizable lipids described herein, pharmaceutically acceptable salts thereof, and / or stereoisomers of any of the foregoing.

[0698] In certain embodiments, lipid compositions of the present disclosure can be used for the delivery of therapeutic agents. In certain embodiments, the therapeutic agent is selected from one or more nucleic acids, including for example mRNA, antisense oligonucleotides, plasmid DNA, microRNA (miRNA), miRNA inhibitors (Anta enough wonderful / antimir), messenger RNA-interference complementary RNA (micRNA), DNA, multivalent RNA, Dicer substrate RNA, complementary DNA (cDNA) etc. Therefore, in certain embodiments, disclosed herein is a method for inducing the expression of desired protein in vitro and / or in vivo by making cells contact with the lipid compositions including one or more novel ionizable lipids as described herein, wherein lipid nanoparticles are encapsulated and expressed to produce desired protein (for example, messenger RNA or plasmid encoding desired protein) or suppress the nucleic acid of the process (for example, miRNA inhibitor) of terminating mRNA expression or associated with it. In certain embodiments, disclosed herein is a method for reducing the expression of target gene and protein in vitro and / or in vivo by making cells contact with the lipid compositions including one or more novel ionizable lipids as described herein, wherein lipid nanoparticles are encapsulated and reduced the nucleic acid (for example, antisense oligonucleotide or small interfering RNA (siRNA)) of target gene expression or associated with it. In some embodiments, disclosed herein are methods for co-delivering one or more nucleic acids (e.g., mRNA and plasmid DNA), alone or in combination, such as can be used to provide effects requiring co-localization of different nucleic acids (e.g., an mRNA encoding a suitable gene modification enzyme and a DNA fragment for incorporation into the host genome).

[0699] In certain embodiments, the lipid composition can be used for raising endogenous protein expression by delivering a specific miRNA of targeting or regulating a group of miRNA of a target mRNA or several mRNA. In certain embodiments, provided herein is a method for raising endogenous protein expression, the method comprising delivering a miRNA inhibitor of the miRNA of one or more miRNAs regulating one or more mRNAs of targeting. In certain embodiments, the lipid composition can be used for lowering protein level and / or mRNA level of (for example, silencing) target gene. In certain embodiments, provided herein is a method for lowering protein and / or mRNA level of (for example, silencing) target gene.

[0700] In some embodiments, the lipid compositions can be used to deliver mRNA and plasmids for transgene expression.In some embodiments, provided herein are methods for delivering mRNA and plasmids for transgene expression.

[0701] In some embodiments, the lipid composition can be used to induce a pharmacological effect produced by protein expression, for example, by increasing erythropoiesis by delivering a suitable erythropoietin mRNA, or protecting from infection by delivering an mRNA encoding a suitable antigen or antibody. In some embodiments, provided herein are methods for inducing a pharmacological effect produced by protein expression, for example, by increasing erythropoiesis by delivering a suitable erythropoietin mRNA, or protecting from infection by delivering an mRNA encoding a suitable antigen or antibody.

[0702] Non-limiting exemplary embodiments of the ionizable lipids disclosed herein, lipid compositions comprising the ionizable lipids, and their use for delivering agents (e.g., therapeutic agents such as nucleic acids) and / or regulating gene and / or protein expression are described in further detail below.

[0703] In some embodiments, the present disclosure relates to a method of gene editing comprising contacting a cell with an LNP composition. In some embodiments, the present disclosure relates to any gene editing method described herein comprising cutting DNA.

[0704] In some embodiments, the present disclosure relates to methods of cleaving DNA comprising contacting a cell with an LNP composition.

[0705] In some embodiments, the present disclosure relates to any method of cutting DNA as described herein, wherein the cutting step comprises introducing a single-stranded DNA nick. In some embodiments, the present disclosure relates to any method of cutting DNA as described herein, wherein the cutting step comprises introducing a double-stranded DNA break. In some embodiments, the present disclosure relates to any method of cutting DNA as described herein, wherein the LNP composition comprises 2 types of Cas mRNA and a guide RNA nucleic acid. In some embodiments, the present disclosure relates to any method of cutting DNA as described herein, further comprising introducing at least one template nucleic acid into a cell. In some embodiments, the present disclosure relates to any method of cutting DNA as described herein, comprising contacting a cell with an LNP composition comprising a template nucleic acid.

[0706] In some embodiments, the present disclosure relates to any of the methods of gene editing described herein, wherein the method comprises administering an LNP composition to an animal, such as a human. In some embodiments, the present disclosure relates to any of the methods of gene editing described herein, wherein the method comprises administering an LNP composition to a cell, such as a eukaryotic cell.

[0707] In some embodiments, the present disclosure relates to any method of gene editing as described herein, wherein the method includes administering an mRNA formulated in a first LNP composition and a second LNP composition, wherein the first LNP composition and the second LNP composition include one or more of mRNA, gRNA, gRNA nucleic acid, and template nucleic acid. In some embodiments, the present disclosure relates to any method of gene editing as described herein, wherein the first LNP composition and the second LNP composition are administered simultaneously. In some embodiments, the present disclosure relates to any method of gene editing as described herein, wherein the first LNP composition and the second LNP composition are administered sequentially.

[0708] In some embodiments, the present disclosure relates to any of the methods of gene editing described herein, wherein the method comprises administering an mRNA and a guide RNA nucleic acid formulated in a single LNP composition. In some embodiments, the present disclosure relates to any of the methods of gene editing described herein, wherein the gene editing produces a gene knockout. In some embodiments, the present disclosure relates to any of the methods of gene editing described herein, wherein the gene editing produces a gene correction.

[0709] In some embodiments, the present disclosure relates to methods for delivering interfering RNA to the lungs of mammalian subjects in vivo.

[0710] In some embodiments, methods of treating a disease or condition in a mammalian subject are provided. In some embodiments, these methods comprise administering a therapeutically effective amount of a lipid composition of the present disclosure to a subject suffering from a disease or condition associated with the expression or overexpression of a gene that can be reduced, decreased, downregulated, or silenced by the lipid composition.

[0711] Examples

[0712] The following examples are for illustrative purposes only and are not intended to limit the scope of the present invention in any way.

[0713] Example 1: Synthesis of Compound 2230

[0714]

[0715] Step 1:

[0716] To a solution of 3-(dimethylamino)propanoic acid (0.2 g, 1.30 mmol, 1 eq., HCl) and oxalyl dichloride (826.30 mg, 6.51 mmol, 569.86 μL, 5 eq.) in DCM (5 mL) was added two drops of DMF (9.52 mg, 130.20 μmol, 10.02 μL, 0.1 eq.). The mixture was degassed and purged with N 2 three times and stirred at 20 ° C. under an N 2 atmosphere for 10 hours. The reaction mixture was concentrated under reduced pressure to give 3-(dimethylamino)propanoyl chloride (0.2 g, crude product, HCl) as a yellow oil.

[0717] Step 2:

[0718] To a solution of (2S)-4-hydroxy-1-(6-oxo-6-undecanyloxy-hexyl)pyrrolidine-2-carboxylic acid [5-(1-octylnonyloxy)-5-oxo-pentyl] ester (100.00 mg, 135.48 μmol, 1 eq), 3-(dimethylamino)propanoyl chloride (93.24 mg, 541.91 μmol, 4 eq, HCl) in DCM (3 mL) was added TEA (123.38 mg, 1.22 mmol, 169.71 μL, 9 eq) at 0 ° C. The mixture was stirred at 20 ° C for 12 hours. The reaction mixture was diluted with H2O 20 mL and extracted with 60 mL of EtOAc (20 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO , petroleum ether / ethyl acetate / NH ·H O=1 / 0 / 0.1 to 3 / 1 / 0.1) and preparative HPLC (column: Phenomenex Luna C18 100×30mm×5μm; mobile phase: [water (HCl)-ACN]; B%: 45%-75%, 10 minutes) to obtain a residue. The residue was adjusted to pH=7 with saturated NaHCO aqueous solution and extracted with 60mL EtOAc (20mL×3). The combined organic layers were dried over Na SO , filtered and concentrated under reduced pressure to obtain a residue. The residue was then purified by column chromatography (SiO2, petroleum ether / ethyl acetate / NH3·H2O=1 / 0 / 0.1 to 5 / 1 / 0.1) to give 2230, (2S)-4-[3-(dimethylamino)propanoyloxy]-1-(6-oxo-6-undecanoxy-hexyl)pyrrolidine-2-carboxylic acid [5-(1-octylnonyloxy)-5-oxo-pentyl] ester (17 mg, 20.30 μmol, 14.99% yield, 100% purity) as a yellow oil.

[0719] 1 H NMR(400MHz, CDCl3),5.21-5.27(m,1H),4.86-4.89(m,1H),4.14-4.16(m, 2H),4.06(t,J=6.4Hz,2H),3.44-3.55(m,1H),3.10-3.26(m,1H),2.45-2.7 3(m,7H),2.32-2.33(m,10H),2.16-2.28(m,1H),2.05-2.06(m,1H),1.60- 1.65(m,6H),1.51-1.52(m,6H),1.27-1.31(m,46H),0.89(t,J=6.8Hz,9H). LCMS:(1 / 2M+H +):419.2 at 2.971 minutes.

[0720] Example 2: Synthesis of Compound 2260

[0721]

[0722] Step 1:

[0723] A solution of heptadecan-9-ol (10 g, 38.99 mmol, 1 eq), 5-bromovaleric acid (7.06 g, 38.99 mmol, 1 eq), DMAP (952.72 mg, 7.80 mmol, 0.2 eq) and EDCI (7.47 g, 38.99 mmol, 1 eq) in DCM (70 mL) was stirred at 20 ° C for 12 hours. The combined organic phases were diluted with 200 mL of EtOAc and washed with 600 mL of water (200 mL × 3) and 400 mL of brine (200 mL × 2), dried over anhydrous Na SO , filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO , petroleum ether / ethyl acetate = 20 / 1 to 10 / 1) to give 1-octylnonyl 5-bromovalerate (25 g, 59.60 mmol, 76.42% yield) as a colorless oil.

[0724] 1 H NMR(400MHz, CDCl3),4.85-4.91(m,1H),3.42(t,J=6.8Hz,2H),2.34(t,J=7.2Hz,2H),1.90-1 .93(m,2H),1.79-1.81(m,2H),1.52-1.57(m,4H),1.27-1.51(m,24H),0.89(t,J=6.4Hz,6H).

[0725] Step 2:

[0726] A mixture of (2S)-1-tert-butoxycarbonyl-4-hydroxy-pyrrolidine-2-carboxylic acid (2.30 g, 9.93 mmol, 1 eq), 1-octylnonyl 5-bromovalerate (5 g, 11.92 mmol, 1.2 eq), CsCO (7.12 g, 21.85 mmol, 2.2 eq) in DMF (60 mL) was stirred at 20 ° C under N atmosphere for 12 hours. The reaction mixture was quenched by adding 10 mL of H O at 0 ° C. The mixture was extracted with 30 mL of EtOAc (10 mL × 3), and the combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 3 / 1) to give (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid O1-tert-butyl ester O2-[5-(1-octylnonyloxy)-5-oxo-pentyl] ester (4.5 g, 3.95 mmol, 39.75% yield, 50% purity) as a white solid.

[0727] 1 H NMR(400MHz, CDCl3),4.86-4.89(m,1H),4.17-4.39(m,4H),3.50-3.69(m,2H),2.33-2.34 (m,2H),1.61-1.72(m,4H),1.42-1.52(m,14H),1.25-1.30(m,25H),0.88(t,J=6.8Hz,6H).

[0728] Step 3:

[0729] To a solution of (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 01-tert-butyl ester 02-[5-(1-octylnonyloxy)-5-oxo-pentyl] ester (4.00 g, 7.02 mmol, 1 equiv) in DCM (50 mL) was added TFA (23.10 g, 202.60 mmol, 15.00 mL, 28.86 equiv). The mixture was stirred at 20 ° C for 5 hours. The reaction mixture was adjusted to pH = 7 with saturated aqueous NaHCO 3 solution and extracted with 600 mL of EtOAc (200 mL×3), dried over Na 2 SO 4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 0 / 1 to ethyl acetate / MeOH = 3 / 1) to give (2S)-4-hydroxypyrrolidine-2-carboxylic acid [5-(1-octylnonyloxy)-5-oxo-pentyl] ester (2.5 g, 4.52 mmol, 64.45% yield, 85% purity) as a yellow oil.

[0730] 1H NMR(400MHz, CDCl3),4.86-4.89(m,1H),4.37-4.45(m,1H),4.15-4.25(m,2H),3.82-4.14(m,1H),2.97-3.15 (m,2H),2.33-2.35(m,2H),1.69-1.70(m,4H),1.50-1.52(m,4H),1.26-1.32(m,26H),0.88(t,J=6.8Hz,6H).

[0731] Step 4:

[0732] To a solution of (2S)-4-hydroxypyrrolidine-2-carboxylic acid [5-(1-octylnonyloxy)-5-oxo-pentyl] ester (500.00 mg, 1.06 mmol, 1 eq) and undecyl 6-bromohexanoate (446.26 mg, 1.28 mmol, 1.2 eq) in DMF (10 mL) was added KCO (441.37 mg, 3.19 mmol, 3 eq). The mixture was stirred at 80° C. for 12 h. The reaction mixture was diluted with 20 mL of H O and extracted with 60 mL of EtOAc (20 mL×3). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate / NH3H2O=10 / 1 / 1 to 1 / 1 / 0.5) to give 2260, (2S)-4-hydroxy-1-(6-oxo-6-undecanoxy-hexyl)pyrrolidine-2-carboxylic acid [5-(1-octylnonyloxy)-5-oxo-pentyl] ester (0.6 g, 715.32 μmol, 67.20% yield, 88% purity) as a yellow oil.

[0733] 1 H NMR(400MHz, CDCl3),4.86-4.91(m,1H),4.28-4.49(m,1H),4.13-4.16(m,2H),4.06(t,J=6.4Hz,2H),3.07-3.54(m,2H),2.48-2.65 (m,3H),2.28-2.34(m,4H),1.95-2.23(m,2H),1.60-1.64(m,6H),1.50-1.52(m,6H),1.27-1.35(m,44H),0.89(t,J=6.4Hz,9H),(M+H + ):738.3. LCMS: (M+H + ):738.3, lasting 2.843 minutes.

[0734] Example 3: Synthesis of Compound 2231

[0735]

[0736] Step 1:

[0737] To a solution of 3-(dimethylamino)propanoic acid (0.2 g, 1.30 mmol, 1 eq., HCl) and oxalyl dichloride (826.30 mg, 6.51 mmol, 569.86 μL, 5 eq.) in DCM (5 mL) was added two drops of DMF (9.52 mg, 130.20 μmol, 10.02 μL, 0.1 eq.) at 20° C. The mixture was stirred at 20° C. under an N atmosphere for 10 hours. The reaction mixture was concentrated under reduced pressure to give 3-(dimethylamino)propanoyl chloride (0.2 g, crude product, HCl) as a yellow oil.

[0738] Step 2:

[0739] To a suspension of (2S)-4-hydroxy-1-(6-oxo-6-undecanyloxy-hexyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (200 mg, 256.34 μmol, 1 eq), DMAP (6.26 mg, 51.27 μmol, 0.2 eq), TEA (207.51 mg, 2.05 mmol, 285.44 μL, 8 eq) and 4A molecular sieves (100 mg) in DCM (15 mL) was added 3-(dimethylamino)propanoyl chloride (220.52 mg, 1.28 mmol, 5 eq, HCl) in DCM (10 mL) at 0° C. The mixture was stirred at 20° C. under an N atmosphere for 8 h. The reaction mixture was diluted with 20 mL of H O and extracted with 60 mL of EtOAc (20 mL×3). The organic layer that merges is through Na SO Drying, filter and under reduced pressure concentrate to obtain residue.Residue is passed through column chromatography (SiO , petroleum ether / ethyl acetate / NH H O=1 / 0 / 0.1 to 3 / 1 / 0.1) and preparative HPLC (post: Phenom Luna C18100×30mm×5 μm; Mobile phase: [water (HCl)-ACN]; B%: 55%-85%, 10 minutes) purifying, to obtain residue.Residue is used saturated NaHCO The aqueous solution is adjusted to pH=7, and extracted with 60mL EtOAc (20mL×3).The organic layer that merges is through Na SO Drying, filter and under reduced pressure concentrate to obtain residue. The residue was then purified by column chromatography (SiO2, petroleum ether / ethyl acetate / NH3·H2O=1 / 0 / 0.1 to 5 / 1 / 0.1) to give 2231, (2S)-4-[3-(dimethylamino)propanoyloxy]-1-(6-oxo-6-undecanoxy-hexyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (40 mg, 45.49 μmol, 13.33% yield, 100% purity) as a yellow oil.

[0740] 1 H NMR(400MHz, CDCl3),5.21-5.27(m,1H),4.84-4.90(m,1H),4.04-4.13(m,4H),3.08-3.54(m,2H),2.32-2.65(m,7H),2 .29-2.31(m,10H),2.27-2.28(m,2H),1.63-1.65(m,8H),1.60-1.62(m,6H),1.27-1.52(m,48H),0.89(t,J=6.4Hz,9H). LCMS:(1 / 2M+H + ):879.6 at 2.155 minutes.

[0741] Example 4: Synthesis of Compound 2270

[0742]

[0743] Step 1:

[0744] To a mixture of 8-bromooctanoic acid (10g, 44.82mmol, 1 equivalent) in DCM (1000mL), DMAP (1.10g, 8.96mmol, 0.2 equivalent), heptadecan-9-ol (11.50g, 44.82mmol, 1 equivalent) and EDCI (8.59g, 44.82mmol, 1 equivalent) was added, and degassed with N2 purged 3 times. The mixture was stirred at 20°C under N2 atmosphere for 8 hours. The reaction was diluted with 200mL EtOAc, and washed with 600mL water (200mL×3) and 400mL brine (200mL×2), over anhydrous Na2SO4 dried, filtered and concentrated under reduced pressure to obtain residue. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate=1 / 0 to 1 / 0) to give 1-octylnonyl 5-bromovalerate (25 g, 59.60 mmol, 76.42% yield) as a colorless oil.

[0745] 1 H NMR(400MHz, CDCl3),4.86-4.89(m,1H),3.41(t,J=7.2Hz,2H),2.29(t,J=7.6Hz,2H),1.80-1.90(m,2H ),1.60-1.63(m,2H),1.44-1.51(m,4H),1.34-1.35(m,2H),1.27-1.33(m,28H),0.89(t,J=6.8Hz,6H).

[0746] Step 2:

[0747] A mixture of (2S)-1-tert-butoxycarbonyl-4-hydroxy-pyrrolidine-2-carboxylic acid (3.34 g, 14.44 mmol, 1 eq), 1-octylnonyl 8-bromooctanoate (8 g, 17.33 mmol, 1.2 eq), CsCO (10.35 g, 31.78 mmol, 2.2 eq) in DMF (60 mL) was stirred at 20 ° C under N atmosphere for 8 hours. The reaction mixture was quenched by adding 10 mL of H O at 0 ° C. The mixture was extracted with 30 mL of EtOAc (10 mL × 3), and the combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 3 / 1) to give (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid O1-tert-butyl ester O2-[8-(1-octylnonyloxy)-8-oxo-octyl] ester (6 g, 9.81 mmol, 67.89% yield) as a white solid.

[0748] Step 3:

[0749] To a solution of (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 01-tert-butyl ester 02-[8-(1-octylnonyloxy)-8-oxo-octyl] ester (5.5 g, 8.99 mmol, 1 eq) in DCM (50 mL) was added TFA (23.10 g, 202.59 mmol, 15 mL, 22.54 eq). The mixture was stirred at 20 ° C for 5 hours. The reaction mixture was adjusted to pH = 7 with saturated aqueous NaHCO 3 solution and extracted with 600 mL of EtOAc (200 mL×3), dried over Na 2 SO 4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 0 / 1 to ethyl acetate / MeOH = 3 / 1) to give [5-(1-octylnonyloxy)-5-oxo-pentyl](2S)-4-hydroxypyrrolidine-2-carboxylate (2.5 g, 4.52 mmol, 64.45% yield, 85% purity) as a yellow oil.

[0750] 1 H NMR(400MHz, CDCl3),4.85-4.89(m,1H),4.45-4.47(m,1H),4.02-4.18(m,3H),2.99-3.19(m,2H),2.29-2.31(m,4H),2 .07-2.27(m,1H),2.05-2.06(m,1H),1.61-1.66(m,4H),1.50-1.52(m,4H),1.26-1.35(m,30H),0.88(t,J=6.8Hz,6H).

[0751] Step 4:

[0752] To a solution of (2S)-4-hydroxypyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (2 g, 3.91 mmol, 1 eq.), 6-bromohexanoic acid undecyl ester (1.64 g, 4.69 mmol, 1.2 eq.) in DMF (20 mL) was added KCO (1.62 g, 11.72 mmol, 3 eq.). The mixture was stirred at 80 ° C. for 8 hours. The reaction mixture was diluted with 20 mL of H O and extracted with 60 mL of EtOAc (20 mL×3). The combined organic layers were dried over NaSO, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate / NH3H2O=10 / 1 / 1 to 1 / 1 / 0.5) to give 2270, (2S)-4-hydroxy-1-(6-oxo-6-undecanoxy-hexyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (3 g, 3.85 mmol, 98.39% yield, 100% purity) as a yellow oil.

[0753] 1 H NMR(400MHz, CDCl3),4.84-4.90(m,1H),4.49-4.52(m,1H),4.04-4.39(m,5H),3.05-3.66(m,2H),2.48-2.69 (m,2H),1.94-2.32(m,6H),1.60-1.66(m,8H),1.50-1.52(m,6H),1.27-1.34(m,48H),0.89(t,J=6.8Hz,9H). LCMS:(M+H + ):780.5 at 2.889 minutes.

[0754] Example 5: General Reaction Scheme for the Synthesis of Exemplary Ionizable Lipid Compounds

[0755] A general reaction scheme for the synthesis of exemplary ionizable lipid compounds containing a heterocyclic core structure (eg, an N-containing core) is shown in Scheme 1.

[0756]

[0757] A general reaction scheme for the synthesis of exemplary ionizable lipid compounds containing a cycloalkyl core structure is shown in Scheme 2.

[0758]

[0759] Non-limiting examples of alternative starting heterocyclic or cycloalkyl core structures for preparing exemplary ionizable lipid compounds in Schemes 1 or 2 are shown in Scheme 3.

[0760]

[0761] Example 6: Preparation of lipid nanoparticle compositions with or without cargo

[0762] Exemplary lipid nanoparticle compositions.

[0763] Prepare exemplary lipid nanoparticle compositions, so that the mol ratio of ionizable lipid: structural lipid: sterol: PEG-lipid is respectively 50:10:38.5:1.5.For example, the exemplary lipid nanoparticle compositions in this example are shown in the table below.The exemplary ionizable lipid for each exemplary lipid nanoparticle composition is compound 2230, 2231, 2260 and 2270 (LNP 2230, LNP 2231, LNP 2260, LNP 2270).

[0764]

[0765] To prepare these compositions, the lipids according to the table above were dissolved in ethanol, mixed in the above molar ratios and diluted in ethanol (organic phase) to obtain a total lipid concentration of 5.5 mM.

[0766] Comparative lipid nanoparticle compositions.

[0767] A lipid nanoparticle composition containing C12-200 (LNP C12-200) was prepared as a control such that the molar ratios of C12-200:DOPE:cholesterol (14:0):DMPE-PEG2k were 35:16:46.5:2.5, respectively. C12-200 is a commercially available ionizable lipid and has the chemical name 1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol). The lipid was dissolved in ethanol. The lipids were mixed in the molar ratios indicated above and diluted in ethanol (organic phase) to obtain a total lipid concentration of 5.5 mM.

[0768] Prepare another lipid nanoparticle composition containing MC3 (LNP MC3) as a control, so that the mol ratio of MC3:DSPC:cholesterol:14:0DMPE-PEG2k is respectively 50:38.5:10:1.5.MC3 is a commercially available ionizable lipid with chemical name 4-(dimethylamino)butyric acid (6Z, 9Z, 28Z, 31Z)-triacontane-6,9,28,31-tetraene-19-yl ester.Lipid is dissolved in ethanol.Lipid is dissolved in ethanol.These lipids are mixed with the mol ratio of above-mentioned indication, and diluted in ethanol (organic phase), to obtain the total lipid concentration of 5.5mM.

[0769] Lipid nanoparticle compositions encapsulating mRNA.

[0770] mRNA solutions (aqueous phase, fluc:EPO mRNA) were prepared using RNase-free water and 100 mM citrate buffer at pH 3 to give a final concentration of 50 mM citrate buffer and 0.167 mg / mL mRNA concentration (1:1 Fluc:EPO). The ionizable lipids and mRNA of the formulations were maintained at an ionizable lipid nitrogen:mRNA phosphate (N:P) ratio of 15:1 for the LNP C12-200 control and 6:1 for the exemplary lipid nanoparticle compositions (LNP 2230, LNP 2231, LNP 2260, LNP 2270) and for the LNP MC3 control.

[0771] For each LNP composition, the lipid mixture and mRNA solution were mixed at a total flow rate of 9 ml / min in a 1:3 volume ratio on a NanoAssemblrIgnite (Precision Nanosystems, Inc.). The resulting composition was then loaded into a Slide-A-Lyzer G2 dialysis cassette (10k MWCO) and dialyzed for 2 hours at room temperature in 1x PBS of 200 times the sample volume with gentle stirring. PBS was updated and the composition was further dialyzed for at least 14 hours at 4°C with gentle stirring. The dialyzed composition was then collected and concentrated by centrifugation at 2000xg using an Amicon ultracentrifugal filter (100k MWCO). The concentrated particles were characterized for size, polydispersity, and particle concentration using a Zetasizer Ultra (Malvern Panalytical), and mRNA encapsulation efficiency was characterized using the Quant-iT RiboGreen RNA Assay Kit (ThermoFisher Scientific).

[0772] For pKa measurements, TNS assays were performed according to the method described in Sabnis et al., Molecular Therapy, 26(6): 1509-19 (incorporated herein by reference in its entirety). Briefly, 20 buffers (10 mM sodium phosphate, 10 mM sodium borate, 10 mM sodium citrate, and 150 mM sodium chloride in distilled water) with unique pH values ​​ranging from 3.0 to 12.0 were prepared using 1 M sodium hydroxide and 1 M hydrochloric acid. 3.25 μL of LNP composition (0.04 mg / mL mRNA in PBS) was incubated with 2 μL of TNS reagent (0.3 mM in DMSO) and 90 μL of buffer for each pH value (as described above) in a 96-well black wall plate. Each pH condition was performed in triplicate. TNS fluorescence was measured using a Biotek Cytation plate reader at excitation / emission wavelengths of 321 / 445 nm. The fluorescence values ​​were then plotted and fitted using a 4-parameter sigmoidal curve. From the fit, the pH value that yielded half-maximal fluorescence was calculated and reported as the apparent LNP pKa value.

[0773] The table below shows particle characterization data for each exemplary lipid nanoparticle composition (LNP 2230, LNP 2231, LNP 2260, LNP2270).

[0774] LNP Size (nm) PDI Embedding efficiency% pKa 2230 87.57 0.10 92.4 4.84 2260 62.62 0.14 90 4.72 2270 68.41 0.02 88.7 4.85 2231 91.57 0.05 93.9 5.03

[0775] Example 7: In vivo bioluminescence imaging

[0776] In this example, exemplary lipid nanoparticle compositions (LNP 2230, LNP 2231, LNP 2260, LNP 2270) and comparative lipid nanoparticle compositions (LNP C12-200 and LNP MC3) encapsulating mRNA (EPO) prepared according to Example 6 were used.

[0777] Bioluminescence screening.

[0778] 8-9 week old female Balb / c mice were used for bioluminescence-based ionizable lipid screening. Mice were obtained from Jackson Laboratories (JAX catalog number: 000651) and acclimated for one week before operation. The animals were placed under a heating lamp for a few minutes before being introduced into a confinement chamber. The tail was wiped with an alcohol pad (Fisher Scientific), and for each of the above LNP compositions, 100 μL of a lipid nanoparticle composition containing 10 μg total mRNA (5 μg Fluc+5 μg EPO) was injected intravenously using a 29G insulin syringe (Covidien). 4-6 hours after administration, 200 μL of 15 mg / mL D-luciferin (GoldBio) was injected into the animals and placed in a fixed nose cone in an IVIS Lumina LT imager (PerkinElmer). Imaging was performed using LivingImage software. Whole body bioluminescence is captured when automatic exposure, and animal is taken out from IVIS and placed in CO2 compartment and euthanized.After each animal is placed in dorsal position, cardiac puncture is carried out to it, and 25G insulin syringe (BD) is used to carry out blood collection. Once all blood samples have been collected, just use table centrifuge to rotate test tube 10 minutes with 2000G, and blood plasma is divided into independent Ai Bende pipe (Eppendorftube) (Fisher Scientific Company), and is stored at-80 ℃ for subsequent EPO quantitative.Use EPO MSD test kit (Meso Scale Diagnostics Company (Meso Scale Diagnostics)) to determine the EPO level in blood plasma.

[0779] hEPOMSD measurement results.

[0780] The reagents used to measure hEPO levels include:

[0781] MSD Wash Buffer (#R61AA-1)

[0782] MSD EPO kit (#K151VXK-2)

[0783] ○MSD GOLD 96-spot Streptavidin Plate

[0784] ○Thinner 100

[0785] ○Thinner 3

[0786] ○Thinner 43

[0787] ○Calibrator 9

[0788] ○Capture Ab

[0789] ○Detect Ab

[0790] ○MSD GOLD Read Buffer B

[0791] General procedure. Coat the plate. Add 200 μL of biotinylated capture antibody to 3.3 mL of Diluent 100 and mix by vortexing. Add 25 μL of this solution to each well of the provided MSD GOLD Small Spot Streptavidin Plate. Seal the plate with an adhesive plate seal and incubate at room temperature with shaking for 1 hour or at 2–8°C overnight. Wash the plate three times with at least 150 μL / well of 1X MSD Wash Buffer.

[0792] Preparation of calibrator standards. The calibrator vial is placed at room temperature. Reconstruct each calibrator vial by adding 250 μL of diluent 43 to a glass vial, thereby obtaining a calibrator stock solution concentrated 5 times. The reconstructed calibrator is inverted at least 3 times and balanced at room temperature for 15-30 minutes, and then briefly vortexed. Prepare calibrator standard 1 by adding 50 μL of reconstructed calibrator to 200 μL of diluent 43 and vortexing. Prepare calibrator standard 2 by adding 75 μL of calibrator standard 1 to 225 μL of diluent 43 and vortexing. Four times the serial dilutions are repeated 5 times in addition, to produce a total of 7 calibrator standards. Vortex mix between each serial dilution. Diluent 43 is used as calibrator standard 8 (zero calibrator).

[0793] Sample and Calibrator Addition: Add 25 μL of Diluent 43 to each well. Add 25 μL of the prepared calibrator standard or sample to each well. Seal the plate with an adhesive plate seal and incubate at room temperature for 1 hour with shaking.

[0794] Preparation and addition of detection antibody solution. The detection antibody solution is provided as a 100x stock solution. The working solution is 1x. Add 60 μL of the supplied 100x detection antibody to 5940 μL of Diluent 3. Wash the plate three times with at least 150 μL / well of 1x MSD Wash Buffer. Add 50 μL of the detection antibody solution prepared above to each well. Seal the plate with an adhesive plate seal and incubate at room temperature with shaking for 1 hour.

[0795] Sample reading. Wash the plate three times with at least 150 μL / well of 1x MSD Wash Buffer. Add 150 μL of MSD GOLD Read Buffer B to each well. Analyze the plate on the MSD instrument to read EPO levels.

[0796] The table below shows the average radiance level for each exemplary lipid nanoparticle composition (LNP 2230, LNP 2231, LNP 2260, LNP 2270) as determined by in vivo bioluminescence imaging.

[0797]

[0798] The mean spleen:liver radiation ratios of the exemplary lipid nanoparticle compositions (LNP 2230, LNP 2231) were determined compared to the comparative lipid nanoparticle compositions (LNP C12-200, LNP MC3) and are shown in FIG. Figure 1 As shown in the figure, the exemplary lipid nanoparticle compositions (LNP 2230, LNP 2231) exhibited significantly higher spleen to liver ratios (>>1 v. <<0.1) than the spleen to liver ratios of the comparative lipid nanoparticle compositions (LNP C12-200, LNP MC3), indicating that unlike the standard delivery primarily through the liver exhibited by the comparative lipid nanoparticle compositions, the exemplary lipid nanoparticle compositions exhibited surprisingly high delivery to the spleen in addition to liver delivery.

[0799] Thus, lipid nanoparticles employing the novel ionizable lipids described herein demonstrate selective delivery of therapeutic cargo outside the liver and are expected to have less hepatotoxicity due to lower lipid levels in the liver.

[0800] Example 8: Synthesis of exemplary ionizable lipid compounds.

[0801] 8.1. Synthesis of Compound 2290

[0802]

[0803] Step 1:

[0804] To a solution of 8-bromooctanoic acid (4.35g, 19.50mmol, 1 equivalent) and heptadecan-9-ol (5g, 19.50mmol, 1 equivalent) in DCM (100mL) is added EDCI (4.48g, 23.39mmol, 1.2 equivalents) and DMAP (1.19g, 9.75mmol, 0.5 equivalents). The mixture is stirred at 15 ° C for 8 hours. The reaction mixture is quenched at 15 ° C by adding 200mL H o, and then extracted with 600mL EtOAc (200mL × 3). The combined organic layer is washed with 400mL brine (200mL × 2), through Na sO dried, filtered and concentrated under reduced pressure to obtain residue. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate=1 / 0 to 20 / 1) to give 1-octylnonyl 8-bromooctanoate (35 g, 75.83 mmol, 97.24% yield) as a colorless oil.

[0805] 1 H NMR(400MHz, CDCl3),4.84-4.90(m,1H),3.41(t,J=6.8Hz,2H),2.29(t,J=7.6Hz,2H),1.82-1 .88(m,2H),1.62-1.65(m,2H),1.42-1.52(m,6H),1.25-1.36(m,28H),0.89(t,J=7.2Hz,6H).

[0806] Step 2:

[0807] By 8-bromooctanoic acid 1-octyl nonyl ester (1g, 2.17mmol, 1.2 equivalents), (2S) -1- tert-butoxycarbonyl -4-hydroxy - pyrrolidine -2- carboxylic acid (417.51mg, 1.81mmol, 1 equivalent), CsCO (1.29g, 3.97mmol, 2.2 equivalents) in DMF (10mL) mixture degassed and N2 purged 3 times, and then the mixture was stirred at 15 DEG C under N2 atmosphere for 8 hours. The reaction mixture was quenched at 15 DEG C by adding 50mL H2O, and then extracted with 150mL EtOAc (50mL × 3). The combined organic layer was washed with 100mL brine (50mL × 2), through Na2SO4 dried, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate = 20 / 1 to 3 / 1) to give (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 01-tert-butyl ester 02-[8-(1-octylnonyloxy)-8-oxo-octyl] ester (4.55 g, 7.44 mmol, 82.37% yield) as a colorless oil.

[0808] 1 H NMR(400MHz, CDCl3),4.84-4.90(m,1H),4.18-4.52(m,3H),4.06-4.10(m,1H),3.42-3.72 (m,2H),2.21-2.39(m,3H),2.07-2.11(m,1H),1.25-1.67(m,48H),0.88(t,J=6.8Hz,6H).

[0809] Step 3:

[0810] To a solution of (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 01-tert-butyl ester 02-[8-(1-octylnonyloxy)-8-oxo-octyl] ester (4.5 g, 7.35 mmol, 1 eq) in DCM (30 mL) was added TFA (23.10 g, 202.59 mmol, 15 mL, 27.55 eq). The mixture was stirred at 15 ° C for 3 hours. The reaction mixture was quenched at 15 ° C by adding 60 mL of anhydrous NaHCO 3 and then extracted with 150 mL of EtOAc (50 mL × 3). The combined organic layers were washed with 100 mL of brine (50 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give (2S)-4-hydroxypyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (3.76 g, 7.35 mmol, 100.00% yield) as a colorless oil.

[0811] Step 4:

[0812] To a solution of (2S)-4-hydroxypyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (2 g, 3.91 mmol, 1 eq) and 6-bromohexanoic acid undecyl ester (1.64 g, 4.69 mmol, 1.2 eq) in DMF (40 mL) was added KCO (1.62 g, 11.72 mmol, 3 eq) and KI (324.37 mg, 1.95 mmol, 0.5 eq). The mixture was stirred at 50 ° C for 8 hours. The reaction mixture was quenched at 15 ° C by adding 50 mL of H O and extracted with 150 mL of EtOAc (50 mL × 3). The combined organic layers were washed with 100 mL (50 mL × 2) of brine, dried over NaSO, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20 / 1 to 1 / 1) to give (2S)-4-hydroxy-1-(6-oxo-6-undecanoxy-hexyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (1.6 g, 2.05 mmol, 52.48% yield) as a colorless oil.

[0813] 1 H NMR(400MHz, CDCl3),4.86-4.90(m,1H),4.24-4.53(m,1H),4.04-4.15(m,4H),2.99-3.69(m,2H),1 .84-2.84(m,8H),1.59-1.68(m,8H),1.45-1.54(m,6H),1.15-1.44(m,50H),0.89(t,J=7.8Hz,9H). LCMS:(M+H + ):780.4 at 13.579 minutes.

[0814] Step 5:

[0815] To a solution of 3-pyrrolidin-1-ylpropionic acid (100 mg, 698.41 μmol, 1 eq) in DCM (5 mL) was added (COCl) (443.23 mg, 3.49 mmol, 305.68 μL, 5 eq) and DMF (5.10 mg, 69.84 μmol, 5.37 μL, 0.1 eq). The mixture was stirred at 15 ° C for 2 hours. The reaction mixture was concentrated under reduced pressure to give 3-pyrrolidin-1-ylpropanoyl chloride (138 mg, 696.65 μmol, 99.75% yield, HCl) as a yellow solid.

[0816] Step 6:

[0817] To a suspension of (2S)-4-hydroxy-1-(6-oxo-6-undecyloxy-hexyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (200 mg, 256.34 μmol, 1 eq), TEA (77.82 mg, 769.03 μmol, 107.04 μL, 3 eq) and DMAP (15.66 mg, 128.17 μmol, 0.5 eq) in DCM (3 mL) was added [3-pyrrolidin-1-ylpropanoyl chloride (126.95 mg, 640.85 μmol, 2.5 eq, HCl) in DCM (1 mL) dropwise at 15° C. The mixture was stirred at 15° C. under N atmosphere for 2 h. The reaction mixture was quenched at 15°C by adding 10 mL of saturated NaHCO and then extracted with 30 mL of EtOAc (10 mL × 3). The combined organic layers were washed with 20 mL of brine (10 mL × 2), dried over NaSO, filtered and concentrated under reduced pressure to give a residue. The residue was analyzed by preparative TLC (SiO 2,The product was purified by HPLC-MS / MS:[EtOAc:MeOH=10:1) to give (2S)-1-(6-oxo-6-undecanyloxy-hexyl)-4-(3-pyrrolidin-1-ylpropionyloxy)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (100 mg, 108.24 μmol, 49.00% yield, 98% purity) as a colorless oil.

[0818] 1 H NMR(400MHz, CDCl3),5.19-5.31(m,1H),4.84-4.89(m,1H),4.04-4.15(m,4H),3.43-3.55(m,1H),3.09-3.26(m,1H),2.49-2.81(m,1 0H),2.24-2.36(m,5H),1.95-2.22(m,1H),1.80(s,3H),1.59-1.68(m,8H),1.44-1.54(m,6H),1.12-1.42(m,50H),0.85-0.93(m,9H).

[0819] LCMS: (M+H + ):905.4 at 1.950 / 2.035 minutes.

[0820] 8.2. Synthesis of Compound 2291

[0821]

[0822] Step 1:

[0823] To a suspension of (2S)-4-hydroxy-1-(6-oxo-6-undecyloxy-hexyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (1 g, 1.28 mmol, 1 eq), TEA (648.47 mg, 6.41 mmol, 891.99 uL, 5 eq) and DMAP (78.29 mg, 640.85 μmol, 0.5 eq) in DCM (9 mL) was added a solution of prop-2-enoyl chloride (464.02 mg, 5.13 mmol, 418.04 μL, 4 eq) in DCM (3 mL) dropwise. The mixture was stirred at 15 ° C. under an N atmosphere for 3 hours. The reaction mixture was quenched at 15 ° C. by adding 10 mL of H O and then extracted with 30 mL of EtOAc (10 mL × 3). The combined organic layers were washed with 20 mL of brine (10 mL × 2), dried over Na SO , filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO , petroleum ether / ethyl acetate=20 / 1 to 8 / 1) to give (2S)-1-(6-oxo-6-undecyloxy-hexyl)-4-prop-2-enoyloxy-pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (300 mg, 359.60 μmol, 28.06% yield) as a colorless oil.

[0824] Step 2:

[0825] A mixture of (2S)-1-(6-oxo-6-undecyloxy-hexyl)-4-prop-2-enoyloxy-pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (300 mg, 359.60 μmol, 1 equivalent), 2-(methylamino)ethanol (27.01 mg, 359.60 μmol, 28.89 μL, 1 equivalent) in toluene (3 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 90 ° C. under N2 atmosphere for 8 hours. The reaction mixture was concentrated under reduced pressure to obtain a residue. The residue was purified by preparative HPLC (column: Phenylephant Luna C18 100×30 mm×5 μm; mobile phase: [water (HCl)-ACN]; B%: 45%-75%, 10 minutes) to obtain a solution. The solution was adjusted to pH = about 7 with saturated NaHCO 3 and extracted with EtOAc (20 mL×3). The organic layer was washed with brine (20 mL×2), dried over Na 2 SO 4 , filtered, and the filtrate was concentrated under reduced pressure to give (2S)-4-[3-[2-hydroxyethyl(methyl)amino]propanoyloxy]-1-(6-oxo-6-undecanyloxy-hexyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (30 mg, 32.59 μmol, 9.06% yield, 98.8% purity) as a colorless oil.

[0826] 1 H NMR(400MHz, CDCl3),5.15-5.31(m,1H),4.81-4.93(m,1H),4.01-4.18(m,4H),3.39-3.72(m,3H),3.04-3.3 1(m,1H),1.97-2.88(m,18H),1.59-1.66(m,8H),1.47-1.55(m,6H),1.23-1.38(m,48H),0.84-0.95(m,9H). LCMS:(M+H + ):909.7 at 9.772 minutes.

[0827] 8.3. Synthesis of Compound 2292

[0828]

[0829] Step 1:

[0830] To a solution of 3-(dimethylamino)propanoic acid (100 mg, 651.01 μmol, 1 eq, HCl) in DCM (5 mL) was added (COCl) (354.59 mg, 2.79 mmol, 244.55 μL, 4 eq) and DMF (5.10 mg, 69.84 μmol, 5.37 μL, 0.1 eq). The mixture was stirred at 15 °C for 2 h. The mixture was concentrated under reduced pressure to give 3-(dimethylamino)propanoyl chloride (112 mg, 650.96 μmol, 99.99% yield, HCl) as a yellow solid.

[0831] Step 2:

[0832] At 0 ° C, to a solution of (2S) -4-hydroxy -1- (6- oxo -6- undecyloxy - hexyl) pyrrolidine -2- carboxylic acid [8- (1- octyl nonyloxy) -8- oxo - octyl] ester (200 mg, 256.34 μ mol, 1 eq) in DCM (10 mL) was added TEA (129.69 mg, 1.28 mmol, 178.40 μ L, 5 eq) and 3- (dimethylamino) propionyl chloride (112 mg, 650.96 μ mol, 2.54 eq, HCl). The mixture was stirred at 15 ° C for 3 hours. The reaction mixture was quenched at 15 ° C by adding 10 mL of NaHCO 3 and then extracted with 30 mL of EtOAc (10 mL × 3). The combined organic layers were washed with 20 mL of brine (10 mL × 2), dried over Na SO 4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO2, EtOAc:MeOH=10:1) to give (2S)-4-[4-(dimethylamino)butanoyloxy]-1-(6-oxo-6-undecanoxy-hexyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (33 mg, 36.42 μmol, 14.7% yield, 98.6% purity) as a colorless oil.

[0833] 1 H NMR(400MHz, CDCl3),5.11-5.34(m,1H),4.84-4.90(m,1H),4.03-4.14(m,4H),3.43-3.54(m,1H),3.09-3.25(m,1H), 2.03-2.77(m,19H),1.77-1.82(m,2H),1.60-1.65(m,8H),1.49-1.52(m,6H),1.27-1.34(m,48H),0.87-0.90(m,9H).

[0834] LCMS: (M / 2+1): 893.4 at 10.022 min.

[0835] 8.4. Synthesis of Compound 2293

[0836]

[0837]

[0838] Step 1:

[0839] A solution of (2S)-1-tert-butoxycarbonyl-4-hydroxy-pyrrolidine-2-carboxylic acid (10 g, 43.24 mmol, 1 equivalent) in MeOH (50 mL) and H o (20 mL) was adjusted to pH=7.0 with cesium carbonate (8.45 g, 25.95 mmol, 0.6 equivalent). The mixture was concentrated under reduced pressure to obtain a residue. The residue was dissolved in DMF (100 mL), and BnBr (7.40 g, 43.24 mmol, 5.14 mL, 1 equivalent) was then added at 25 ° C. The mixture was degassed and purged with N 3 times, and then stirred at 25 ° C under N atmosphere for 8 hours. The reaction mixture was diluted with 50 mL H o, extracted with 300 mL EtOAc (100 mL × 3). The combined organic layer was washed with 100 mL brine, dried over Na sO, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate = 8 / 1 to 2 / 1) to give (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 02-benzyl 01-tert-butyl ester (13 g, 40.45 mmol, 93.54% yield) as a colorless oil.

[0840] 1 H NMR(400MHz, CDCl3),7.31-7.40(m,5H),4.99-5.16(m,3H),4.23-4.29(m,2H),3.35-3. 55(m,1H),3.10-3.30(m,1H),2.10-2.40(m,1H),1.80-1.90(m,1H),1.20-1.40(m,9H).

[0841] Step 2:

[0842] To a solution of (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 02-benzyl 01-tert-butyl ester (13 g, 40.45 mmol, 1 eq) in EtOAc (80 mL) was added HCl / EtOAc (4 M, 80 mL, 7.91 eq) dropwise at 20 ° C. The mixture was stirred at 25 ° C. under an N atmosphere for 4 hours. The reaction mixture was filtered, and the residue was collected and concentrated under reduced pressure to give (2S)-4-hydroxypyrrolidine-2-carboxylic acid benzyl ester (9 g, 34.92 mmol, 86.33% yield, HCl) as a white solid.

[0843] Step 3:

[0844] To a solution of (2S)-4-hydroxypyrrolidine-2-carboxylic acid benzyl ester (1g, 3.88mmol, 1 equivalent, HCl) in DMF (70mL) was added DIEA (1.00g, 7.76mmol, 1.35mL, 2 equivalents) at 25°C and stirred for 0.5 hours under N2 atmosphere. 6-bromohexanoic acid undecyl ester (1.36g, 3.88mmol, 1 equivalent) and KI (128.83mg, 776.06μmol, 0.2 equivalents) were added to the mixture and stirred for 8 hours at 50°C under N2 atmosphere. The reaction mixture was diluted with 50mL H2O and extracted with 300mL EtOAc (150mL×2). The combined organic layers were washed with 200mL brine (100mL×2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate = 20 / 1 to 5 / 1) to give benzyl (2S)-4-hydroxy-1-(6-oxo-6-undecanoxy-hexyl)pyrrolidine-2-carboxylate (2.8 g, 5.72 mmol, 49.12% yield) as a colorless oil.

[0845] 1 H NMR(400MHz, CDCl3),7.25-7.55(m,5H),5.14-5.25(m,2H),4.25~4.48(m,1H), 4.05(t,J=6.8Hz,2H),3.15-3.65(m,2H),2.55-2.75(m,1H),2.40-2.55(m,1H) ,2.30-2.40(m,1H),2.20-2.30(m,2H),2.05-2.15(m,1H),1.90-2.00(m,1H),1 .55-1.75(m,4H),1.40-1.50(m,2H),1.20-1.35(m,18H),0.89(t,J=6.4Hz,3H).

[0846] Step 4:

[0847] By 8- chloro- 8- oxo- octanoic acid methyl ester (3.22g, 15.60mmol, 2.21mL, 1 equivalent), heptadecan- 9- alcohol (4g, 15.60mmol, 1 equivalent) and pyridine (1.23g, 15.60mmol, 1.26mL, 1 equivalent) in THF (20mL) mixture at 70 DEG C under N2 atmosphere stirred for 6 hours.The reaction mixture is filtered and concentrated under reduced pressure to give a residue.The residue is purified by column chromatography (SiO2, petroleum ether / ethyl acetate=1 / 0 to 20 / 1) to give suberic acid O1- methyl ester O8- (1- octyl nonyl) ester (3.6g, 8.44mmol, 54.10% yield) as a colorless oil.

[0848] Step 5:

[0849] To a solution of 1-methyl suberate 8-(1-octylnonyl) ester (3.6 g, 8.44 mmol, 1 equivalent) in THF (15 mL) was added dropwise LiOH.HO (424.88 mg, 10.12 mmol, 1.2 equivalents) in HO (1 mL) at 25 ° C. The mixture was stirred at 25 ° C. under an N atmosphere for 4 hours. The reaction mixture was diluted with 500 mL HO and extracted with 60 mL EtOAc (30 mL × 2). The combined organic layers were dried over Na SO , filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO , petroleum ether / ethyl acetate = 10 / 1 to 5 / 1) to give 8-(1-octylnonyloxy)-8-oxo-octanoic acid (2.1 g, 5.09 mmol, 60.32% yield) as a colorless oil.

[0850] Step 6:

[0851] To a solution of 8-(1-octylnonyloxy)-8-oxo-octanoic acid (2.1 g, 5.09 mmol, 1 eq) in DCM (25 mL) was added (COCl) (3.23 g, 25.45 mmol, 2.23 mL, 5 eq) and DMF (37.20 mg, 508.91 μmol, 39.15 μL, 0.1 eq) dropwise at 0 ° C. The mixture was stirred at 25 ° C. under N2 atmosphere for 2 hours. The reaction mixture was concentrated under reduced pressure to give the crude product 8-chloro-8-oxo-octanoic acid 1-octylnonyl ester (2.3 g, crude product) as a colorless oil and used in the next step without further purification.

[0852] Step 7:

[0853] By (2S) -4- hydroxy -1- (6- oxo -6- undecyloxy - hexyl) pyrrolidine -2- carboxylic acid benzyl ester (0.4g, 816.85 μ mol, 1 equivalent), 8- chloro -8- oxo - octanoic acid 1- octyl nonyl ester (704.27mg, 1.63mmol, 2 equivalents) and pyridine (64.61mg, 816.85 μ mol, 65.93 μ L, 1 equivalent) in THF (15mL) mixture at 60 DEG C under N2 atmosphere stirred 8 hours.The reaction mixture is filtered, and the filtrate is diluted with 10mL H2O, then extracted with 60mL EtOAc (30mL × 2).The organic layer combined is through Na2SO4 dry, filtered and concentrated under reduced pressure to obtain residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 10 / 1) to give 01-[(5S)-5-benzyloxycarbonyl-1-(6-oxo-6-undecanyloxy-hexyl)pyrrolidin-3-yl] 08-(1-octylnonyl) suberate (330 mg, 373.17 μmol, 45.68% yield) as a colorless oil.

[0854] 1 H NMR(400MHz, CDCl3),7.31-7.39(m,5H),5.14-5.25(m,3H),4.85-4.89(m,1H),4.06(t,J=6.8Hz,2H),3.10-3.55(m,2H), 2.20-2.75(m,11H),2.05-2.20(m,1H),1.58-1.75(m,6H),1.40-1.55(m,6H),1.20-1.35(m,48H),0.89(t,J=6.4Hz,9H).

[0855] Step 8:

[0856] To a solution of Pd / C (500 mg, 10% purity) in EtOAc (400 mL) was added 1-[(5S)-5-benzyloxycarbonyl-1-(6-oxo-6-undedecyloxy-hexyl)pyrrolidin-3-yl] suberate 8-(1-octylnonyl) ester (500 mg, 565.41 μmol, 1 equiv). The mixture was stirred at 25° C. under H at 15 Psi for 5 hours. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give (2S)-4-[8-(1-octylnonyloxy)-8-oxo-octanoyl]oxy-1-(6-oxo-6-undedecyloxy-hexyl)pyrrolidine-2-carboxylic acid (350 mg, crude product) as a colorless oil.

[0857] Step 9:

[0858] To a solution of (2S)-4-[8-(1-octylnonyloxy)-8-oxo-octanoyl]oxy-1-(6-oxo-6-undedecyloxy-hexyl)pyrrolidine-2-carboxylic acid (200 mg, 251.83 μmol, 1 eq) and CsCO (164.10 mg, 503.66 μmol, 2 eq) in DMF (5 mL) was added 2-bromo-N,N-dimethyl-ethylamine (45.94 mg, 302.19 μmol, 1.2 eq). The mixture was stirred at 25 ° C for 8 hours. The mixture was added to H O (10 mL) and extracted with EtOAc (10 mL×3). The organic layer was washed with brine (10 mL×2), dried over Na SO, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) and by preparative TLC (SiO2, ethyl acetate:MeOH = 1:0, with addition of 1% NH3.H2O) to give O1-[(5S)-5-[2-(dimethylamino)ethoxycarbonyl]-1-(6-oxo-6-undecanyloxy-hexyl)pyrrolidin-3-yl] ester O8-(1-octylnonyl) suberate (125 mg, 143.01 μmol, 56.79% yield, 99% purity) as a colorless oil.

[0859] 1 H NMR(400MHz, CDCl3),5.14-5.25(m,1H),4.85-4.89(m,1H),4.23-4.28(m,2H),4.05(t,J=6.8Hz,2H),3.10-3.60(m,2H), 2.25-2.80(m,18H),2.00-2.10(m,1H),1.58-1.65(m,8H),1.40-1.55(m,6H),1.20-1.35(m,46H),0.89(t,J=6.4Hz,9H).

[0860] LCMS: (M+H + ):865.7 at 10.196 / 10.709 minutes.

[0861] 8.5. Synthesis of Compound 2294

[0862]

[0863] Step 1:

[0864] To a solution of heptadecan-9-ol (10 g, 38.99 mmol, 1 equivalent) and 7-bromoheptanoic acid (8.82 g, 42.17 mmol, 1.08 equivalent) in DCM (100 mL) was added DMAP (2.38 g, 19.50 mmol, 0.5 equivalent) and EDCI (8.97 g, 46.79 mmol, 1.2 equivalents). The mixture was stirred at 20 ° C for 8 hours. The mixture was added to H2O (200 mL) and extracted with EtOAc (50 mL × 3). The organic layer was washed with brine (50 mL × 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to obtain 7-bromoheptanoic acid 1-octyl nonyl ester (12 g, 26.81 mmol, 68.77% yield) as a colorless oil.

[0865] Step 2:

[0866] To a solution of (2S)-1-tert-butoxycarbonyl-4-hydroxy-pyrrolidine-2-carboxylic acid (950 mg, 4.11 mmol, 1 eq) and 1-octylnonyl 7-bromoheptanoate (2.02 g, 4.52 mmol, 1.1 eq) in DMF (50 mL) was added CsCO (2.94 g, 9.04 mmol, 2.2 eq). The mixture was stirred at 20 ° C for 8 hours. The mixture was added to H O (50 mL) and extracted with EtOAc (20 mL × 3). The organic layer was washed with brine (20 mL × 2), dried over Na SO, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to give (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 01-tert-butyl ester 02-[7-(1-octylnonyloxy)-7-oxo-heptyl] ester (1.5 g, 2.51 mmol, 61.07% yield) as a colorless oil.

[0867] Step 3:

[0868] A solution of (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-[9-(1-octylnonyloxy)-9-oxo-nonyl] ester (1.5 g, 2.40 mmol, 1 equiv) in DCM (30 mL) and TFA (6.93 g, 60.78 mmol, 4.50 mL, 25.36 equiv) was stirred at 20 ° C for 2 hours. The mixture was concentrated under reduced pressure to give a residue. The residue was dissolved in EtOAc (20 mL), and the organic layer was washed with saturated NaHCO (50 mL × 4), brine (20 mL × 2), dried over Na SO, filtered and concentrated under reduced pressure to give (2S)-4-hydroxypyrrolidine-2-carboxylic acid [9-(1-octylnonyloxy)-9-oxo-nonyl] ester (1 g, 1.90 mmol, 79.36% yield) as a colorless oil.

[0869] Step 4:

[0870] To a solution of (2S)-4-hydroxypyrrolidine-2-carboxylic acid [7-(1-octylnonyloxy)-7-oxo-heptyl] ester (0.5 g, 1.00 mmol, 1 eq), KCO (416.49 mg, 3.01 mmol, 3 eq) and KI (83.38 mg, 502.26 μmol, 0.5 eq) in DMF (20 mL) was added undecyl 6-bromohexanoate (386.02 mg, 1.10 mmol, 1.1 eq). The mixture was stirred at 50° C. for 8 h. The mixture was added to H O (20 mL), extracted with EtOAc (20 mL×3), and the organic layer was washed with brine (20 mL×2), dried over Na SO, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) and by preparative HPLC (column: Phenylene Gel Luna C18 100 × 30 mm × 5 μm; mobile phase: [water (HCl) -ACN]; B%: 55% -85%, 10 minutes) to give a solution. Saturated NaHCO 3 was added to the solution until pH = about 7 and extracted with EtOAc (20 mL × 3). The organic layer was washed with brine (20 mL × 2), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give (2S) -4-hydroxy-1- (6-oxo-6-undecanyloxy-hexyl) pyrrolidine-2-carboxylic acid [7- (1-octylnonyloxy) -7-oxo-heptyl] ester (1 g, 1.31 mmol, 64.96% yield) as a colorless oil.

[0871] 1H NMR(400MHz, CDCl3),4.84-4.91(m,1H),4.25-4.55(m,1H),4.04-4.20(m,4H),3.05-3.75(m,2H),1 .91-2.85(m,9H),1.60-1.70(m,8H),1.45-1.55(m,6H),1.20-1.40(m,46H),0.89(t,J=6.4Hz,9H). LCMS:(M+H + ):766.4 at 13.405 minutes.

[0872] Step 5:

[0873] To a solution of 3-(dimethylamino)propanoic acid (300 mg, 1.95 mmol, 1 eq, HCl) in DCM (5 mL) was added (COCl) (991.60 mg, 7.81 mmol, 683.86 μL, 4 eq) and DMF (14.27 mg, 195.30 μmol, 15.03 μL, 0.1 eq) and stirred at 20° C. for 2 h. The mixture was concentrated under reduced pressure to give 3-(dimethylamino)propanoyl chloride (336 mg, 1.95 mmol, 99.99% yield, HCl) as a yellow solid.

[0874] Step 6:

[0875] To a solution of (2S)-4-hydroxy-1-(6-oxo-6-undecanyloxy-hexyl)pyrrolidine-2-carboxylic acid [7-(1-octylnonyloxy)-7-oxo-heptyl] ester (200 mg, 261.03 μmol, 1 eq), DMAP (15.95 mg, 130.52 μmol, 0.5 eq) and TEA (132.07 mg, 1.31 mmol, 181.66 μL, 5 eq) in DCM (10 mL) was added 3-(dimethylamino)propanoyl chloride (112.00 mg, 650.96 μmol, 2.49 eq, HCl) under N at 0° C., and the mixture was then stirred at 20° C. for 1 hour. The mixture was added to saturated NaHCO (20 mL) and extracted with EtOAc (10 mL×3). The organic layer is washed with salt water (10mL×2), dried over NaSO, filtered and concentrated under reduced pressure. The residue is purified by column chromatography (SiO , petroleum ether / ethyl acetate=10 / 1 to 0 / 1) and purified by preparative HPLC (column: Phenylephrine LunaC18 100×30mm×5μm; mobile phase: [water (HCl)-ACN]; B%: 45%-75%, 10 minutes) to obtain a solution. Saturated NaHCO is added to the solution until pH=about 7, and extracted with EtOAc (20mL×3). The organic layer was washed with brine (20 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give (2S)-4-[3-(dimethylamino)propanoyloxy]-1-(6-oxo-6-undecanoxy-hexyl)pyrrolidine-2-carboxylic acid [7-(1-octylnonyloxy)-7-oxo-heptyl] ester (70 mg, 80.90 μmol, 30.99% yield, 100% purity) as a yellow oil.

[0876] 1 H NMR(400MHz, CDCl3),5.20-5.28(m,1H),4.83-4.90(m,1H),4.03-4.15(m,4H),3.43-3.55(m,1H),3.09-3.2 7(m,1H),2.00-2.80(m,17H),1.55-1.70(m,8H),1.45-1.55(m,6H),1.20-1.40(m,48H),0.86-0.90(m,9H). LCMS:(M+H + ):865.4 at 9.871 / 9.920 minutes.

[0877] 8.6. Synthesis of Compound 2295

[0878]

[0879] Step 1:

[0880] To a solution of heptadecan-9-ol (10 g, 38.99 mmol, 1 equivalent) and 9-bromononanoic acid (10 g, 42.17 mmol, 1.08 equivalent) in DCM (100 mL) was added DMAP (2.38 g, 19.50 mmol, 0.5 equivalent) and EDCI (8.97 g, 46.79 mmol, 1.2 equivalents). The mixture was stirred at 20 ° C for 8 hours. The mixture was added to H2O (200 mL) and extracted with EtOAc (100 mL × 3). The organic layer was washed with brine (100 mL × 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=1 / 0 to 5 / 1) to obtain 9-bromononanoic acid 1-octyl nonyl ester (15 g, 31.54 mmol, 80.89% yield) as a colorless oil.

[0881] Step 2:

[0882] To a solution of (2S)-1-tert-butoxycarbonyl-4-hydroxy-pyrrolidine-2-carboxylic acid (5 g, 21.62 mmol, 1 eq) and 1-octylnonyl 9-bromononanoate (12.34 g, 25.95 mmol, 1.2 eq) in DMF (100 mL) was added CsCO (15.50 g, 47.57 mmol, 2.2 eq). The mixture was stirred at 20 ° C for 8 hours. The mixture was added to H O (200 mL) and extracted with EtOAc (100 mL × 3). The organic layer was washed with brine (100 mL × 2), dried over Na SO, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to give (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 01-tert-butyl ester 02-[9-(1-octylnonyloxy)-9-oxo-nonyl] ester (10 g, 15.98 mmol, 73.89% yield) as a colorless oil.

[0883] 1 H NMR(400MHz, CDCl3),4.85-4.89(m,1H),4.05-4.55(m,4H),3.40-3.80(m,2H),2.25-2.40(m,3H),2 .05-2.15(m,1H),1.60-1.75(m,4H),1.40-1.60(m,14H),1.20-1.35(m,32H),0.88(t,J=6.4Hz,6H).

[0884] Step 3:

[0885] A solution of (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-[9-(1-octylnonyloxy)-9-oxo-nonyl] ester (10 g, 15.98 mmol, 1 equivalent) in DCM (60 mL) and TFA (57.75 g, 506.48 mmol, 37.50 mL, 31.70 equivalents) was stirred at 20 ° C for 2 hours. The mixture was concentrated under reduced pressure to give a residue. The residue was dissolved in EtOAc (100 mL), washed with saturated NaHCO (200 mL × 2) and brine (200 mL × 2), dried over Na SO, filtered and concentrated under reduced pressure to give (2S)-4-hydroxypyrrolidine-2-carboxylic acid [9-(1-octylnonyloxy)-9-oxo-nonyl] ester (7 g, crude product) as a yellow oil.

[0886] Step 4:

[0887] To a solution of (2S)-4-hydroxypyrrolidine-2-carboxylic acid [9-(1-octylnonyloxy)-9-oxo-nonyl] ester (2 g, 3.80 mmol, 1 eq), KCO (1.58 g, 11.41 mmol, 3 eq) and KI (315.71 mg, 1.90 mmol, 0.5 eq) in DMF (100 mL) was added undecyl 6-bromohexanoate (1.59 g, 4.56 mmol, 1.2 eq). The mixture was stirred at 50 ° C for 8 hours. The mixture was added to H O (20 mL) and extracted with EtOAc (20 mL×3). The organic layer was washed with brine (20 mL×2), dried over Na SO, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) and by preparative HPLC (column: Phenylene Gum Luna C18 100×30 mm×5 μm; mobile phase: [water (HCl)-ACN]; B%: 55%-80%, 10 minutes) to give (2S)-4-hydroxy-1-(6-oxo-6-undecanoxy-hexyl)pyrrolidine-2-carboxylic acid [9-(1-octylnonyloxy)-9-oxo-nonyl] ester (2 g, 2.52 mmol, 66.20% yield) as a yellow oil.

[0888] 1 H NMR(400MHz, CDCl3),4.85-4.90(m,1H),4.20-4.55(m,1H),4.00-4.15(m,4H),3.05-3.60(m,2H),1 .90-2.80(m,9H),1.55-1.75(m,8H),1.45-1.55(m,6H),1.20-1.40(m,50H),0.88(t,J=6.4Hz,9H).

[0889] Step 5:

[0890] To a solution of 3-(dimethylamino)propanoic acid (100 mg, 651.01 μmol, 1 eq, HCl) in DCM (5 mL) was added (COCl) (330.53 mg, 2.60 mmol, 227.95 μL, 4 eq) and DMF (4.76 mg, 65.10 μmol, 5.01 μL, 0.1 eq). The mixture was stirred at 20 ° C for 2 hours. The mixture was concentrated under reduced pressure to give 3-(dimethylamino)propanoyl chloride (112 mg, crude product, HCl) as a yellow solid. 3-(Dimethylamino)propanoyl chloride (112 mg, 650.96 μmol, 2.59 eq, HCl) was then added to a solution of (2S)-4-hydroxy-1-(6-oxo-6-undecanyloxy-hexyl)pyrrolidine-2-carboxylic acid [9-(1-octylnonyloxy)-9-oxo-nonyl] ester (200 mg, 251.81 μmol, 1 eq), DMAP (15.38 mg, 125.91 μmol, 0.5 eq) and TEA (127.41 mg, 1.26 mmol, 175.25 μL, 5 eq) in DCM (5 mL) under N at 0° C., and the mixture was then stirred for 1 hour at 20° C. The mixture was added to saturated NaHCO (20 mL) and extracted with EtOAc (10 mL×3). The organic layer was washed with brine (10 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) and further purified by preparative TLC (SiO2, ethyl acetate / MeOH = 5: 1, with addition of 3% NH3.H2O) to afford (2S)-4-[3-(dimethylamino)propanoyloxy]-1-(6-oxo-6-undecanyloxy-hexyl)pyrrolidine-2-carboxylic acid [9-(1-octylnonyloxy)-9-oxo-nonyl] ester (100 mg, 108.58 μmol, 43.12% yield, 97% purity) as a yellow oil.

[0891] 1 H NMR(400MHz, CDCl3),5.20-5.29(m,1H),4.85-4.89(m,1H),4.03-4.18(m,4H),3.44-3.55(m,1H),3.09-3.2 6(m,1H),2.05-2.80(m,19H),1.60-1.65(m,8H),1.45-1.55(m,6H),1.18-1.40(m,50H),0.86-0.91(m,9H). LCMS:(M+H+ ):893.5 at 10.397 / 10.417 minutes.

[0892] 8.7. Synthesis of Compound 2296

[0893]

[0894] Step 1:

[0895] To a solution of 5-bromopentan-1-ol (10g, 59.86mmol, 1 equivalent) and dodecanoic acid (12.59g, 62.86mmol, 1.05 equivalents) in DCM (100mL) was added EDCI (22.95g, 119.73mmol, 2 equivalents) and DMAP (3.66g, 29.93mmol, 0.5 equivalents) at 0°C. The mixture was stirred for 8 hours at 20°C. At 0°C, the reaction mixture was quenched by adding mL of H2O2O0, and then extracted with 300mL of EtOAc (100mL×3). The combined organic layer was washed with 300mL of saturated brine (100mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate=100 / 1 to 5 / 1) to give 5-bromopentyl dodecanoate (15 g, 42.94 mmol, 71.72% yield) as a white solid.

[0896] Step 2:

[0897] To a solution of (2S)-4-hydroxypyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (800 mg, 1.56 mmol, 1 eq) in DMF (10 mL) was added KCO (648.13 mg, 4.69 mmol, 3 eq) and KI (129.75 mg, 781.59 μmol, 0.5 eq). 5-bromopentyl dodecanoate (600.70 mg, 1.72 mmol, 1.1 eq) was then added to the mixture. The mixture was stirred at 50 ° C for 8 hours. The reaction mixture was quenched at 0 ° C by adding 20 mL of H O and then extracted with 60 mL of EtOAc (20 mL × 3). The combined organic layers were washed with 60 mL of saturated brine (20 mL × 3), dried over NaSO, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to give (2S)-1-(5-dodecanoyloxypentyl)-4-hydroxy-pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (820 mg, 1.05 mmol, 67.23% yield) as a yellow oil.

[0898] Step 3:

[0899] To a solution of 3-(dimethylamino)propanoic acid (400 mg, 2.60 mmol, 1 eq, HCl) in DCM (10 mL) was added DMF (9.52 mg, 130.20 μmol, 10.02 μL, 0.05 eq) and (COCl) (396.63 mg, 3.12 mmol, 273.54 μL, 1.2 eq) at 0° C. The mixture was stirred at 0° C. for 2 hours. The mixture was concentrated under reduced pressure to give 3-(dimethylamino)propanoyl chloride (450 mg, crude product, HCl) as a white solid.

[0900] Step 4:

[0901] To a solution of (2S)-1-(5-dodecanoyloxypentyl)-4-hydroxy-pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (400 mg, 512.68 μmol, 1 eq) in DCM (10 mL) was added TEA (518.78 mg, 5.13 mmol, 713.59 μL, 10 eq) and 3-(dimethylamino)propanoyl chloride (352.83 mg, 2.05 mmol, 4 eq, HCl) at 0 ° C. The mixture was stirred at 20 ° C for 3 hours. The reaction mixture was quenched at 0 ° C by adding 10 mL of H2O and then extracted with 30 mL of EtOAc (10 mL × 3). The combined organic layers were washed with 30 mL of saturated brine (10 mL × 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Phenylephrine Luna C18 100×30 mm×5 μm; mobile phase: [water (HCl)-ACN]; B%: 45%-75%, 10 minutes) to give a solution. The solution was adjusted to pH=8 with saturated NaHCO 3 and extracted with 30 mL of EtOAc (10 mL×3). The combined organic layers were dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure to give (2S)-4-[3-(dimethylamino)propanoyloxy]-1-(5-dodecanoyloxypentyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (108 mg, 51.58 μmol, 10.06% yield, 42% purity) as a colorless oil.

[0902] 1H NMR(400MHz, CDCl3),5.21-5.28(m,1H),4.84-4.88(m,1H),4.10-4.13(m,2H),4.06(t,J=6.8Hz,2H),3.12-3.55(m,2H), 1.97-2.35(m,7H),2.40-2.57(m,12H),1.60-1.65(m,6H),1.50-1.52(m,6H),1.26-1.38(m,50H),0.89(t,J=6.8Hz,9H).

[0903] LCMS: (M+H + ):879.4 at 10.062 minutes.

[0904] 8.8. Synthesis of Compound 2297

[0905]

[0906] Step 1:

[0907] To a solution of 4-benzyloxybutyric acid (2 g, 10.30 mmol, 1.82 mL, 1 eq) in DCM (20 mL) was added DMF (15.05 mg, 205.95 μmol, 15.85 μL, 0.02 eq) and (COCl) (1.57 g, 12.36 mmol, 1.08 mL, 1.2 eq) at 0° C. The mixture was stirred at 0° C. for 2 hours. The mixture was concentrated under reduced pressure to give 4-benzyloxybutyryl chloride (2.2 g, crude product) as a white solid.

[0908] Step 2:

[0909] To a solution of (2S)-4-hydroxy-1-(6-oxo-6-undecyloxy-hexyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (1.5 g, 1.92 mmol, 1 equiv) in DCM (20 mL) was added TEA (1.95 g, 19.23 mmol, 2.68 mL, 10 equiv) and 4-benzyloxybutyryl chloride (2.04 g, 9.61 mmol, 5 equiv) at 0 ° C. The mixture was stirred at 20 ° C for 3 hours. The reaction mixture was quenched at 0 ° C by adding 20 mL of H2O and then extracted with 60 mL of EtOAc (20 mL × 3). The combined organic layers were washed with 60 mL of brine (20 mL × 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20 / 1 to 1 / 1) to give (2S)-4-(4-benzyloxybutyryloxy)-1-(6-oxo-6-undecanoxy-hexyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (1.3 g, 1.36 mmol, 70.70% yield) as a yellow oil.

[0910] Step 3:

[0911] To a solution of (2S)-4-(4-benzyloxybutyryloxy)-1-(6-oxo-6-undecanyloxy-hexyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (600 mg, 627.34 μmol, 1 eq) in EtOAc (10 mL) was added Pd / C (0.3 g, 10% purity) and Pd(OH) / C (0.3 g, 427.25 μmol, 20% purity, 6.81e-1 eq). The mixture was stirred at 20° C. under a H atmosphere (15 psi) for 8 h. The mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Phenylephrine Luna C18 100×30 mm×5 μm; mobile phase: [water (HCl)-ACN]; B%: 50%-80%, 10 minutes). The mixture was then adjusted to pH=8 with saturated NaHCO 3 and extracted with 30 mL of EtOAc (10 mL×3). The combined organic layers were dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure to give (2S)-4-(4-hydroxybutyryloxy)-1-(6-oxo-6-undecanyloxy-hexyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (191 mg, 220.48 μmol, 35.15% yield) as a colorless oil.

[0912] 1H NMR(400MHz, CDCl3),5.15-5.28(m,1H),4.85-4.88(m,1H),4.03-4.12(m,4H),3.27-3.73(m,4H),2.26-2.72(m ,11H),1.86-1.91(m,2H),1.60-1.70(m,8H),1.45-1.55(m,6H),1.26-1.34(m,48H),0.89(t,J=5.2Hz,9H).(M+H + ):866.8.

[0913] LCMS: (M+H + ):866.8 at 13.884 minutes.

[0914] 8.9. Synthesis of Compound 2298

[0915]

[0916]

[0917] Step 1:

[0918] To a solution of 7-bromoheptyl-1-ol (3.60 g, 18.46 mmol, 1.05 equivalents) and 2-octyldecanoic acid (5 g, 17.58 mmol, 1 equivalent) in DCM (100 mL) was added DMAP (1.07 g, 8.78 mmol, 0.5 equivalents) and EDCI (4.04 g, 21.10 mmol, 1.2 equivalents). The mixture was stirred at 20 ° C for 8 hours. The mixture was added to H2O (200 mL) and extracted with EtOAc (200 mL × 3). The organic layer was washed with brine (200 mL × 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=1 / 0 to 5 / 1) to obtain 2-octyldecanoic acid 7-bromoheptyl ester (7 g, 15.17 mmol, crude product) as a colorless oil.

[0919] Step 2:

[0920] To a solution of (2S)-1-tert-butoxycarbonyl-4-hydroxy-pyrrolidine-2-carboxylic acid (3 g, 12.96 mmol, 1 eq) and 7-bromoheptyl 2-octyldecanoate (6.99 g, 15.18 mmol, 1.17 eq) in DMF (100 mL) was added CsCO (9.30 g, 28.53 mmol, 2.2 eq). The mixture was stirred at 20 ° C for 8 hours. The mixture was added to H O (20 mL) and extracted with EtOAc (20 mL × 3). The organic layer was washed with brine (20 mL × 2), dried over Na SO, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to give (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 01-tert-butyl 02-[7-(2-octyldecanoyloxy)heptyl] ester (5 g, 8.17 mmol, 62.99% yield) as a colorless oil.

[0921] Step 3:

[0922] A solution of (2S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-[7-(2-octyldecanoyloxy)heptyl] ester (5 g, 8.18 mmol, 1 equiv) in DCM (30 mL) and TFA (23.10 g, 101.30 mmol, 15.02 mL, 24.79 equiv) was stirred at 20 ° C for 2 hours. The mixture was concentrated under reduced pressure to give a residue, and the residue was dissolved with EtOAc (20 mL). The organic layer was washed with saturated NaHCO (50 mL×4) and brine (20 mL×2), dried over Na SO, filtered and concentrated under reduced pressure to give (2S)-4-hydroxypyrrolidine-2-carboxylic acid 7-(2-octyldecanoyloxy)heptyl ester (4 g, crude product) as a colorless oil.

[0923] Step 4:

[0924] To a solution of (2S)-4-hydroxypyrrolidine-2-carboxylic acid 7-(2-octyldecanoyloxy)heptyl ester (2 g, 3.91 mmol, 1 eq), KCO (1.62 g, 11.72 mmol, 3 eq) and KI (324.36 mg, 1.95 mmol, 0.5 eq) in DMF (20 mL) was added 5-bromopentyl dodecanoate (1.50 g, 4.30 mmol, 1.1 eq). The mixture was stirred at 50 ° C for 8 hours. The mixture was added to H O (20 mL) and extracted with EtOAc (20 mL × 3). The organic layer was washed with brine (20 mL × 2), dried over Na SO, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO , petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) and by preparative HPLC (column: Phenylene Gel Luna C18 100 × 30 mm × 5 μm; mobile phase: [water (HCl) -ACN]; B%: 50% -80%, 10 minutes) to give a solution. Saturated NaHCO was added to the solution until the solution had a pH of about 7 and extracted with EtOAc (20 mL × 3). The organic layer was washed with brine (20 mL × 2), dried over Na SO , filtered and concentrated under reduced pressure to give (2S) -1- (5-dodecanoyloxypentyl) -4-hydroxy-pyrrolidine-2-carboxylic acid 7- (2-octyldecanoyloxy) heptyl ester (2 g, 2.56 mmol, 65.59% yield) as a colorless oil.

[0925] 1 H NMR(400MHz, CDCl3),4.25-4.55(m,1H),3.95-4.25(m,6H),3.05-3.75(m,2H),1.80-2.85 (m,8H),1.60-1.70(m,8H),1.40-1.55(m,6H),1.23-1.40(m,48H),0.89(t,J=6.4Hz,9H).

[0926] LCMS: (M+H + ):780.4 at 13.242 and 13.267 minutes.

[0927] Step 5:

[0928] To a solution of 3-(dimethylamino)propanoic acid (300 mg, 1.95 mmol, 1 eq, HCl) in DCM (5 mL) was added (COCl) (991.60 mg, 7.81 mmol, 683.86 μL, 4 eq) and DMF (14.27 mg, 195.30 μmol, 15.03 μL, 0.1 eq). The mixture was stirred at 20 ° C for 2 hours. The mixture was concentrated under reduced pressure to give 3-(dimethylamino)propanoyl chloride (336 mg, 1.95 mmol, 99.99% yield, HCl) as a yellow solid.

[0929] Step 6:

[0930] Under N2 at 0 ℃ To a solution of (2S)-1-(5-dodecanoyloxypentyl)-4-hydroxy-pyrrolidine-2-carboxylic acid 7-(2-octyldecanoyloxy)heptyl ester (350 mg, 448.60 μmol, 1 eq), DMAP (27.40 mg, 224.30 μmol, 0.5 eq) and TEA (226.97 mg, 2.24 mmol, 312.20 μL, 5 eq) in DCM (10 mL) was added 3-(dimethylamino)propanoyl chloride (294.00 mg, 1.71 mmol, 3.81 eq, HCl), and the mixture was then stirred at 20°C for 10 min. ℃ In the 4-thiazolinyl esters of 4-nitropropene methyl esters, ... The organic layer was washed with brine (20 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give (2S)-4-[3-(dimethylamino)propanoyloxy]-1-(5-dodecanoyloxypentyl)pyrrolidine-2-carboxylic acid 7-(2-octyldecanoyloxy)heptyl ester (132 mg, 148.61 μmol, 45.40% yield, 99% purity) as a yellow oil.

[0931] 1H NMR(400MHz, CDCl3),5.20-5.30(m,1H),4.03-4.17(m,6H),3.25-3.55(m,1H),3.09-3.30(m,1H),2 .00-2.80(m,18H),1.57-1.70(m,8H),1.45-1.55(m,6H),1.15-1.40(m,48H),0.89(t,J=6.8Hz,9H). LCMS:(M+H + ):879.7 at 9.868 minutes.

[0932] 8.10. Synthesis of Compound 2304

[0933]

[0934]

[0935] Step 1:

[0936] To a solution of undecane-1-ol (5 g, 29.02 mmol, 1 equivalent) and DMAP (3.55 g, 29.02 mmol, 1 equivalent) in DMF (10 mL) was added oxepane-2,7-dione (4.46 g, 34.82 mmol, 1.2 equivalents). The mixture was stirred at 20 ° C for 8 hours. The mixture was added to H2O (20 mL) and extracted with EtOAc (20 mL × 3). The organic layer was washed with brine (20 mL × 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to obtain 6-oxo-6-undecyloxy-hexanoic acid (4 g, 13.31 mmol, 45.88% yield) as a white solid.

[0937] 1 H NMR (400MHz, CDCl3), 4.07 (t, J = 6.8 Hz, 2H), 2.33-2.41 (m, 4H), 1.60-1.71 (m, 6H), 1.19-1.41 (m, 17H), 0.89 (m, J = 7.2Hz, 3H).

[0938] Step 2:

[0939] To a solution of 6-oxo-6-undecyloxy-hexanoic acid (2 g, 6.66 mmol, 1 eq) in DCM (10 mL) was added (COCl) (2.53 g, 19.97 mmol, 1.75 mL, 3 eq) and DMF (4.87 mg, 66.57 μmol, 5.12 μL, 0.01 eq). The mixture was stirred at 20 ° C for 2 hours. The mixture was concentrated under reduced pressure to give 6-chloro-6-oxo-hexanoic acid undecyl ester (2.12 g, crude product) as a white solid.

[0940] Step 3:

[0941] To a solution of (2S)-4-hydroxypyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (3 g, 5.86 mmol, 1 eq), TEA (1.78 g, 17.59 mmol, 2.45 mL, 3 eq) and DMAP (71.61 mg, 586.20 μmol, 0.1 eq) in DCM (5 mL) was added 6-chloro-6-oxo-hexanoic acid undecyl ester (1.91 g, 5.99 mmol, 1.02 eq). The mixture was stirred at 20 ° C for 5 hours. The mixture was added to H O (20 mL) and extracted with EtOAc (20 mL×3). The organic layer was washed with brine (20 mL×2), dried over Na SO , filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to give (2S)-4-hydroxy-1-(6-oxo-6-undecanoxy-hexanoyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (2 g, 2.52 mmol, 42.96% yield) as a white solid.

[0942] 1 H NMR(400MHz, CDCl3),4.80-4.90(m,1H),4.40-4.65(m,2H),4.05-4.25(m,4H),3.49-3.88(m,2H),2 .20-2.40(m,8H),1.60-1.75(m,10H),1.40-1.53(m,4H),1.23-1.38(m,46H),0.89(t,J=6.8Hz,9H).

[0943] Step 4:

[0944] To a solution of 3-(dimethylamino)propanoic acid (400 mg, 2.60 mmol, 1 eq, HCl) in DCM (5 mL) was added (COCl) (1.32 g, 10.42 mmol, 911.81 μL, 4 eq) and DMF (19.03 mg, 260.40 μmol, 20.03 μL, 0.1 eq). The mixture was stirred at 20 ° C for 2 hours. The mixture was concentrated under reduced pressure to give 3-(dimethylamino)propanoyl chloride (448 mg, crude product, HCl) as a yellow solid.

[0945] Step 5:

[0946] To a solution of (2S)-4-hydroxy-1-(6-oxo-6-undecyloxy-hexanoyl)pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (500 mg, 629.57 μmol, 1 eq), TEA (318.53 mg, 3.15 mmol, 438.14 μL, 5 eq) and DMAP (38.46 mg, 314.79 μmol, 0.5 eq) in DCM (10 mL) was added 3-(dimethylamino)propanoyl chloride (433.28 mg, 2.52 mmol, 4 eq, HCl) under N at 0° C., and the mixture was then stirred at 20° C. for 1 hour. The mixture was added to saturated NaHCO (20 mL) and extracted with EtOAc (10 mL×3). The organic layer is washed with salt water (10mL × 2), through Na SO dried, filtered and concentrated under reduced pressure. The residue is passed through column chromatography (SiO , petroleum ether / ethyl acetate=10 / 1 to 0 / 1) purified to obtain the product. The product is dissolved in petroleum ether (2mL) and washed with ACN (2mL × 2). The petroleum ether phase is concentrated under reduced pressure to obtain (2S) -4- [3- (dimethylamino) propionyloxy] -1- (6- oxo -6- undecyloxy - hexanoyl) pyrrolidine -2- carboxylic acid [8- (1- octyl nonyloxy) -8- oxo - octyl] ester (200mg, 223.88 μmol, 35.56% yield, 100% purity) as a yellow oil.

[0947] 1H NMR(400MHz, CDCl3),5.33-5.37(m,1H),4.80-4.90(m,1H),4.40-4.75(m ,1H),4.11-4.15(m,2H),4.00–4.10(m,2H),3.85-3.88(m,1H),3.61-3.7 0(m,1H),2.52-2.65(m,2H),2.40-2.50(m,3H),2.15-2.38(m,13H),1.66 -1.70(m,8H),1.45-1.53(m,6H),1.23-1.38(m,46H),0.86-0.91(m,9H). LCMS:(M+H + ):893.7 at 13.385 / 13.687 minutes.

[0948] 8.11. Synthesis of Compound 2305

[0949]

[0950] Step 1:

[0951] By (2S, 4R) -1- tert-butoxycarbonyl -4- hydroxy - pyrrolidine -2- carboxylic acid (835.02mg, 3.61mmol, 1 equivalent), 8- bromooctanoic acid 1- octyl nonyl ester (2g, 4.33mmol, 1.2 equivalents), CsCO (2.59g, 7.94mmol, 2.2 equivalents) in DMF (30mL) mixture degassed and N2 purged 3 times, and then the mixture was stirred at 15 ° C under N2 atmosphere for 8 hours. The reaction mixture was quenched by adding 100mL H2O at 15 ° C, and then extracted with 300mL EtOAc (100mL × 3). The combined organic layer was washed with 200mL brine (100mL × 2), dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20 / 1 to 3 / 1) to give (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylic acid O1-tert-butyl ester O2-[8-(1-octylnonyloxy)-8-oxo-octyl] ester (11 g, 17.71 mmol, 98.08% yield, 98.5% purity) as a colorless oil.

[0952] 1H NMR(400MHz, CDCl3),4.85-4.88(m,1H),4.36-4.51(m,2H),3.64-3.68(m,1H),3.42-3.56 (m,1H),2.06-2.33(m,4H),1.60-1.64(m,5H),1.20-1.55(m,45H),0.88(t,J=6.4Hz,6H).

[0953] Step 2:

[0954] To a solution of (2S, 4R)-4-hydroxypyrrolidine-1,2-dicarboxylic acid O1-tert-butyl ester O2-[8-(1-octylnonyloxy)-8-oxo-octyl] ester (8 g, 13.07 mmol, 1 eq) in DCM (60 mL) was added TFA (46.20 g, 405.19 mmol, 30 mL, 30.99 eq). The mixture was stirred at 15 ° C for 3 hours. The reaction mixture was quenched at 15 ° C by adding 50 mL of NaHCO 3 and then extracted with 150 mL of EtOAc (50 mL × 3). The combined organic layers were washed with 100 mL of brine (50 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue to afford (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (5 g, 9.77 mmol, 74.73% yield) as a colorless oil.

[0955] Step 3:

[0956] To a solution of 6-bromohexanoic acid undecyl ester (819.14 mg, 2.34 mmol, 1.2 eq) and (2S, 4R)-4-hydroxypyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (1 g, 1.95 mmol, 1 eq) in DMF (15 mL) was added KCO (810.18 mg, 5.86 mmol, 3 eq) and KI (162.18 mg, 976.99 μmol, 0.5 eq). The mixture was stirred at 50 ° C for 8 hours. The reaction mixture was quenched at 15 ° C by adding 50 mL of H O and then extracted with 150 mL of EtOAc (50 mL × 3). The combined organic layers were washed with 100 mL of brine (50 mL × 2), dried over NaSO, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate = 1 / 0 to 8 / 1) and by preparative HPLC (column: Phenylene Gel Luna C18 100 × 30 mm × 5 μm; mobile phase: [water (HCl) -ACN]; B%: 50% -80%, 10 minutes) to obtain a solution. Saturated NaHCO 3 (200 mL) was added to the solution and then extracted with EtOAc (50 mL × 2). The organic layer was washed with brine (20 mL × 2), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to obtain (2S, 4R) -4-hydroxy-1- (6-oxo-6-undecanyloxy-hexyl) pyrrolidine-2-carboxylic acid [8- (1-octylnonyloxy) -8-oxo-octyl] ester (3.6 g, 4.60 mmol, 78.52% yield, 99.76% purity) as a yellow oil.

[0957] 1 H NMR(400MHz, CDCl3),4.85-4.90(m,1H),4.51(brs,1H),4.04-4.15(m,4H),3.47-3.49(m,2H),2.5 7-2.78(m,2H),2.26-2.32(m,6H),1.50-1.66(m,17H),1.26-1.35(m,47H),0.88(t,J=6.8Hz,9H).

[0958] Step 4:

[0959] To a solution of 3-(dimethylamino)propanoic acid (300 mg, 1.95 mmol, 1 eq., HCl) in DCM (5 mL) was added (COCl) (743.67 mg, 5.86 mmol, 512.88 μL, 3 eq.) and DMF (14.28 mg, 195.30 μmol, 15.03 μL, 0.1 eq.). The mixture was stirred at 15 °C for 3 h. The reaction mixture was concentrated under reduced pressure to give 3-(dimethylamino)propanoyl chloride (336 mg, 1.95 mmol, 99.99% yield, HCl) as a yellow solid. 3-(Dimethylamino) propionyl chloride (330.78 mg, 1.92 mmol, 3 equivalents, HCl) is added to a solution of (2S, 4R)-4-hydroxy-1-(6-oxo-6-undecyloxy-hexyl) pyrrolidine-2-carboxylic acid [8-(1-octylnonyloxy)-8-oxo-octyl] ester (500 mg, 640.85 μmol, 1 equivalent), TEA (324.24 mg, 3.20 mmol, 445.99 μL, 5 equivalents) and DMAP (39.15 mg, 320.43 μmol, 0.5 equivalents) in DCM (10 mL). The mixture is stirred at 15 ° C for 3 hours. The reaction mixture is quenched at 15 ° C by adding 10 mL NaHCO3 aqueous solution and then extracted with 30 mL EtOAc (10 mL × 3). The organic layer was washed with 20 mL (10 mL × 2) of salt water, dried over Na SO , filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO , petroleum ether / ethyl acetate=1 / 0 to 3 / 1) and purified by preparative HPLC (column: Phenom Luna C18 100 × 30 mm × 5 μm; mobile phase: [water (HCl)-ACN]; B%: 45%-75%, 10 minutes) to give a solution. Saturated NaHCO was added to the solution (200 mL) and then extracted with EtOAc (50 mL × 2). The organic layer was washed with brine (20 mL x 2),...

Claims

1. A compound of formula (I): A pharmaceutically acceptable salt thereof or a stereoisomer of any of the foregoing, in: is a cyclic or heterocyclic moiety; Y is alkyl, hydroxy, hydroxyalkyl or A does not exist, it is -O-, -N(R 7 )-, -O-alkylene-, -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-、-N(R 7 )C(O)N(R 7 )-, -S-, -SS- or a divalent heterocyclic ring; Each of X and Z is independently absent and is -O-, -CO-, -N(R 7 )-, -O-alkylene-; -alkylene-O-, -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-or-S-; Each R 7 is independently H, alkyl, alkenyl, cycloalkyl, hydroxy, hydroxyalkyl or aminoalkyl; Each M is independently a biodegradable moiety; R 30 , R 40 , R 50 , R 60 , R 70 , R 80 , R 90 , R 100 , R 110 and R 120 Each of the above is independently H, C1-C1 optionally interrupted by heteroatoms or substituted by OH, SH or halogen. 16 Branched or unbranched alkyl or C1-C 16 branched or unbranched alkenyl, or cycloalkyl or substituted cycloalkyl; Each of l and m is an integer from 1 to 10; t1 is an integer from 0 to 10; and W is hydroxy, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted amino, substituted or unsubstituted aminocarbonyl, or substituted or unsubstituted heterocyclyl or heteroaryl.

2. The compound according to claim 1, wherein Y is hydroxy or 3. The compound according to claim 2, having the following structure:

4. The compound according to claim 1 or 3, wherein With formula The structure, in: Each of G1, G2, G3, G4, G5, G6 and G7 is independently C(R')(R"), O or N, provided that no more than two of G1-G7 are O or N; R' and R" are each independently absent and are H, alkyl, or two R's from two adjacent G's that together form a second 5- to 7-membered cyclic ring or heterocycle; and n1 and n2 are each independently 0 or 1.

5. The compound according to claim 4, wherein Selected from the group consisting of pyrrolidine, piperidine, piperazine, cyclohexane, cyclopentane, tetrahydrofuran, tetrahydropyran, morpholine and dioxane.

6. The compound according to claim 4, wherein Selected from the group consisting of:

7. The compound according to claim 6, wherein Selected from the group consisting of:

8. The compound according to claim 1 or 3, wherein X is absent, -O- or -C(O)-.

9. The compound according to claim 1 or 3, wherein Z is -O-, -C(O)O- or -OC(O)-.

10. The compound according to claim 1 or 3, wherein R 30 , R 40 , R 50 and R 60 Each of is H or a C1-C4 branched or unbranched alkyl group.

11. The compound according to claim 10, wherein R 30 , R 40 , R 50 and R 60 Each of is H.

12. The compound according to claim 1 or 3, wherein: R 70 is H; and R 80 and R 90 Each of which is independently H or Cl-C 12 branched or unbranched alkyl group; and R 100 is H; and R 110 and R 120 Each of which is independently H or Cl-C 12 branched or unbranched alkyl, provided that R 80 and R 90 At least one of is not H, and R 110 and R 120 At least one of them is not H.

13. The compound according to claim 12, wherein Independently selected from the group consisting of: where t is 0, 1, 2, 3, 4, or 5.

14. The compound according to claim 1 or 3, wherein l is an integer from 3 to 7.

15. The compound according to claim 1 or 3, wherein m is an integer from 1 to 5.

16. The compound according to claim 1 or 3, wherein M is -OC(O)-, -C(O)O-, -N(R 7 )C(O)-、-C(O)N(R 7 )-、-C(OR 13 )-O-、-C(O)O(CH2) r -、-C(O)N(R 7 )(CH2) r -OR-C(OR 13 )-O-(CH2) r -, where each R 7 R is independently H, alkyl, alkenyl, cycloalkyl, hydroxyalkyl or aminoalkyl; 13 Is it branched or unbranched C3-C 10 alkyl, and r is 1, 2, 3, 4 or 5.

17. The compound of claim 16, wherein M is -OC(O)- or -C(O)O-.

18. The compound according to claim 1 or 3, wherein A is absent, -O-, -N(R 7 )-、-N(R 7 )C(O)-、 -OC(O)- or -C(O)O-, where R 6 are independently H, alkyl, hydroxy, hydroxyalkyl, amino, aminoalkyl, thiol, thiolalkyl or N + (R 7 )3-alkylene-Q-; and R 7 It is H or C1-C3 alkyl.

19. The compound according to claim 1 or 3, wherein t1 is 0, 1, 2, 3 or 4.

20. The compound of claim 1 or 3, wherein W is hydroxy, hydroxyalkyl, or one of the following moieties: in: Each Q independently does not exist and is -O-, -C(O)-, -C(S)-, -C(O)O-, -C(R 7 )2-、-C(O)N(R 7 )-、-C(S)N(R 7 )-or-N(R 7 )-; Each R 6 are independently H, alkyl, hydroxy, hydroxyalkyl, alkoxy, amino, aminoalkyl, alkylamino, thiol, thiolalkyl or N + (R 7 )3-alkylene-Q-; Each R 8 are independently H, alkyl, hydroxyalkyl, amino, aminoalkyl, thiol or thiolalkyl, or two R 8 Together with nitrogen atoms, they can form a ring; each q is independently 0, 1, 2, 3, 4 or 5; and Each p is independently 0, 1, 2, 3, 4 or 5.

21. The compound according to claim 1 or 3, wherein W is OH, in: q is 0, Each R 8 are independently H, C1-C3 alkyl or hydroxyalkyl, or two R 8 Together with the nitrogen atom, it forms a 5-membered ring which is optionally substituted by one or more alkyl groups, Each R 6 are independently H, hydroxy, hydroxyalkyl, alkoxy, amino, aminoalkyl, alkylamino, C1-C3 alkyl or -Q-alkylene-N + (R 7 )3, Each Q does not exist independently and is -O-, -C(O)-, -N(R 7 )-、-C(R 7 )2-、-C(O)O-、-C(O)N(R 7 )-or-C(S)N(R 7 )-,and Each R 7 are independently H, C1-C3 alkyl, hydroxy or hydroxyalkyl.

22. The compound according to claim 1 or 3, wherein W is OH, 23. The compound according to claim 1 or 3, wherein Y or yes: OH、 Each R c is independently H or C1-C3 alkyl, and each t1 is independently 1, 2, 3 or 4.

24. The compound according to claim 1 or 3, wherein Y or yes: OH、 25. The compound according to claim 1 or 3, wherein: X does not exist and is -O- or –C(O)-; Z is –O-, –C(O)O- or –OC(O)-; M is -OC(O)- or -C(O)O-; Y or yes: OH、 Each R c are independently H or C1-C3 alkyl; Each t1 is independently 1, 2, 3 or 4; R 30 , R 40 , R 50 and R 60 Each of is H or C1-C4 branched or unbranched alkyl; R 70 is H; and R 80 and R 90 Each of which is independently H or Cl-C 12 Branched or unbranched alkyl group; R 100 is H; and R 110 and R 120 Each of which is independently H or Cl-C 12 branched or unbranched alkyl, provided that R 80 and R 90 At least one of is not H, and R 110 and R 120 At least one of is not H; l is 3 to 7; and m is 1 to 5.

26. A compound according to any one of claims 1 to 25, having the formula:

27. The compound according to claim 26, which has the formula: in: Each m1 is independently an integer from 3 to 6, Each l1 is independently an integer from 4 to 8, m2 and l2 are each independently an integer from 0 to 3; R 80 and R 90 are each independently an unsubstituted C5-C8 alkyl group; or R 80 is H or unsubstituted C1-C4 alkyl, and R 90 is unsubstituted C5-C 11 Alkyl; and R 110 and R 120 are each independently an unsubstituted C5-C8 alkyl group; or R 110 is H or unsubstituted C1-C4 alkyl, and R 120 is unsubstituted C5-C 11 alkyl.

28. The compound according to claim 27, which has the formula: in yes: OH、 29. The compound according to claim 27 or 28, wherein R 80 is H or unsubstituted C1-C2 alkyl, and R 90 It is an unsubstituted C6-C 10 Alkyl; and R 110 and R 120 Each is independently an unsubstituted C5-C8 alkyl.

30. The compound according to claim 27, wherein R 80 , R 90 , R 110 and R 120 Each is independently an unsubstituted C5-C8 alkyl.

31. A compound according to any one of claims 1 to 25, having the formula:

32. The compound according to claim 31, which has the formula: in: Each m1 is independently an integer from 3 to 6, Each l1 is independently an integer from 4 to 8, m2 and l2 are each independently an integer from 0 to 3; R 80 and R 90 are each independently an unsubstituted C5-C8 alkyl group; or R 80 is H or unsubstituted C1-C4 alkyl, and R 90 is unsubstituted C5-C 11 Alkyl; and R 110 and R 120 are each independently an unsubstituted C5-C8 alkyl group; or R 110 is H or unsubstituted C1-C4 alkyl, and R 120 is unsubstituted C5-C 11 alkyl.

33. The compound according to claim 32, which has the formula: in yes: OH、 34. The compound according to claim 32 or 33, wherein R 80 is H or unsubstituted C1-C2 alkyl, and R 90 It is an unsubstituted C6-C 10 Alkyl; and R 110 and R 120 Each is independently an unsubstituted C5-C8 alkyl.

35. The compound according to claim 32 or 33, wherein R 80 , R 90 , R 110 and R 120 Each is independently an unsubstituted C5-C8 alkyl.

36. The compound of any one of claims 1 to 35, wherein the pKa of the protonated form of the compound is from about 4.5 to about 8.

0.

37. The compound of claim 36, wherein the pKa of the protonated form of the compound is from about 4.6 to about 7.

8.

38. The compound according to claim 1 or 3, having one of the following structures:

39. A lipid composition comprising a compound according to any one of the preceding claims, wherein the lipid composition is LNP.

40. The lipid composition of claim 39, further comprising a second lipid.

41. The lipid composition of claim 40, wherein the lipid composition comprises the compound and the second lipid in a ratio of about 1:

1.

42. The lipid composition of claim 40, wherein the second lipid is a cationic, anionic, ionizable or zwitterionic lipid.

43. The lipid composition of claim 39, further comprising a sterol and a PEG lipid.

44. according to the lipid composition described in claim 39, it further comprises sterol, PEG lipid, phospholipid and / or neutral lipid.

45. A pharmaceutical composition comprising a lipid composition according to any one of claims 39 to 44 and a pharmaceutically acceptable excipient.

46. ​​The pharmaceutical composition of claim 45, further comprising a therapeutic agent.

47. The pharmaceutical composition of claim 45, wherein the therapeutic agent is a nucleic acid molecule.

48. The pharmaceutical composition of claim 47, wherein the nucleic acid molecule is RNA or DNA.

49. The pharmaceutical composition of claim 48, wherein the nucleic acid molecule is RNA, wherein the RNA comprises mRNA.

50. The pharmaceutical composition of claim 46, wherein the therapeutic agent is a protein or a small molecule drug.

51. The pharmaceutical composition of claim 45, wherein the pharmaceutical composition is a vaccine.

52. A method of delivering a therapeutic agent to a subject, the method comprising administering to the subject a pharmaceutical composition according to any one of claims 45 to 51.

53. A method for delivering a therapeutic agent to the pancreas, spleen or lung of a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition according to any one of claims 45 to 51.

54. The method of claim 53, wherein less than 50%, 30% or 10% of the therapeutic agent is delivered to the liver.

55. The method of claim 53, wherein greater than 50%, 70%, or 90% of the therapeutic agent is delivered to the pancreas, spleen, and / or lungs of the subject.

Citation Information

Patent Citations

  • Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof

    US10086013B2

  • Lipids and lipid nanoparticle formulations for delivery of nucleic acids

    US10221127B2

  • Liposomal apparatus and manufacturing methods

    US20040142025A1

  • Sterilization method

    US20060008378A1

  • Systems and methods for manufacturing liposomes

    US20070042031A1